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ASSESSING, MODIFYING, AND COMBINING DATA FIELDS FROM THE
VIRGINIA OFFICE OF THE CHIEF MEDICAL EX4MIPTER (OCME) DATASET AND
THE VIRGINIA DEPARTMENT OF FORENSIC SCIENCE (DFS) DATASETS IN
ORDER TO COMPARE CONCENTRATIONS OF SELECTED DRUGS
By Amy Elizabeth Henin
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2006
Major Director: R.K. Elswick, Jr., Ph.D.
Associate Professor and Interim Chair
Department of Biostatistics

The Medical Examiner of Virginia (ME) dataset and the Virginia Department of
Forensic Science Driving Under the Influence of Drugs (DUI) datasets were used to
determine whether people have the potential to develop tolerances to diphenhydramine,
cocaine, oxycodone, hydrocodone, methadone, and morphine. These datasets included the
years 2000-2004 and were used to compare the concentrations of these six drugs between
people who died from a drug-related cause of death (of the drug of interest) and people
who were pulled over for driving under the influence. Three drug pattern groups were

xiv
created to divide each of the six drug-specific datasets in order to compare concentrations
between individuals with the drug alone, the drug and ethanol, or a poly pharmacy of drugs
(multiple drugs). An ANOVA model was used to determine if there was an interaction
effect between the source dataset (ME or DUI) and the drug pattern groups. For
diphenhydramine and cocaine, an interaction was statistically significant, but for the other
drugs, it was not significant. The other four drug-specific datasets showed that the DUI
and ME were statistically significantly different from each other, and all of those datasets
except for methadone showed that there was a statistically significant difference between at
least two drug pattern groups. Showing that all of these datasets showed differences
between the ME and DUI datasets did not provide sufficieilt evidence to suggest the
development of tolerances to each of the six drugs. One exception was with methadone
because there were 14 individuals that had what is defined as a "clinical 'lethal' blood
concentration". These individuals provide some evidence for the possibility of developing
tolerances.
The main outcomes of this study include suggesting changes to make to the ME
datasets and the DUI datasets with regard to the way data is kept and collected. Several
problems with the fields of these datasets arose before beginning the analysis and had to be
corrected. Some of the changes suggested are currently being considered at the Virginia
Office of the Chief Medical Examiner as they are beginning to restructure their database.

CHAPTER 1

Introduction
1.1

Introduction to Datasets
The datasets analyzed and presented in this thesis were provided by the Virginia

Department of Forensic Science (DFS) and the Virginia Office of the Chief Medical
Exanliner (OCME). The Medical Examiner (ME) dataset came from the OCME and
included data on all persons from the years 2000-2004 who received a toxicological screen
as a result of an autopsy throughout the Commonwealth of Virginia. The Driving Under
the Influence of drugs (DUI) datasets came from the DFS and contained the demographic
and drug data on all persons suspected of, stopped for, and given a blood test for DUI
during the years 2000-2004.
1.2

Initial Questions of Interest
One of the original goals for this project was to compare concentrations of

tetrahydrocannabinol (THC) between the ME and DUI datasets and among different drug
drug patterns groups in the DUI dataset in order to have information available for the
Virginia General Assembly for crafting legislation dealing with THC and driving. THC is

the main active ingredient in marijuana, and currently, there are no laws in Virginia that
address concentration limits for marijuana or THC. The General Assembly of Virginia
uses information similar to the information in these datasets to create and amend current
laws regarding drugs and legal limits.
Other goals for this project were to identify concentrations of THC that impair or
intoxicate individuals, to see how ethanol combined with THC affects individuals, and to
look at drug combinations of THC and other identifiable drugs to see if the effects are
additive.
1.3

Problems with Initial Questions and the New Questions
Upon receiving the ME and D-UIdatasets, problems were encountered that did not

allow the investigation of the questions regarding THC. Because THC is not considered
lethal, there were no cases in the ME dataset that had THC data; therefore, the ME data
was not helpfil in answering questions regarding THC.
In the DUI dataset, there was no information about why the individual was stopped

for DUI, so it was not possible to determine whether certain individuals were more or less
intoxicated than others. This was problematic when trying to collect information about
THC for the General Assembly that characterized the degree of intoxication; therefore, the
current information contained in the DUI dataset was insufficient for assisting legislation
or in the development of laws regarding concentrations of THC.
Since .thedatasets did not have enough information to answer the questions
regarding THC, other questions were posed for this project. These questions included
comparing concentrations between the ME and DUI datasets and comparing concentrations

between created drug pattern groups for diphenhydramine, cocaine, oxycodone,
hydrocodone, methadone, and morphine. Answering these questions would be a first step
in determining if individuals in the DUI dataset had developed tolerances to any of these
drugs. These questions are answered in the following chapters.

1.4

Introduction to Subsequent Chapters
This chapter has described the motivation behind this thesis as well as a brief

introduction to the datasets and the questions of interest. Chapter 2 gives a description of
the datasets, the problems encountered with them, and the solutions to these problems.
The analysis is detailed in Chapter 3 where there is a general introduction, a methods
section, and results sections for each of the six drugs of interest. Chapter 4 is a summary
chapter that includes recommendations to the DFS and OCME on how to better collect the
data for their database and suggestions for future projects using these datasets. Throughout
this thesis, there will be sections that seem to repeat what has already been stated, but the
repeated material was deemed necessary for clarity.

Chapter 2
Sources of the Datasets and Preparation for Analysis

2.1

Sources

2.1.1 Medical Examiner Dataset
The Medical Examiner (ME) dataset is a subset of the database kept by the Office
of the Chief Medical Examiner for the Commonwealth of Virginia. This dataset was
provided, with permission, by Dr. Joseph J. Saady and the Office of the Chief Medical
Examiner (OCME). The OCME collects data and maintains the ME database for the
Commonwealth of Virginia. Located in Richmond, Virginia, the OCME is the central
office for the medical examiner system throughout the Commonwealth. All autopsy
information from any medical examiner in Virginia is entered into the ME database.
Currently, there are no laws that mandate the OCME keep and maintain the ME
database, but annual reports concerning fatalities linked with family violence, children, and
motor vehicles are required by the Virginia General Assembly. The Virginia General
Assembly requires that the Chief Medical Examiner (and committee) "provide ongoing
surveillance of fatal family violence occurrences and promulgate an annual report based on
4

accumulated data"'. Information on children's death is also required to be annually
reported to the Virginia General Assembly by the Chief Medical Examiner [and
committee12. These reports should include information on "(i) violent and unnatural child
deaths, (ii) sudden child deaths occurring within the first 18 months of life, and (iii) those
fatalities for which the cause or manner of death was not determined with reasonable
medical ~ e r t a i n t ~ , "The
~ . reports concerning deaths of children will be public records,
provided there is no identifying information2. The annual reports concerning fatalities
involving family violence and deaths of children are to be supplied to the Governor and the
General Assembly. All medical examiners must also make monthly reports to the
Commissioner regarding deaths due to motor vehicle accidents3. The OCME also uses the
ME database and the information it contains for other research projects in addition to the
mandatory annual reports.
The ME dataset that was used for this project included demographic, drug, and
death information on all persons receiving a toxicological screen as a result of an autopsy,
in Virginia, during the years 2000-2004. The cases in this dataset were limited to those
persons who received a toxicological screen during autopsy because the purpose of this
study is to look at drug concentrations. Persons not receiving toxicological screens would
not have any drug information in their records. The ME dataset received for this project
consisted of 2642 individuals and 6026 records. In the original dataset, an individual had a
record for each of the drugs found during the autopsy. This dataset was reformatted to
include only one observation per case number, and this record combined all information
from the multiple observations for each case. The process used to reformat the data is
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described in Section 2.2. Once the data was reformatted, any person not receiving a
toxicological screen was removed, and the final ME dataset had 2623 observations - one
per case number.
Each record in the ME dataset contained the following information: case number,
age, gender, fatality (general cause of death), cause of death (detailed description of cause
of death), manner of death (e.g. suicide, homicide, natural, undetermined), place of injury
and place of death (regional information), premise of death (location information such as
home, water, hospital, etc.), drugs found during autopsy, concentrations of those drugs, and
the tissue where the drug(s) was detected. Some of these variable fields required major
restructuring for use in analysis, e.g. f a t a l i t y , premise o f d e a t h , and c a u s e
o f d e a t h . The reorganization of these fields is described in Section 2.2.1. Other fields
were used in the analysis in their present condition (with no corrections or restructuring),
and some fields were corrected and then used only for descriptive purposes. The initial
dataset was received as a Microsoft Excel @ file and was imported into JMP @ for initial
inspection of distributions and frequencies of the different fields. Once a general view of
the dataset was established, the data was imported into SAS @ for preparation and analysis.
2.1.2 Driving Under the Influence Dataset
The Driving Under the Influence of drugs (DUI) dataset used for this project
originally was received in two separate datasets that are both collected and maintained by
the Virginia Department of Forensic Science (DFS). The first of these datasets contained
demographic information, and the second contained drug information. These datasets were
supplied, with permission, by Dr. Joseph J. Saady and the DFS. The data contained in
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these datasets are typically used to generate frequency reports to the Virginia General
Assembly to help amend and create laws concerning the legal limits of drugs with respect
to driving. Previous uses of these datasets have included descriptive reports of
demographic information (age, race, gender, etc.) and locality reports of people suspected
of DUI in Virginia, when this information was available. 'This information is used to draw
conclusions about drivers who are using drugs and the areas where driving while
intoxicated is a problem.
At this time, there are no laws concerning the collection or maintenance of these
two datasets, but statistical reports from the DUI data are used by the Virginia General
Assembly and sometimes results in laws concerning legal and illegal concentrations of
drugs while driving. In the Code of Virginia, blood concentrations of the following
substances have been deemed illegal, "(a) 0.02 milligrams of cocaine per liter of blood, (b)
0.1 milligrams of methamphetamine per liter of blood, (c) 0.01 milligrams of
phencyclidine per liter of blood, or (d) 0.1 milligrams of 3,4methylenedioxymethamphetamine per liter of blood,'*. It is also "unlawful to drive or

operate any motor vehicle, engine or train if a blood alcohol concentration is 0.08 percent
or more by weight by volume or 0.08 grams or more per 210 liters of breath as indicated
by a chen~icaltest administered,". By collecting the information contained in the DUI
dataset, the DFS can ascertain more information about other drugs and the concentrations
that impair drivers throughout the state of Virginia.
Both the demographic and drug datasets of the DUI data used for this project
spanned the years 2000-2004. The demographic dataset contained the descriptive
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information for all persons suspected of, stopped for, and given a blood test for DUI. This
dataset included case numbers, age, race, gender, location of where the subject was
detained, and the type of court. The drug dataset contained all drug information, including
the case numbers, the drugs found in the blood test, the amount of the drug found, and
whether the drug was detected at a concentration "less than", "greater than", "not
detected", "quantitated", etc. for the amount that was reported. The drugs detected in the
blood test were screened in a precise order specified by the tier system that is described in
Section 2.2.5. The guidelines for the tier system are shown in Appendix A.
A driver can be stopped for suspicion of DUI more than one time during the fouryear period encompassed in these datasets. In order to avoid repeating information in the
datasets (including the same driver more than once), a random sample of case numbers
were sent to the DFS to look for individuals who might appear in the dataset more than
once. This potential problem is addressed in Section 2.2.4. By definition, being stopped
by a police officer for suspicion of DUI does not mean that the driver was convicted of
DUI.
The demographic and drug datasets were combined together, based on the case
numbers, to form one DUI dataset. The DUI demographic dataset originally included
12,365 individuals, but only 11,819 were unique case numbers. This problem is addressed
in Section 2.2.2. The DUI drug dataset contained 48,907 observations, but in this dataset,
an identifiable individual could have as many observations as the number of drugs tested
for during the blood test, whether or not these drugs were detected. The multiple
observations problem was not addressed until the demographic and drug DUI datasets
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were combined. When the two datasets were joined together, the pooled dataset contained
55,148 observations with all demographic and drug information in one dataset. This
dataset was then reformatted to include only one observation per case number. The
process used to reformat this dataset is described in detail in Section 2.2. There were
11,926 individuals in the new dataset, and each individuai's record contained all
information from the previous multiple observations. This DUI dataset with 11,926 unique
individuals was then merged with the 2623 unique individuals in the ME dataset for use in
the analysis of the specific drugs and their concentrations.
2.2

Problems

2.2.1 Problems with Free Text Fields
A field is defined as "a named subdivision of a record containing a specificallydefined piece of information within a systemw5.A fiee text field is a field with data
"containing no formal or predefined structure other than the normal use of grammar and
punctuation"5. Generally, free text fields should be avoided in the development of
databases because of the unlimited number of possible responses. "The data typed into the
computer is often entered in a hurry. The language includes abbreviations,jargon,
misspelled words, and incorrect grammar,"6. These multiple responses usually need to be
combined to form general categories for use in analysis. For example, these non-uniform
responses could include misspellings, different punctuation, dissimilar orderings of words,
and the use of similar or detailed explanations. Although free text fields are valid and
sometimes usable, the fiee text fields in this project required major reorganizing to make
new fields that were functional for analysis.
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Two of the free text fields in the ME dataset, fatality and premise of

death,were restructured for use in analysis. This reconstruction consisted of the creation
of a new field that combined several response levels of the original free text field. An
example of this alteration was to the field fata1it y , which contained information
regarding a general cause of death. Originally, the field contained 23 levels such as
"asphyxia: aspirationlcafk coronary", "asphyxia: mechanical/positional", and "asphyxia:
plastic bag". All three of these levels were joined to form "asphyxia" in the new variable
field, fatalnew. The field fatality initially consisted of 23 levels that were reduced
to 14 levels in fatalnew,including the new categories "asphyxia", "CO poisoning",
"vehicle", and "drug poisoning" and some of the original categories. The new variable
included the levels "alcohol/drug withdrawal", "asphyxia", "beating/blows/blunt
instrument", "burnslfire", "carbon monoxide poisoning", "cutting instrument/stab",
"drowning", "drug poisoning", "explosion", "falVpush", "gun: handgun", "lethal
injection", "undetermined", and "vehicle".
A similar alteration was made to premise of death,which contained location
information regarding the death of an individual. The initial field contained 45 responses
such as "street: adjacent", "street: alley", street: bridge", "street: ditch", "street: driveway",
"street: highway", "street: interstate", "street: nonspecified" "street: parking", and "street:
sidewalk". These 10 levels were combined to form a new category "street" in a new field,

premisenew. The 45 initial levels of premise of death were reduced to 28 levels
in premi senew by creating four new categories: "street", "water", "home", and
"hospital", and keeping some of the original categories from premise of death. The
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four new categories combined 2 1 of the original levels from p r emise o f death. An
example of how SAS 8 was used to decrease the number of levels is seen in the following
code.
if fatality = 'ASPHYXIA: ASPIRATION/CAFE CORONARY' I
fatality = 'ASPHYXIA: MECHANICAL/POSITIONAL' I fatality =
'ASPHYXIA: PLASTIC BAG' then fatklnew = 'Asphyxia';

With regard to grammatical differences, the only field in the ME dataset that
displayed this problem was cause of death. The original field cause of death
had 1724 responses for 2642 individuals, and many of these levels were different only
because of misspelled words, different punctuation, synonyms for the same words, or
listing the same drugs in a different order. Some examples of misspelled words in the

cause of death field were "intoxiciation", "intoxicatikon", "poinsoning",
"poisoining", "herion", and "cintributing". Misspellings were found by visually searching
through a frequency table of the cause of death field and looking for observations
that were similar to other observations with the only difference being a misspelling.
Once these misspelled words were identified, SAS 8 was used to scan the cause

of death field for the misspelled word, and if it was found, it was replaced with the
correct spelling. An example of how misspelled words were corrected is seen in the
following code where the misspelled word "intoxiciation" is replaced with the correct
spelling "intoxication". Not all misspelled words were corrected because there were too
many misspellings to detect them all by scrolling through the frequency tables.
Approximately 100 grammar problems were found and corrected, and 3003 changes were
made to the cause of death field for the 2642 cases in the ME dataset.

index = find(cause-of-death, 'INTOXICIATION',' i t ) ;
if index ne 0 then temp = substrn(cause~of~death,l,index-1)
II
'INTOXICATION' I I
substrn(cause~of~death,index+l3,length(cause~of~death)
1;
else temp = cause-of-death;
cause-of-death = temp;

Some observations for cause of d e a t h were only different in the punctuation.
These punctuation differences included having double spaces between words, periods at
the end of some cases, spaces between commas, and using "&", "and" "d/t", "d/t to" or
"due to" inconsistently. In all of these cases, one example was chosen as the standard
form, and the others were modified to match the standard form of the punctuation. An
example of .the grammatical fix is seen in the following SAS 8 code.

index = find(cause-of-death, 'DUE TO', 'i');
if index ne 0 then temp = substrn(cause-of-death,l,index-1) 1 )
'D/T' I I
substrn(cause~of~death,index+6,length(cause~of~death)
);
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'D/TTO', ' i t ) ;
if index ne 0 then temp = substrn(cause~of~death,l,index-1)
(1
'D/T' 1 )
substrn(cause~of~death,index+6,length(cause~of~death)
1;
else temp = cause-of-death;
cause-of-death = temp;

Using synonyms for some words also posed a problem in the cause of death
field. "A synonym is created when two different names are used for the same information
(attribute). If an attribute resides in more than one entity [record], insure that all entities
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[records] use the same attribute name,"7. For example, "overdose", "poisoning",
"toxicity", and "intoxication" all have the sanle meaning in c a u s e of d e a t h , but
different medical examiners used these words interchangeably in their description for
c a u s e of d e a t h . "Using more than one name for the same attribute causes many
problems,"7. In this example, all variations of "overdose", "poisoning", "toxicity", and
"intoxication" were changed to "poisoning" in order to provide consistency within this
field.
Yet another problem with this free text field was different orderings of words. The
field c a u s e of death contained a detailed description of the cause of death including
the drugs tha.t were attributable to death and the specific cause such as asphyxia, poisoning,
lethal injection, drowning, etc. In several instances, a detailed cause of death was the same
as another with the only difference being the ordering of the drugs. For example, one cause
of death was "acute ethanol and opiate poisoning", and another cause of death was "acute
opiate and ethanol poisoning". These two causes of death are the same for purposes of
analysis, but they appear as two different responses.
Originally, one of the main variable fields of interest for analysis, c a u s e of
d e a t h contained a large number of non-uniform levels, and only parts of it were
corrected. "Typographical errors are not trivial matters. A user can have little confidence
in a database in which many typographical errors o~cur,"~.
Because there were so many
errors in c a u s e of d e a t h , it was not the only field used to help choose the individuals
from the ME dataset to include in analysis. Other fields were used to determine the cases
where an individual died from an actual drug overdose. These fields included fa t a l n e w
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and drug l e v e l , which was renamed to amount in a process described in Section
2.2.6. Those cases where the person died of a drug overdose were the ones of interest from
the ME dataset to include in analysis. The DUI datasets did not have problems with free
text fields, but they did have problems with demographic information and missing data.
2.2.2 Problems with Demographic Fields

A demographic variable (or field) is "a varying characteristic that is a vital or social
statistic of an individual, sample group, or population, for example, age, sex,
socioeconomic status, racial origin, edu~ation,"~.The DUI demographic dataset contained
demographic information on drivers who were stopped by police for suspicion of "driving
under the.influenceWof drugs and received a blood test. When a suspect is stopped for
driving under the influence, he or she "may be required to perform field sobriety tests, and
the police officer usually asks them to blow into a Breathalyzer device to detect alcoh01"'~.
If the police officer thinks the driver is impaired and the Breathalyzer device shows no
ethanol or not enough to explain the impairment, then the driver is taken by the police
officer to a location where a blood sample is ~ollected'~.
Because demographic information does not change for a particular person, a case
number in the demographic dataset should appear only one time; however, some case
numbers were listed multiple times within this dataset. Upon investigation, it was
discovered that any change in a record was accomplished by appending an updated record
to the end of the database instead of correcting the existing entry. By appending these
"new," updated records instead of replacing them, a case number could appear more than
once in the dataset, one for every time the record was entered. To rectify this problem, the
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last record added to the database for each case was assumed to have the most current
information, and any previous records for the same case number were removed from the
dataset.
Some of the demographic information in the DUI dataset was identified as being
invalid due to laws concerning driver's license age. To possess a driver's license
(including a driving permit) in the United States, a person must be at least fourteen years of
age. The minimum driving age is usually 16, but this age varies by state1l . Farm permits
or school permits can be issued to drivers under 16 (but not younger than 14) in special
circumstances in some states12. Using age 14 as the cutoff age for possessing a driver's
license (or permit), there were some cases where the ages were too young to be legally
driving, i,e. ages 0, 8, and 13. Eleven case numbers with ages less than 14 were sent to the
DFS for verification. The ages were determined to be a clerical error, but a correct age
could not be established. Because the correct age could not be found, the ages for these
cases were set to missing. The problem of missing demographic information is discussed
in the next section, but because of the magnitude of this problem, adding the 11 missing
ages (due to clerical errors) did not pose any major problems for the dataset. These 11
cases were kept in the dataset (with missing ages) to keep the maximum number of
observations possible for analysis.
Problems were also identified with the field race. Race can be determined by
many methods, including self-report or observation by another party. In the ME dataset,
race was not recorded, but a racial description was reported in the DUI demographic
dataset. The race field in the DUI dataset was usually determined by the police officer.
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"Some jurisdictions may require that the officer check the DMV [Department of Motor
Vehicles] record, but mostly the officer decides,"13. In this dataset, race is not reported in a
standard way because it was either self-reported by the individual (from the DMV record)
or observed by the police officer; therefore, the information in the race field is prone to
error.
2.2.3 Problem with Missing Data

A nearly universal problem with datasets or databases is missing observations, and
this problem was especially apparent in the DUI datasets. The missing data problem
appeared when the DUI demographic and drug datasets were combined to form one da.taset
with all DUI information. The DUI demographic dataset contained case number,
r a c e , g e n d e r , a g e , c o u r t t y p e d e s c r i p t i o n , and c o u r t name. The DUI
drug dataset contained c a s e number, d r u g , amount, and p r e s e n c e . The datasets
were joined by matching the case numbers in each dataset to create one dataset with both
demographic and drug information.
Numerous case numbers appeared in the demographic dataset that did not appear in
the drug dataset and vice versa. When the case numbers were matched, if a case number
did not appear in the demographic dataset, then there was no demographic information to
attach to the drug information, producing instances of missing demographic data. This
missing information posed a problem because roughly half of the number of observations
had missing values for a g e ; therefore, age could not be used to accurately characterize
the DUI dataset. About 100 observations were missing all demographic data. On the other
hand, if a case number appeared in the demographic dataset and not in the drug dataset,
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then there was no corresponding drug information for that case number when the two
datasets were combined. Approximately 6000 of the 11,926 cases had missing drug data,
which created a smaller pool of observations to select individuals for the analyses.
Because of the high percentage of missing demographic information for a g e , the 11 ages
that were set to missing (mentioned in the previous section) did not notably increase the
amount of missing demographic data.
The ME dataset had some missing data, but a far lower percentage of the
information was missing in this dataset. For example, g e n d e r had only one missing
observation. There was not much missing data in the ME dataset, and consequently, it was
not considered problematic for .the analysis.
2.2.4 Problem with Independence Assumption
"Independence of observations refers to the notion that the value of one datum is
unrelated to any other datum. In other words, knowing the value of one observation gives
.
an individual appear in the
you no information about the value of any ~ t h e r , " ' ~Having
dataset more than once would violate the assumption of independence and cause problems
in the analysis of the datasets. If any individual had been stopped for suspicion of driving
under the influence more than once, then he or she appeared in th.e dataset under two
different case numbers. Because an individual could be stopped for suspicion of DUI more
than once over the course of four years and thus, appear in the dataset more than once, a
random sample of 10% (1 192) of the case numbers from the combined DUI dataset was
sent to the DFS to cross-reference the case numbers with last names, looking for people
who had been stopped more than once. The purpose for doing this cross-reference was to
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estimate the number of individuals with multiple traffic stops and the impact (if any) on the
independence assumption.
The results of this cross-reference test were inconclusive. The dataset "does not
capture the proper data to ensure the query would produce good

result^"'^.

Because a

unique identifier, such as social security number, was not collected in this dataset, the
search could only be by name, gender, race, and date of birth". Birthdates and names are
not unique identifiers (neither are race are gender), so that combination is reliable to
determine if people appear in the DUI dataset more than once. No combination of those
four variables would guarantee unique individuals. From the list of case numbers provided
to the DFS, "the names do not match between submission 1 and 2, submission 1 might
have J. Smith with DOB of 6/12/1956 and Submission 2 might have John Smith without at
DOB, so there is no reliable way to get this data [meaning the reoccurrence of an
individual in the data set^"'^.
2.2.5 Problem with Data Completeness (Underestimation)
Drugs listed in the DUI drug dataset were found using a tier system designed by
Dr. Joseph J. Saady and the DFS (Appendix A). Because the DFS adopted this tier system
to rapidly respond to DUI requests and maintain quality and validity within the program
and to save time and money for the Commonwealth, some of the drug information in the
DUI dataset is underestimated. Underestimation is "an estimation that is too low"I6 or "an
estimate that is less than the true or actual ~alue,"'~.
The tier system was designed so that once a drug, or group of drugs, was found at a
concentration high enough for probable conviction of DUI, no other testing was done to
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detect other drugs. The first drug tested was always ethanol, and if ethanol was found at
the cutoff concentration (0.09 %), then the blood was not tested for the presence of other
substances. Thus, there was a potential for all drugs other than ethanol to be
underestimated. If the concentration of ethanol was not sent or high enough for probable
conviction, then tests were done for a second group of drugs (Level I1 drugs). Level I1
drugs include, but are not limited to, Amphetamines, Barbiturates, Cannabinoids,
Benzodiazepines, and Opiates. If no Level I1 drugs are found at a concentration high
enough for probable conviction, then the blood is tested for Level I11 substances, such as
Antihistimines, Antidepressants/Antipsychotics,hypnotics, muscle relaxants, and
ketamine. If no Level I11 drugs are found at an illegal concentration, the blood is no longer
tested and .the drug information is likely not sufficient evidence for conviction.
This tier system presents an underestimation problem for the DUI dataset because
the number of drugs found is clearly less than the "true or actual"16 number of drugs that
were present in an individual at the time of the traffic stop. Underestimation is not a
problem for ethanol because all blood samples were tested for ethanol. Using the tier
system's testing protocol causes Level I1 and Level I11 drugs to be underestimated, but due
to the design of the tier system, Level I11 drugs will be more severely underestimated than
the Level I1 drugs.
By using the tier system, the effect of underestimation on the DUI dataset results in
several problems. First, the number of drugs that were found in the DUI dataset and the
number of individuals using these drugs are both measures that are underestimated. The
concentration levels are possibly underestimated as well in this dataset because while the
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range of concentrations could span the entire range of drugs possibly found in blood, it is
more likely that if more drugs were detected in more cases then the ranges of the drugs
would expand.
A second problem with underestimation occurs with ,thereported concentration.
When detecting a drug, the tier system's testing protocol (Appendix A) specifies lower and
higher reporting limits for each drug (or group of drugs). The guidelines for the testing
protocol instruct the laboratory to stop testing for a drug if the upper limit is reached. If
the lower reporting limit for a drug is detected, then the lower reporting limit amount is
recorded in .the amount field. "Less than" is recorded in the p r e s e n c e field to report
that the drug was detected below the lower reporting limit for that drug. On the other
hand, if an upper limit for a drug is reached, then the upper limit amount is recorded in
amount. "Greater than" is recorded in p r e s e n c e . When either of these situations takes
places, an adjustment had to be made to the concentration amount to accurately reflect the
amount of drug in a person's system. For concentrations that have a "less than" value for
p r e s e n c e , the concentration is considered to be one half of the concentration reported,
and for concentrations with a "greater than" value for p r e s e n c e , 15% of the amount
reported is added to the concentration. This rule was determined by Dr. Saady in order to
use the most accurate concentrations. The details of this adjustment are discussed in the
last paragraph of Section 2.2.6.
2.2.6

Problem with Converting Character Fields to Numeric Fields
The ME dataset was joined with the DUI datasets by concatenating the two

datasets. "Concatenating is combining two or more data sets one after the other into a

single data set. The number of observations in the new data set is the sum of the number
of observations in the original data sets, and the order is all the observations from the first
data set followed by all observations from the second data set and so on,"'7. Problems
with concatenating datasets occur when some fields appear in one dataset but not in the
others and when some fields have different characteristics, attributes, or formats in the
datasets. In order to concatenate the datasets, it must be determined what information
should be assembled and collected from each of the source datasets to have in the final
combined dataset. After determining what information to keep from each dataset, a format
needs to be determined for the final dataset. Since all datasets being concatenated must fit
into the chosen final format, any number of the fields from these datasets needs to be
modified, including field names, types, and contents. Any extra information from either
dataset is removed before concatenating the two sets.

In the ME dataset, the original variable field drug level contained a
concentration amount and the units of measurement for each drug found. Thus, drug
level was a character field. A character field can contain any series of letters, numbers,

and special characters1*. The corresponding variable field amount in the combined DUI
dataset was a numeric field, "containing only numbers, including numbers in E-notation,
and sometimes a decimal point or minus sign,"'* because it contained only the
concentration amount with no associated unit of measurement. Because amount (from
the DUI dataset) was a numeric field and d r u g level (from the ME dataset) was a
character field, d r u g level was converted to a numeric field in order to combine the
two datasets. This conversion created the character to numeric problem discussed next.
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To facilitate the conversion from character to numeric, new fields were created to
contain the numeric part "concentration" of drug level and the character part "units of
measurement" of drug level from the ME dataset. The concentration field of drug
level (from the ME dataset) was named amount to match the name of the field in the
DUI dataset, and unit was the field created for the unit of measurement.
Some of the case numbers in the ME dataset did not have a unit of measurement
associated with the concentration, so a standard unit was fixed to each concentration. This
standard unit of measurement was determined by the specific drug and the tissue where the
drug was detected. Table 1 shows the tissues and the corresponding units of measurement.
Certain cases in the ME dataset did not have a specific concentration and contained only
"present" for drug level. These cases were not used in analysis for that drug because
an exact concentration amount could not be determined.
Table 1: Tissues and the Corresponding Unit of Measurement

Unit of Measurement

Tissue

Drug
Ethanol

All

Grams % (gI1OOmL)

All (except ethanol)

Bile

mgkg

All (except ethanol)

Blood

mg/L

All (except ethanol)

Brain

mgk2

All (except ethanol)

Gastric

mg/L

All (except ethanol)

Liver

mg/kg

All (except ethanol)

Urine

mg/L

All (except ethanol)

Vitreous

mg/L
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In the DUI dataset, amount was kept as numeric, and an additional field was
created for the unit of measurement. In a blood test, the unit of measurement for all drugs
is "rng/L" with the exception of ethanol, which is measured in "grams percent"'g. This
standard unit of measurement was added to the created field unit for all observations in
the DUI dataset.
Another field in the DUI dataset was presence,and this field characterized
amount as "less than" or "greater than" the concentration reported, as "quantitated" at

that concentration, or "not detected". If presence was labeled as "less than", the
amount was estimated to be one half of the value reported, which was usually the lower

limit of detection. If presence was labeled as "greater than", then amount was
calculated to be 15% higher than the reported concentration, which was usually the upper
limit of detection. If presence was "not detected", then those cases were not used for
the analysis of the particular drug. "Quantitated" values for presence were used as the
values were reported. The field presence was only found in the DUI dataset. For the

ME dataset, presence was always set to missing, and amount was assumed to be
"quantitated."
2.3 Creation of New Fields (Compatibility for Concatenating)
Many new fields were created to use during analysis. These fields were created by
grouping levels of the original variable fields, splitting existing fields into separate fields,
or using information from one variable field in order to create multiple fields to divide the
information into a more usable format.
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The ME dataset was originally designed so that a case number could appear more
than once in the dataset, with the maximum number of observations per case number equal
to the number of drugs found during an autopsy. The original DUI drug dataset was
designed in the same manner as the ME dataset, with the possibility of more than one
observation per case number, and the maximum observations per case number equal to the
number of drugs tested in the blood sample. When the two DUI datasets were merged
together, the demographic information for a case number was replicated for the number of
observations for that case in the DUI drug dataset. Both the ME and the combined DUI
datasets had the possibility for multiple observations per case. For analysis, it was needed
to combine the multiple observations for each case into a single observation that contained
all of the pertinent information for each individual from the many observations.
Converting these datasets from multiple observations per case number into a
dataset that had only one observation per case nuniber involved the creation of 695 new
variable fields to create a field for each of the 139 drugs, their concentrations, their
presences, and their unit of measurement. Five arrays, each consisting of 139 fields (one
for each of the 139 drugs found in either dataset), were created to sift through the multiple
observations to combine all of the information into one observation for each case number.
The first array, names, contained the names of all 139 drugs and was used to compare to
the field d r u g to check whether or not a drug was listed (found) for a particular case
number. The next array, d r u g s , contained 139 fields which either contained a "1" if the
drug was listed for a case number or "." if the drug was not listed. The array a m o u n t s
contained a numeric value for the concentration level, and l e v e l s contained a unit of
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measurement for each drug found. Each of these two arrays, a m o u n t s and l e v e l s ,
contained 139 fields to match each of the 139 drugs. The last array, p r e s s , contained the
information from the DUI field presence. Since p r e s e n c e was not in the ME dataset,
when the two datasets were combined, press was set to missing for any observation that
came from the ME dataset. The field names in all of the arrays (except d r u g s ) were
distinguished by the name of the drug followed by an underscore and then a letter that
differentiated the variable fields between each array. The field names in d r u g s did not
have an underscore or letter; they were merely the drugs themselves. For example, the
fields in drugs include names like "acetaminophen," "ethanol," and "gammahydroxybutyrate." In the other arrays, the fields included names such as
"acetaminophen-n" for names, "acetaminophen-c" for a m o u n t s , "acetaminophenq"
for p r e s s , and "acetaminophen_l" for levels. The SAS 0 code that illustrates this
process follows the next paragraph.

SAS @ was then used to create a single observation from the multiple observations
by using a loop that retained the case number. If the subsequent observation and the
previous observation had the same case number then the information for those records
were combined. The arrays mentioned previously allowed for the new record (a single
entry per case number) to contain information about whether a drug was tested ( d r u g s ) ,
the concentration (amounts), the unit of measurement ( 1eve 1s), and the presence
( p r e s s ) for each drug. The following SAS 0 code shows how the DUI dataset was
transformed from a dataset with multiple observations per case number to a dataset with
only one observation per case number. The SAS 0 code for the ME dataset differs slightly
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due to the different variable fields in the dataset. The full SAS 09 code can be seen in
Appendix D.

if first.case-number then do;
do i = 1 to 139 by 1;
drugsIi1 =
amounts{i} =
levels{i) = " ;
press{i} =
number-of-drugs = 0;
end;
end ;
do i =1 to 139 by 1;
if drug=upcase(names{i)) then do;
drugs{i}=l;
amounts{i}=amount;
levels{i} = unit;
press{i} = presence;
number-of-drugs = number-of-drugs+l;
end ;
end;
if 1ast.case-number then output;

.;
'

I

.;

;

Other fields were also created for this project. As mentioned earlier, the variable
fields f atalnew and premisenew were both created in the ME dataset to correct the
original fatality and premise of death fields. The field fa talnew was created
to assist in subsetting the data into separate drug datasets for analysis. Premi senew was
created to have location information for the cause of death that could be used in the
analysis. The two datasets (ME and DUI) contained some of the same information in
fields with different names, so new fields were created to aid in combining the two
datasets. For example, in the ME dataset, the information regarding a person's gender was
in a field called sex,and in the DUI dataset the field was called gender. A new field
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g e n d e r was created in the ME dataset and set equal to the values from sex. The field
sex was then dropped from the ME dataset.

As mentioned in Section 2.2.6, d r u g l e v e l (ME dataset) was separated into two
separate fields. The numeric piece of information (the part containing the concentration)
became a m o u n t , which was the same in the DUI dataset. The field u n i t was created for
both datasets, but the values for each dataset were different. The details creating the field
u n i t for each of the datasets was discussed in Section 2.2.6 with the problem of
converting character fields to numeric fields. Another variable field, d a t a b a s e , was
created in each of the datasets (ME and DUI). The database field contained character
information regarding the original dataset affiliation and was used as an identifier of the
source dataset after the ME and DUI datasets were combined.
2.4

Final Numbers

2.4.1 ME Dataset
The ME dataset initially contained 6026 records, 2642 unique case numbers, and
15 variable fields in a Microsoft Excel @ file. These fields contained information on age,
race, gender, fatality, cause of death, premise of death, place of injury and place of death,
drugs detected during an autopsy, drug concentration, and tissue where the drug was
detected. After encountering numerous problems with the fields in the ME dataset, some
of the fields were corrected for use in analysis.
The fields, f a t a l i t y and p r e m i s e o f d e a t h , were restructured by
combining multiple levels of the original free text fields. Creating new fields, such as
f a t a l n e w and p r e m i s e n e w combined many of the original levels (responses) into a
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smaller number of levels in each of the two fields. Examples of combining the levels were
discussed in Section 2.2.1 as well as other free text problems.
The new field fatalnew was used as a filter for the ME dataset to remove those
persons who did not die from "drug poisoning". The purpose of premi senew was for
descriptive information on the location for the cause of death.
Other free text problems encountered in the cause of death field consisted of
many types of grammatical errors including misspelled words, different punctuation,
different orderings of words, and synonyms for specific words. Once these grammatical
problems were addressed, cause of death was used as another filter to create the
specific drug datasets for use in analysis. Approximately 100 grammatical errors were
corrected in the cause of death field. Section 2.2.1 described the details of the free
text problems encountered and the respective fixes to these problems.
Some new fields were created in order to match variable field names between the
two datasets because some fields were designed as character fields for one dataset and as
numeric for another dataset. This problem was addressed in Section 2.2.6. An additional
695 fields were created to keep track of the 139 listed drugs and their information
including names, whether a drug was detected during an autopsy, the concentrations of the
drugs, units of measurement, and information regarding the "presence" of the drugs
(Section 2.3). The 139 "presence" variable fields were created to use the information
regarding lower and upper recording limits from the tier system from the DUI dataset. The
array consisting of the 139 names of drugs was only used to compare the listed drug with

29
the d r u g field in each of the two datasets to see whether it was detected in an individual.
Once the comparison was made, these 139 fields were deleted from the filial dataset.
Some specific names of drugs in the ME dataset were renamed to match the names
of the same drug in the DUI dataset. An example of this correction was
"methylenedioxyamphetamine" which was changed to "mda". Not all of these drugs were
used for analysis, but they were changed in the dataset for possible future use. Nineteen
records in the ME dataset were removed from the dataset because the cases did not receive
a toxicological screen as a result of an autopsy.
After all of these corrections and amendments were made, the final ME dataset
consisted of 2623 records, 2623 unique individuals, and 577 variables.
2.4.2 DUI Dataset
The DUI dataset originally consisted of two datasets - one with demographic data
and one with drug data. The DUI demographic dataset contained 12,365 records, but the
records were not 12,365 unique individuals. In the demographic dataset, 11,819 case
numbers were distinctive. Information in the DUI demographic dataset included case
number, age, gender, race, court type, and court name (location of jurisdiction). The DUI
drug dataset consisted of 48,907 records, and in this dataset, a case could have multiple
observations up to the number of drugs tested for in the blood sample. The variable fields
in the drug dataset included case number, drugs detected during blood test, concentration
of drug, and presence of the drug.
The 11,819 unique case numbers from the DUI demographic dataset were matched
with the case numbers in the DUI drug dataset to combine the two datasets into one dataset
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with all possible information. Some of the case numbers appeared in one or ,the other of
the two datasets (demographic and drug), but not in both. When this happened, sections of
data in the combined dataset were missing. A section of case numbers had drug
information with no demographic information and vice versa. This resulted in a problem
with missing data (Section 2.2.3). Having missing drug data was more common than
having missing demographic data, but both situations occurred when the two datasets were
combined. Once the two DUI datasets were combined into one dataset, the resulting
dataset had 55,148 records.
Other problems needed to be addressed in order to combine the collective DUI
dataset with the ME dataset. These problems included creating new variable fields (both
datasets) (Section 2.3 and 2.4.1), addressing problems with underestimation and
independence (DUI only) (Sections 2.2.5 and 2.2.4), and converting character fields to
numeric fields (ME only) (Section 2.2.6). After these problems were addressed and
amendments were made, the DUI dataset needed to be reformatted to include only one
observation per person. (When the demographic and drug datasets were combined, the
drug dataset contained multiple observations per case, and the demographic information
was duplicated to match the nuniber of observations in the drug dataset for each record.)
By reformatting the DUI dataset, each case number appeared only one time, and each of

these records contained all the data for each drug tested and detected. This final dataset
had 1 1,926 records and 577 variable fields. Close to half of the records (-6000) had
missing drug information, and about other 100 records had completely missing
demographic information.
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2.4.3 Combined Dataset
With both the DUI and ME datasets in formats compatible with each other, the two
datasets could be joined together for ease of analysis. The joint dataset that included all
2623 ME records and 11,926 DUI records, and had 14,549 records total. This dataset
included all individuals from the source datasets, including some individuals from the ME
dataset who did not die from "drug poisoning". Using the variable field fa talnew as a
filter, 70 persons having a cause of death other than "drug poisoning" were
eliminated from the dataset. The final dataset consisted of 14,479 total records and 577
variable fields from either the DUI or the ME dataset. These records compose the base
dataset from which all of the smaller .drug datasets were generated.

CHAPTER 3
Analysis of the Drug-Specific Datasets
3.0

The Analysis of the Combined Dataset
This chapter begins with an introduction of the combined dataset used for the

analyses and the process that was used to select the smaller, drug-specific datasets. A short
description of the combined dataset, including the number of observations from each of the
contributing datasets (ME and DUI), and the variable fields in the final dataset are
presented in Section 3.1. The remainder of this section (Section 3.1) describes how the six
datasets (one for each drug of interest) were created. The methods section (Section 3.2)
details the process used to break down each of the six datasets into categories to compare
the concentrations of the drug between the two source datasets (ME and DUI) and between
each of the three drug pattern groups. After specifying the process used to divide each
dataset into the drug pattern groups, Section 3.2 describes the statistical methods that were
used for each of the six datasets. Section 3.3 contains the results of the analyses of the six
drug-specific datasets. This section is composed of six parts - one for each of the drug-
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specific dataset. Section 3.4 summarizes the results from all six analyses and gives general
conclusions of all analyses.
3.1

Introduction
The original ME and DUI datasets were combined into a final dataset that was

subsequently divided into six smaller datasets (one for each drug of interest). The final
dataset contained 14,479 individuals and 577 variable fields. (There were a couple of
additional fields added to the drug datasets for transformation purposes and combining of
the drug pattern groups.) The variable fields in the final dataset included case number,
a g e , r a c e d e s c r i p t i o n , c o u r t n a m e , c o u r t type d e s c r i p t i o n ,
c u r r e n t d a t e , c a u s e o f d e a t h , m a n n e r o f death,date o f i n j u r y ,
date o f d e a t h , p l a c e o f i n j u r y , p l a c e o f d e a t h , f a t a l n e w ,
pr emi senew, g e n d e r , d a t a b a s e , c o u n t(used to determine how many corrections

were made to the c a u s e o f d e a t h field), bac (listed the tissue where the drug was
detected), 139 variable fields that indicate the name of the drug, 139 fields that give the
concentrations of each of the drugs, 139 fields with the unit of measurement, 139 fields that
give information on presence of the drug, number o f drugs (a counter field that
specifies the number of drugs that were detected in someone's system), i n d e x f a t a l
(denoting whether or not the c a u s e o f d e a t h field was attributable to a drug
poisoning), and g r o u p (indicates whether the individual had the only the drug of interest,
the drug and ethanol, or the drug and any other combination of drugs). The variable field
g r o u p is discussed in more detail in Section 3.2. (A table with all of these variable fields
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and a description is seen in Appendix E.) Out of the 14,479 cases in the final dataset, 2553
came from the ME dataset and 1 1,926 came from the DUI datasets.
As mentioned in Chapter 1, there were six drugs of interest for this project. These
drugs were diphenhydramine, cocaine, oxycodone, hydrocodone, methadone, and
morphine. A separate dataset was created for each of the six drugs; each dataset was a
subset of the final combined dataset where the subset contained all persons with the drug
of interest. These six datasets were used to assess differences in concentrations of the drug
of interest between the ME and DUI datasets and between the three drug pattern groups.
Initially, the ME dataset contained cases that included other tissues such as liver, brain,
urine, etc. These tissues were sampled when a blood sample was not available2'. Because
of differences in the unit of measurements between various tissue sources, only those
samples taken in blood were used to compare concentrations since all individuals in the
DUI dataset received blood tests. (Because blood was the oly tissue sampled for in the
DUI dataset, any individual from the DUI dataset who tested positive for the drug of
interest was included in the respective drug dataset.)
3.2

Methods
Each dataset was created by excluding individuals from the final combined dataset

that did not have a positive screen for the specific drug for the analysis. First, individuals
who did not receive a toxicological screen as a result of an autopsy were excluded from the
ME dataset prior to combining the ME and DUI datasets. For the ME dataset, a second
inclusion criterion was that individuals must have died from a drug-related death due to the
drug of interest (f a t a l n e w must have "drug poisoning" as the factor). Third, individuals
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who did not have the specific drug of interest in their system were excluded (i.e., the
concentration was zero, missing, or "not detected"). Finally, some individuals were
excluded based on clinical judgment. "It was a clinical decision. If a particular drug level
was too low, it was determined to be an incidental finding and not a cause of death, and the
case was excluder2'. This clinical decision was only for cases in the ME dataset. A
detailed flow chart of the filtering system used to create the six smaller datasets is seen in
Appendix B.
Following the creation of the six drug-specific datasets, the cases were divided into
three drug pattern groups; the groupings were determined using clinical criteria. "The
groups were chosen based on practicality. We definitely wanted to have the drug alone
because it is informative and previous studies have been done with the drug alone. Ethanol
is the most abused drug and there are many circumstances of ethanol and a drug. Because
ethanol is so prevalent, that was the reason for the second group. The "poly pharmacy"
drug pattern group was chosen because there was no other option

Using this

criteria, a new field, g r o u p , was created to distinguish between the different drug pattern
groups. The first category in g r o u p consisted of those individuals who had only the drug
of interest detected in their system. In the DUI dataset, all individuals were initially tested
for ethanol, so for an individual from the DUI dataset to be in Group 1, the concentration
for ethanol (and all other drugs) had to be "0 mg/L" or "missing" in the blood sample.
(Section 2.2.5 details the tier system and the process for which drugs were screened in the
DUI dataset). Group 2 contained individuals who had both the specific drug and ethanol in
their system. Finally, Group 3 contained any other combination with the drug of interest
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and thus, was considered a poly pharmacy group. All three of the created drug pattern
groups were mutually exclusive, i.e., if an individual was in one of these drug pattern
groups, then the same individual could not be in another drug pattern group (within the
same drug dataset). It is important to note the possibility that individuals may appear in
multiple drug-specific subgroups because of the nature of the poly pharmacy group (Group

The analysis of the data began with a normal quantile plot constructed for each drug
pattern group and each source dataset to assess if the blood concentration data followed an
approximately normal distribution. Because the blood concentration data is bounded at
zero and because of the likelihood of unusually high concentrations (especially in the ME
dataset), it was anticipated that the blood concentration data would be positively skewed.
If the blood concentrations were skewed positively then the drug concentration data were
log-transformed in an attempt to transform the data to be approximately normal. The
means of the log concentrations of all drugs for each of the drug pattern groups were
calculated with the equivalent untransformed concentration amount. The log-transformed
data was reported in "log (mg/L)" units, and the untransformed data was reported in
"mg/L" units. For ease in interpretation of the concentrations, the untransformed (original
metric) data in lieu of the log-transformed data is given whenever an amount is reported.
Using a statistical "rule of thumb," the minimum number needed to calculate a
confidence interval, is 12. "The width of a confidence interval, involving estimation of
variability and sample size, decreases rapidly until 12 observations are reached and then
decreases less rapidly"22. In certain cases, samples sizes as small as 11 were accepted
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based upon clinical judgment. Otherwise, if a drug pattern group had less than 12, an
adjustment had to be made to the drug pattern groups. The options for adjustments were to
combine the drug pattern group with a different drug pattern group or to omit that category
from the analysis of that drug, so the number of drug pattern groups was either three (the
number created) or two (if two drug pattern groups were combined or one was left out of
the analysis).
A quantile box plot is a plot that summarizes the distribution of points for a specific
factor level. The two ends of the box display the 25thand 75thquartiles. The space
between these two ends is known as the interquartile range, and the line that crosses the
middle of the box is the median (or 5othpercentile). Each box has lines that extend from
each end of the box, called whiskers, that mark the furthest points in either direction23.
Quantile box plots of the concentrations were produced for each of the drug pattern groups
and each source dataset for both the log-transformed and untransfonned data. The box
plots were used to visually inspect for overlaps between the source datasets, within each
drug pattern group. The box plots seen in the following sections show the concentrations
before and after the log transformation. Each pair of box plots (transformed and
untransfonned) is displayed on the same scale, and some of the box plots show expanded
versions for the DUI dataset. When the DUI datasets were put on the same scale as the ME
datasets, the plots of the DUI data appeared condensed, and thus, it is frequently difficult to
see the details of the plots.
A two-factor analysis of variance (ANOVA) model was fit to each of the six
datasets in order to detect statistical differences between the mean blood concentration for
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the two source datasets (ME and DUI) and for the three drug pattern groups. For this
model, the dependent variable field (y) is always the log blood concentration of the drug of
interest (due to the non normality of the untransformed concentrations) and the independent
fields are database (P) and group (a). An additional term was also added to allow for
an interaction (a p) between database and group. The two-factor ANOVA model is
given,
Yiik =~u+ai
+Pi+(aP),j +gii,

where y;k is the log of the drug concentration from the ithdrug pattern group (i = 1,2, 3),
the jth source dataset (j= 1,2), and the kthobservation. The grand mean of the log
concentrations is p, ai is the effect due to the ithdrug pattern group (1 = drug only, 2 = drug
and ethanol, 3 = drug with any other drug combination), P, is the effect due to the jth source
is the interaction effect between the ithlevel of a and the

dataset (1 = ME, 2 = DUI),
jth level of p, and

is the random error associated with y;,k. The assumptions for the two-

factor ANOVA model are that the errors (Cijk)are independent and identifcally distributed

-

~
with a normal distribution ( E ~ ,N(0,02)).
When fitting the two-factor ANOVA, an interaction term was considered significant
at a = 0.10, and thus, it was retained in the model; otherwise, the interaction was removed
from the model, and the model was rerun. The alpha was set at 0.10 for testing the
interaction in order to mitigate the possibility of inappropriately removing the interaction
term (a Type I1 error). In this case that the interaction term was removed from the model,
the comparison of the two source datasets and the comparison of the three drug pattern
groups is a straight-forward test of the main effects. A Tukeyysmultiple comparison
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procedure was used to assess the nature of differences between the three levels of the drug
pattern groups while controlling the overall alpha level.
If the p-value associated with the interaction was less than 0.10, then the
comparison of the source datasets and the drug pattern groups were made within the
interaction term. In other words, because of the presence of the interaction, the comparison
of the source datasets must be made within each of the drug pattern groups. Similarly, the
comparison of the drug pattern groups must be made within each of the source datasets.
Again, a Tukey's multiple comparison procedure was used to determine individual
differences while controlling the overall alpha level. Tukey's multiple comparison
procedure makes all possible pairwise comparisons to detect any differences. The results
of the ANOVA models and the Tukey tests are discussed in each of the sections respective
to the drug of interest.
Residual by predicted plots and normal quantile plots of the residuals for all six
drug datasets are seen in Appendix C. The residual by predicted plots are inspected to see
if the residuals are randomly scattered above and below the horizontal line at zero and that
there is not systematic pattern to the residuals; this is a check of the common variance
assumption and of the model adequacy. The normal quantile plots of the residuals are used
to verify the normality assumption of the residuals for the ANOVA model.
3.3

Results
The results section is divided into six subsections - one for each of the drug-

specific datasets. Each section contains a short description of the dataset, a table with the
number of observations per drug pattern group and per source dataset, and a table of
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demographic information for each drug pattern group divided by dataset (ME and DUI).
The normal quantile plots before and after the log transformations for each drug pattern
group and source dataset are displayed as well as the pairs of box plots; these box plots
show the effect of using the log-transformed concentrations and the untransformed
concentrations for the ME and the DUI datasets and the levels in the group field. The
results of the analyses will vary depending on the drug of interest.
3.3.1 Diphenhydramine (Level 111)
"Diphenhydramine is an antihistamine, used to treat allergies, motion sickness,
allergic reactions, insomnia, cough, nausea, and phenothiazine drug-induced abnormal
muscle movement,"24 Diphenhydramine is commonly known by its trade name, Benadryl
@, and is frequently used by cancer patients, people with allergies or nausea, or by people

who have Parkinson's disease24. "Diphenhydramine (DPH)-related deaths in adults are
extremely rare, and detailed autopsy studies are rarer

however, there were some

cases in the ME dataset with a cause of death attributable to diphenhydramine.
Using the filters mentioned in Section 3.2, the diphenhydramine dataset generated
from the final dataset consisted of 2 13 cases. Of these 213 individuals, 102 came from the
ME dataset and 111 came from the DUI dataset. Table 2 breaks down .the 2 13 observations
by drug pattern group and by dataset (ME or DUI). Because there were only two
individuals in Group 2 for the ME dataset, Groups 2 and 3 were combined for the analysis
of diphenhydramine. The combined group (Groups 2 and 3) consisted of 89 individuals
from the ME dataset and 85 individuals from the DUI dataset for a total of 174
observations in Group 2. Table 3 shows the categorization of the demographics for the two
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source datasets and the two new drug pattern groups. These two drug pattern groups are
Group 1 (diphenhydramine only) and the new group (diphenhydramine with any
combination of drug - including ethanol) that combined Group 2 and Group 3. In this
table, the field age is displayed as a range of the youngest and the oldest, while the
gender and race rows give frequencies of the individuals that fit into each of those

categories. The percentages shown in this table are the percentage of ,the category (cell) in
the source dataset.
Table 2: Number of Observations for Categories in the Diphenhydramine Dataset

Group
1
(diphenhydramine only)
2
(diphenhydramine and ethanol)
3
(any other combination with
diphenhydramine)
Total

ME

DUI

13

26

2

31

87

54

102

111

Table 3: Demographics on the Diphenhydramine Dataset

Source Dataset
Drug Pattern
Group
Race

Gender
Age (in years)

White
Black
Other
Missing

1

--

ME
Combined
(2&3)

--

DUI
Combined
(2&3)

89 (87.3%)

13 (1 1.7%)
3 (2.7%)
0
10 (9%)

54 (48.6%)
3 (2.7 %)
0
28 (25.2%)

7 (6.9%)

32 (31.3%)

11 (9.9%)

35 (31.5%)

Female

6 (5.9%)

57 (55.9%)

5 (4.5%)

23 (20.7%)

Missing

0

0

10(9%)

27(24.3%)

Range

18-66

14-87

18-60

20-69

--

--

--

--

13 (12.7%)

Male

The normal quantile plots for the drug pattern groups and the source datasets for
diphenhydrarnine revealed a non-normal distribution for most of the categories. This type
non-normality is typically corrected by a log transformation, so a log transformation was
employed on the concentration of diphenhydrarnine. The normal quantile plots (before and
after log transformation) are seen in Figures 1,2,3, and 4. From these figures, the log
transformation appears to work very well; thus, the ANOVA was run on the logtransformed concentration for diphenhydrarnine. The first normal quantile plot for each of
these figures shows the data for diphenhydranline concentration before the log
transformation.
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Figure 1: Normal quantile plots for DUI Group 1 (diphenhydramine only) before and after log
transformation
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Figure 2: Normal quantile plots for DUI Groups 2 & 3 (diphenhydramine with any drug - including
ethanol) before and after log transformation
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Figure 3: Normal quantile plots for ME Group 1 (diphenhydramine only) before and after log
transformation
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Figure 4: Normal quantile plots for ME Groups 2 & 3 (diphenhydramine with any drug - including
ethanol) before and after log transformation

The box plots seen in Figure 5 are the set of box plots for the concentriition of
diphenhydramiae for Group 1 for log-transformed and untransfornied data. Each of the
two sets of these box plots has been plotted on the same scale to simplify visual
comparison. Figure 6 shows an expanded box plot for DUI Group 1 (untransformed data).
Figure 7 shows the pair of box plots for the combined group - Groups 2 & 3 - for the ME
and DUI datasets. The box plots in Figures 5 and 7 show the concentrations of the log of
diphenhydramine concentration (left side) for each of the drug pattern groups in each of the
source datasets, and the untransformed data (right side). Figure 8 shows an expanded box
plot for the combined drug pattern group for DUI where the y-axis is modified to
accommodate the inspection of the distribution.
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For ME Group 1, the mean (with log transformation) is 1.53 log (mg/L) units (*
0.413 standard errors) which is equivalent to 4.62 mg/L, and the mean of DUI Group 1 is 2.406 log (mg/L) units (* 0.292 standard errors) [0.09 mg/L]. The range of the
concentrations for the ME Group 1 was -0.942 log (mglL) units to 3.784 log (mg/L) units
[0.39 mg/L to 44 mg/L], and the range for the DUI dataset for Group 1 was -4.605 log
(mg/L) units to 0.742 log (mg/L) units [0.01 mg/L to 2.1 mg/L]. (These means and
standard errors are from the log-transformed concentrations and from untransforming those
means; they will not necessarily match the raw means and standard errors seen in the table
with the results of the Tukey tests.) There does seem to be some overlap between the two
datasets in Group 1, but this is not enough evidence to tell whether or not there is a
significant difference between the two datasets.
DUI
Group 1
Diphenhydramine
Log Transfornled

ME
DUI
Group
1
Group 1
Diphenhydramine Diphenhydramine
Log Transforn~ed

ME
Group 1
Diphenhydramine

-1

-2
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-4

-5

Figure 5: Box plots of Group 1 (diphenhydramine only) for DUI and ME - log transformed and
untransformed data
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Figure 6: Expanded box plot for DUI Group 1 (diphenhydramine only) - untransformed data

Figure 7 shows the pair of box plots for log-transformed and untransformed data for
Groups 2 & 3 combined. The mean of the concentration for the ME combined drug pattern
group is -0.05 log (mg/L) units (* 0.158 standard errors) [0.95 mg/L] and the ragge is from
-0.2 19 log (mg/L) units [0.04 mg/L] to 3.784 log mg/L [44.0 mgIL]. The mean of
concentration for diphenhydramine for the DUI combined drug pattern group is -3.006 log
(mg/L) units (k 0.162 standard errors) [0.05 mg/L] and the range is from -4.605 log (mg/L)
units [0.01 mg/L] to 0.262 log (mg/L) units [1.3 mg/L]. The low ends of each of these
ranges are close, so there is a definite overlap, but the high end of the ME range is much
larger than that of the DUI range.
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Figure 7: Box plots for Groups 2 & 3 (diphenhydramine with any drug including ethanol) for DUI
and ME - log transformed and untransformed data
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Figure 8: Expanded box plot for DUI Groups 2 & 3 (diphenhydramine with any drug - including
ethanol) - untransformed data

When the ANOVA model was fit to the diphenhydramine data it was determined
that the interaction between the group and database fields was significant at the pre-
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determined a = 0.10 level (p-value = 0.0793); therefore, it was kept in the model, and
assessment of the differences in the blood concentrations between the drug pattern groups
and the source datasets was within the interaction. The plot of the means in Figure 9
shows the interaction of the two fields group and database. From Figure 9, it can be
seen that concentration of diphenhydramine between the ME and DUI datasets in Group 1
is a larger difference than ,the difference between the ME and DUI datasets in the
combined drug pattern group.
Plot of the Means
Log-transformed concentration of diphenhydramine

-4

diphenhydrarnine only

poly pharmacy

Drug Pattern Group

Figure 9: Plot of the means for log-transformed diphenhydramine - interaction
By interpreting the assessment of the differences in the blood concentrations between the
drug pattern groups and the source datasets through the interaction, Tukey's test for
multiple comparisons revealed that the ME and DUI dataset are statistically significantly
different from each other both in Group 1 and the combined drug pattern group. Within the
ME dataset, both drug pattern groups are different from each other, but in the DUI dataset,
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Group 1 and the combined drug pattern group (Groups 2 & 3) are not different from each
other. These results of the Tukey's test are summarized in Table 4 where levels not
connected by the same letter are statistically significantly different from each other. Table
4 also shows the means and standard errors for the untransformed concentration of
diphenhydramine.
Table 4: Levels of drug pattern groups and source datasets for diphenhydramine from Tukey's test

Group
ME, Group 1
ME, Combined Group
DUI, Group 1
DUI, Combined Group

Letter
A
B
C
C

Mean(Std. Error)
11.56(3.82)
3.58(0.77)
0.37(0.112)
0.1 15(0.025)

The residual by predicted plot for diphenhydramine is seen in Appendix C and does
not show any pattern between the residuals and the predicted values from the model. It
also seems that the assumption of constant variance is met because all four categories
appear to have roughly the same span on this plot. A normal quantile plot of the residuals
(Appendix C) was also inspected for deviations from normality, but for the
diphenhydramine dataset, the residuals followed an approximately normal distribution.
A clinical range of 8-3 1 mg/L of diphenhydramine is considered a fatal blood
concentration for an i n d i v i d ~ a l ~
Using
~ . this limit, there were no individuals in the DUI
dataset with a "lethal" amount of diphenhydramine in their system, and thus, there is no
evidence to suggest a development of tolerance to diphenhydramine. The high end of the
fatal blood concentration for diphenhydramine was 3 1 mglL, but there were four cases in
the ME dataset that had a concentration of 3 1 mg/L or higher, with the highest being 44
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mglL. All four of these cases listed "suicide" a.s a manner of d e a t h , but they might
still be of clinical interest for a case study. Two of these four individuals had only
diphenhydramine detected, one had diphenhydramine and ethanol, and the last had a poly
pharmacy of drugs in their system.
3.3.2 Cocaine (Level 11)
"Cocaine is a stimulant of the central nervous system and an appetite suppressant,
crea.ting what has been described as a euphoric sense of happiness and increased energy,"27.
Cocaine is most often used as a "recreational drug", but it is sometimes used as a topical
anesthetic for certain types of

One of the problems with determining

information concerning cocaine in deaths is that "since cocaine in blood rapidly hydrolyzes
to benzoylecgonine, cocaine concentrations determined in postmortem blood may not
reflect the presence or true concentration of cocaine in the body at the time of death,"28.
The main metabolite of cocaine is benzoylecgonine, and this metabolite has a longer halflife than cocaine, so the metabolite provides additional information when doing a drug test
that searches for cocaine. The DUI drug tests were all administered via a blood sample, so
using the ME concentrations from brain or tissues other than blood were not an appropriate
comparator to the DUI blood concentrations; therefore, only the blood concentrations from
the ME dataset were used in the comparison.
Using the same inclusion and exclusion criteria mentioned in Section 3.2, the final
cocaine dataset contained 691 cases and 577 variable fields. Of the 691 observations, 359
came from the ME dataset and 332 from the DUI dataset. Detecting benzoylecgonine in a
person's system could lead to the cause of death being "cocaine poisoning" (for an ME
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case) or showing that the individual had taken cocaine prior to being stopped for DUI. If
an individual had benzoylecgonine detected and not cocaine, then he or she was excluded
from the cocaine dataset because a concentration amount of cocaine could not be
established. This means that even if an individual had taken cocaine (as evidenced by the
presence of benzoylecgonine), if no cocaine was determined from the blood sample, then
this individual was excluded from the cocaine dataset.
Table 5 details the number of observations for the three drug pattern groups and the
two datasets (ME and DUI) for the 691 observations. The next table, Table 6, shows the
breakdown of r a c e , g e n d e r , and age for the two source datasets and the three drug
pattern groups. The information in Table 6 shows the frequencies for each of the
categories except in the field age, which is displayed as a range from youngest to oldest.
The demographic information shown in Table 6 is only displayed for descriptive purposes,
and it is not used in the analysis. Because all six categories met the minimum number of
observations requirement, no drug pattern groups were combined or removed for the
analysis of the cocaine dataset.
Table 5: Number of Observations for Categories in the Cocaine Dataset

Group
1

(cocaine only)
2

(cocaine and ethanol)
3
(any other combination with
cocaine)
Total

ME

DUI

129

122

15

146

215

64

359

332

52
Table 6: Demographics on the Cocaine Dataset

ME

Source Dataset

Race

Drug Paitern Group

1

2

3

1

2

3

White

--

--

--

Black

--

--

--

Other

--

--

--

50
(15.1%)
38
(1 1.4%)
1 (.3%)

31
(9.3%)
13
(3.9%)
0

129
(35.9%)
101
(28.1%)
28
(7.8%)

15
(4.2%)
14
(3.9%)
1
(0.3%)

215
(59.9%)
152
(42.3%)
63
(17.5%)

Missing

0

0

O

50
(15.1%)
25
(7.5%)
0
47
(14.2%)
54
(16.3%)
22
(6.6%)
46
(13.9%)

(17.2%
57 )
69
(20.8%)
20
(6%)
57
(17.2%)

35
(10.5%)
9
(2.7%)
20
(6%)

Range

16-68

19-46

19-64

19-53

16-64

17-55

Missing
Male

Gender

Age (in
years)

DUI

Female

20 (6%)

The majority of the normal quantile plots for the drug pattern groups showed nonnormal distribution~.Figures 10, 11, and 12 show the normal quantile plots for the three
drug pattern groups for the DUI dataset before and after the log transformation. For the

ME dataset drug pattern groups, Figures 13, 14, and 15 show the normal quantile plots for
both the untransformed and log-transformed data. Using the log transformation for the
concentration of cocaine, the data appears to be approximately normally distributed. This
log transformation was used for the ANOVA model that was used for analysis of the
cocaine dataset.

DUI
Group 1
Cocaine

.. .

0.4.Ol

.05.10

DUI
Group 1
Cocaine

- . ..

,251 .SO

.75 .90.95

.9%
8

0.350.30.250.20.150.10.050-3

"

-2

-1

0

1

2

3

Normal Quantile Plot

Normal Quantile Plot

Figure 10: Normal quantile plots for DUI Group 1 (cocaine only) before and after log transformation
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Figure 11: Normal quantile plots for DUI Group 2 (cocaine and ethanol) before and after log
transformation
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Figure 12: Normal quantile plots for DUI Group 3 (cocaine with any other combination of drug)
before and after log transformation
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Figure 13: Normal quantile plots for ME Group 1 (cocaine only) before and after log transformation
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Figure 14: Normal quantile plots for ME Group 2 (cocaine and ethanol) before and after log
transformation
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Figure 15: Normal quantile plots for ME Group 3 (cocaine with any other combination of drug) before
and after log transformation
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Box plots were created to compare the concentration of cocaine between the three
drug pattern groups and between the two source datasets. The box plots shown in the
following figures are of the log-transformed data and the untransformed data for each
dataset (ME and DUI) and each drug pattern group. Figure 16 shows the comparisons
between the two datasets for Group 1 (cocaine alone) for both the log-transformed and
untransformed concentration amounts, and Figure 17 shows an expanded version of the
untransformed data for DUI Group 1. When the log-transformed data was used, there was
no need to expand any of the box plots, but when the untransformed data was used and the
scales for the ME and DUI datasets were set to the same scale, the DUI box plot of the
untransformed data needed to be expanded to view the details of the plot. The mean for
the ME dataset for Group 1 is -1.333 log (mg/L) units (f 0.1 11 standard errors) [0.264
mg/L] with the range from -4.605 log (mg/L) units [0.01 mg/L] to 3.689 log (mg/L) units
[40.0 mg/L]. The mean for DUI Group 1 is -3.135 log (mg/L) units (f 0.1 14 standard
errors) [0.04 mg/L] with a range of -5.298 log (mg/L) units E0.005 mg/L] to -0.942 log
(mg/L) units [0.39 mg/L]. For Group 1, the majority of the DUI cases fit into the ME
range, showing some sort of overlap.
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Figure 16: Box plots for Group 1 (cocaine only) for DUI and ME - log-transformed and
untransformed data
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Figure 17: Expanded box plot for DUI Group 1 (cocaine only) - untransformed data

In the next figure, Figure 18, the two pairs of box plots for Group 2 of the cocaine dataset
are shown; Figure 19 shows the expanded box plot for the DUI untraasformed data. The
range for the DUI dataset is larger than it was in Group 1, but the overlap between the ME
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and DUI datasets is still there. For the ME dataset Group 2, the mean is -1.783 log (mg/L)
units (*0.324 standard errors) [0.17 mg/L], and the DUI mean for Group 2 is -3.68 log
(mg/L) units (k 0.104 standard errors) [0.025 mg/L]. The range for the ME dataset for
Group 2 is from -3.507 log (mg/L) units [0.03 mg/L] to 1.686 log (mg/L) units [5.40
mg/L], and the range for DUI Group 2 is from -5.298 log (mg/L) units [0.005 mg/L] to 1.204 log (mg1L) units [0.3 mg/L]. These ranges have some overlap, but the range for this
drug pattern group in the DUI dataset was smaller than that for the ME dataset.
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Figure 18: Box plots for Group 2 (cocaine and ethanol) for DUI and ME - log-transformed and
untransformed data
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Figure 19: Expanded box plot for DUI Group 2 (cocaine and ethanol) - untransformed data

The last figures for the cocaine dataset show the box plots for the log-transformed and
untransformed concentrations for Group 3. Figure 20 shows that the range for DUI Group
3 can be completely encompassed within the range for ME Group 3. Figure 21 shows an
expanded box plot for DUI Group 3 of the untransformed data. The means for the ME and
DUI dataset are -2.812 log (mg/L) units (* 0.086 standard errors) [0.06 mg/L] and -3.723
log (mg/L) units (* 0.157 standard errors) [0.024 mg/L] respectively. The range for Group
3 in the DUI dataset is from -5.298 log (mg/L) units [0.005 mg/L] to -1.273 log (mg/L)
units [0.28 mg/L], while the range for Group 3 in the ME dataset is from -7.264 log (mg/L)
units [0.0007 mg/L] to 1.435 log (mg/L) units [4.2 mg/L]. (These means and ranges are
determined from the log-transformed concentrations of cocaine and by untransforming
these means; they will not necessarily match the means for the untransformed
concentrations that are seen in the table with the Tukey results.)
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Figure 20: Box plots for Group 3 (cocaine with any other combination of drug) for DUI and ME - logtransformed and untransformed data
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Figure 21: Expanded box plot for DUI Group 3 (cocaine with any other combination of drug) untransforrned data

Based only on the box plots, it seems that there might be a difference between the
two source datasets for some drug pattern groups, but perhaps, not all, and that perhaps the
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drug pattern groups are different from each other, within the same dataset. An ANOVA
model was fit to the log-transformed data to see if these conjectures were correct.
When the ANOVA model was fit to the cocaine dataset, it was determined that the
interaction between group and database was significant (p-value = 0.0004). Since this
interaction was significant, assessments of the differences in the blood concentrations
between drug pattern groups and source datasets were tested through the interaction. The
plot of the means for the cocaine dataset is seen in Figure 22, and it shows that the
difference in concentrations between the source datasets (ME and DUI) for Group 3 is
different than the difference in concentrations between the source datasets for Groups 1 and
2. Table 7 shows the results of the Tukey's test with different letters signifying statistical
significant differences between the different levels; categories that do not share the same
letter are statistically significantly different from each other. This table shows that ME
Group 1 and ME Group 2 are different from all of the drug pattern groups in the DUI
dataset, but ME Group 3 is not different from DUI Group 1. Within the ME dataset,
Groups 1 and 2 are not different from each other, but both are different from ME Group 3.
For the DUI dataset, Groups 2 and 3 are not different from each other, but both are
different from Group 1. Table 7 also shows the raw means and standard errors
(untransformed concentrations) for cocaine; the units for these means and standard errors
are mg/L.

Plot of the Means
Log-transformed concentration of cocaine
-1 .o

-4.5
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poly pharmacy

Drug Pattern Groups

-

Figure 22: Plot of the means for log-transformed cocaine interaction
Table 7: Levels of drug pattern groups and source datasets for cocaine from Tukey's test

Group
ME, Group 1
ME, Group 2
ME, Group 3
DUI, Group 1
DUI, Group 2
DUI, Group 3

Letter
A
A
B
B
C
C

Mean(Std. Error)
1.7l(0.403)
0.528(0.35)
0.149(0.028)
0.071(0.007)
0.039(0.003)
0.038(0.005)

The residual by predicted plot for the cocaine dataset is seen in Appendix C, and
this plot shows no obvious pattern of the residuals with the predicted values from the
model. Because there is no pattern of the residuals and there does not seem to be a problem
with constant variance, then the modeling assumptions are verified. The constant variance
assumption is met because for each of the combinations, the variance appears to be the
same. The adequacy of the model is verifed through the fact that there not a systematic
pattern of residuals and the normal quantile plot. The normal quantile plot of the residuals
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for the ANOVA model, also seen in Appendix C, shows an approximately normal
distribution because the data points fall along the diagonal, so the normality assumption in
not violatedin the fitted model.
Using 0.9 - 21 mg/L as the clinically defined, fatal blood concentration for
cocainez6,no cases in the DUI dataset fell within this range, but there was one case in the

ME dataset that exceeded the upper end of the range (21 mg/L) by having 40 mg/L. This
case was a single drug overdose and might be of interest in a case study.
3.3.3 Oxycodone (Level 11)

Oxycodone, commonly known as OxyContin @, Percocet @, or Percodan @ is a
"central nervous system depressant that appears to work through stimulating the opioid
receptors found in the central nervous system that activate responses ranging from
analgesia to respiratory depression to euphoria,"29. According to an article from
www.streetdruns.org, "people who take the drug repeatedly can develop a tolerance or
resistance to the drug's effects,"29.
The dataset created for oxycodone consisted of 487 individuals and 577 fields. This
dataset was created using the same criteria as the previous datasets and excluded those
individuals who did not die from an oxycodone-related drug death, those individuals not
receiving a toxicological screen as a result of an autopsy, and those individuals in .the DUI
dataset that did not register any level of concentration for oxycodone. From the ME
dataset, 263 individuals were included, and from the DUI dataset, 224 individuals were
included. Table 8 shows the number of observations that appear in each drug pattern group
(oxycodone only, oxycodone and ethanol, and oxycodone with any other combination of
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drug) for each of the source datasets, and Table 9 shows the demographic descriptions for
each of these drug pattern groups. In Table 8, the category for oxycodone and ethanol
(Group 2) from the ME dataset had only 11 observations. The general rule of thumb for a
minimum number of observations was 12", but the clinical decision was to leave the drug
pattern groups as is, without combining Group 2 with any of the other drug pattern groups.
One interesting fact to notice in Table 9 is that in ME Group 1 (oxycodone only), there was
an individual with an age of zero; this might be an interesting individual to use for a case
study, once the age is verified.
Table 8: Number of Observations for Categories in the Oxycodone Dataset

Group
1
(oxycodone only)
2
(oxycodone and ethanol)
3
(any other combination with
oxycodone)
Total

ME

DUI

53

31

11

68

199

125

263

224

Table 9: Demographics on theoxycodone Dataset

ME

Source Dataset

Race

Drug Pattern Group

1

2

White

--

--

Black

--

---

Other

11
(4.2%)
1I
(4.2%)

Missing

0

0

Range

0-57

20-46

Missing
Male

Gender

Age (in years)

-53
(20.1%)
40
(15.2%)
13
(4.9%)

Female

O

DUI
3

1

2

3

46
18
77
(20.6%)
(34.4%)
(8%)
3
1
3
-(0.4%) (1.3%) (1.3%)
-0
0
0
12
19
199
45
(75.7%) (5.4%) (8.5%) (20.1%)
11
120
36
58
(45.6%) (4.9%) (16.1%) (25.9%)
8
22
79
13
(30.1%) (3.5%) (5.8%) (9.8%)
12
19
45
O
(5.4%) (8.5%) (20.1%)
20-57
17-59
19-73
18-68

--

,

The normal quantile plots for the concentration of oxycodone showed data that
did not appear normally distributed, so a log transformation was done on the
concentration of oxycodone. The normal quantile plots, before and after the log
transformation, are seen in Figures 23, 24,25,26, 27, and 28. The first three figures
show the normal quantile plots for the DUI dataset for Groups 1,2, and 3, with the
untransformed data on the left, and the log-transformed data on the right. Figures 26,27,
and 28 show the normal quantile plots for the ME dataset. As these figures show, the
normal quantile plots for the log-transformed concentration appear approximately
normally distributed, while the normal quantile plots for the untransformed data show
data that is not normally distributed.
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Figure 23: Normal quantile plots for DUI Group 1 (oxycodone only) before and after log
transformation
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Figure 24: Normal quantile plots for DUI Group 2 (oxycodone and ethanol) before and after log
transformation
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Figure 25: Normal quantile plots for DUI Group 3 (oxycodone with any other combination of drug)
before and after log transformation
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Figure 26: Normal quantile plots for ME Group 1 (oxycodone only) before and after log
transformation
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Figure 27: Normal quantile plots for ME Group 2 (oxycodone and ethanol) before and after log
transformation
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Figure 28: Normal quantile plots for ME Group 3 (oxycodone with any other combination of drug)
before and after log transformation

The following figures show two pairs of box plots for the three drug pattern groups
before and after the log transformation of cocaine. Figure 29 shows the pair of box plots
for Group 1, and Figure 30 shows the expanded box plot for the DUI dataset for Group 1.
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Figure 29: Box plots for Group 1 (oxycodone only) for DUI and ME - log-transformed and
untransformed data
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Figure 30: Expanded box plot for DUI Group 1 (oxycodone only) - untransformed data

The mean of DUI Group 1 is -1.85 log (mg/L) units (h 0.13 1 standard errors) [O. 16 mg/L],
ranging fkom -3.507 log (mg/L) units [0.03 mg/L] to -0.598 log (mg/L) units [0.55 mg/L].
The mean of ME Group 1 is -0.71 85 log (mg/L) units (* 0.0974 standard errors) [0.49
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mg/L] with a range from -2.813 log (mg/L) units [0.06 mg/L] to 0.693 log (mg/L) units
[2.0 mg/L]. The majority of the cases in the DUI dataset for Group 1 fit inside the range

determined by ME Group 1. The box plots seen in Figure 3 1 show Group 2 for the ME
and DUI datasets with and without the log transformation; Figure 3 2 shows the box plot
for untransfonned DUI Group 2 on an expanded scale.
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Figure 31: Box plots for Group 2 (oxycodone and ethanol) for DUI and ME - log-transformed and
untransformed data
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Figure 32: Expanded box plot for DUI Group 2 (oxycodone and ethanol) - untransformed data

For Group 2, the means for the DUI and ME datasets are -2.638 log (mg/L) units (k 0.1 18
standard errors) [0.07 mg/L] and - 1-02 log (mg/L) units (*0.226 standard errors) [0.36
mg/L], respectively. The range for the DUI dataset for this drug pattern group is from 5.298 log (mg/L) units [0.005 mg/L] to -0.916 log (mg/L) units [0.4 mg/L], while the ME
dataset for Group 2 ranges from -1.833 log (mg/L) units [0.16 mg/L] to 0.833 log (mg/L)
units [2.3 mg/L]. There seems to be some overlapping between the two datasets (ME and
DUI) for Group 2.
The box plots for Group 3 for the oxycodone dataset are seen in Figures 33 and 34,
with Figure 34 showing an expanded box plot for the untransformed data for DUI Group 3.
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Figure 33: Box plots for Group 3 (oxycodone with any other combination of drug) for DUI and ME log-transformed and untransformed data
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Figure 34: Expanded box plot for DUI Group 3 (oxycodone with any other combination of drug) untransformed data

For DUI Group 3, the mean is -2.782 log (mg/L) units (* 0.102 standard errors) [0.06
rng/L] and the mean for ME Group 3 is - 1.366 log (mg/L) units (k 0.087 standard errors)
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[0.255 mg/L]. The range for DUI Group 3 is -5.298 log (mg/L) units [0.005 mg/L] to 0.163 log (mg/L) units [0.85 mg/L]. The range for ME Group 3 is from -4.605 log (mg/L)
units [0.01 mg/L] to 2.079 log (mg/L) units [8.0 mg/L]. As ,the ranges show, there is a
much larger spread of the oxycodone concentration for the ME dataset than for the DUI
dataset. Note that the box plots of the log-transformed data do not always show the
differences in the concentrations as well as the box plots of the untransfonned
concentration amounts. (All of these means and ranges are determined by the log
transformed concentrations of oxycodone and by untransforming these values; they are not
necessarily the same values as the untransformed means and standard errors as the ones
seen in the table that displays .theresults of Tukey's test.)
After the box plots were created to visually inspect for obvious differences between
the ME and DUI datasets, an ANOVA model was fit to the log-transformed concentration.
The interaction term between group and database was not significant (p-value =
0.4625), so it was removed from the model. The new model contained only the two
independent variables, and both of these were significant (p-values were both less than
0.0001); therefore, there is a statistically significant difference between the two datasets
(ME and DUI), and there is also a statistically significant difference between at least two of

the three drug pattern groups. The plots of the means for each of the independent fields are
seen in Figures 35 and 36. Because there are only two source datasets, the statistically
significant difference is between the ME and DUI datasets. The drug concentrations from
the ME dataset are significantly higher than the drug concentrations from the DUI dataset
(see Figure 36). With respect to the three levels in the drug pattern groups, the ANOVA
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indicates that there is a significant difference between the levels, but it does not specify
which levels are different from each other. A Tukey's test was done to determine which
differences between the means of the drug pattern groups are statistically significantly
different. Table 10 shows the results of the Tukey's test where levels with different letter
labels are statistically significantly different, and thus, levels that are not connected by the
same letter are significantly different from each other (regardless of the source dataset).
Referring to Table 10, Groups 2 and 3 are not different from each other, but both are
different from Group 1, and from the plot of the means in Figure 35, it seems that Group 1
has a higher concentration of oxycodone than Groups 2 and 3. Table 10 also displays the
means and standard errors of the untransformed, or raw, concentrations of oxycodone. The
means and standard errors reported in Table 10 are in mg/L units.
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Figure 35: Plot of the means for "group" field for log-transformed oxycodone
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Figure 36: Plot of the means for "database" field for log-transformed oxycodone
Table 10: Levels of drug pattern groups for oxycodone from Tukey's test

Group
Group 1
Group 2
Group 3

~etter
A
B
B

Mean(Std. Error)

0.465(0.045)
0.163(0.031)
0.373(0.044)

The residual by predicted plot for oxycodone is seen in Appendix C and shows that
there does not seen1 to be any systematic pattern between the predicted values and the
residuals. The residuals also appear to follow the constant variance assumption since there
seems to be roughly the same span of residuals in each of the categories. A normal
quantile plot of the residuals was also constructed for the ANOVA model (see Appendix
C), and it did not reveal any non-normality of the residuals.
There is not a specified clinical limit that indicates a lethal amount of oxycodone,
so there was not an amount or range to compare the concentrations of oxycodone to for
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either dataset. Since the datasets were determined to be different when it came to
oxycodone concentration, the DUI dataset and the ME dataset did not have enough
evidence to suggest development of tolerance to oxycodone.

3.3.4 Hydrocodone (Level 11)
Hydrocodone is marketed as Vicodin @, Lorcet 09, Lortab 0,and many other trade
names. This drug is used as "an orally active narcotic analgesic and antitus~ive,"~~.
Hydrocodone can be "habit forming and can lead to physical and psychological
addi~tion"~~.
Mixing alcohol with hydrocodone can also cause other health problems30.
The hydrocodone dataset consisted of 542 individuals and 577 variable fields,
including 200 cases from the ME dataset and 342 cases from the DUI dataset. The dataset
for hydrocodone was created using the same criteria as the other datasets, and includes all
individuals from the ME dataset who died from a hydrocodone-related drug death and all
DUI individuals that had hydrocodone detected in their system. Table 11 shows the
number of individuals in each of the drug pattern groups and each source dataset. As Table
11 shows, Group 2 for the ME dataset contained only six individuals, so Groups 2 and 3
were combined for analysis. The combined drug pattern group consisted of 166 individuals
from the ME dataset and 3 15 from the DUI dataset for a total of 48 1 observations. Table
12 shows the demographic breakdown for Group 1 and the combined drug pattern group
(Groups 2 & 3) for the ME and DUI datasets for the hydrocodone.

Table 11: Number of Observations for Categories in the Hydrocodone Dataset
-

-

Group
1
(hydrocodone only)
2
(hydrocodone and ethanol)
3
(any other combination with
hydrocodone)
Total

ME

DUI

34

27

6

121

160

194

200

342

Table 12: Demographics on the Hydrocodone Dataset

Source Dataset

Race

Gender
Age (in years)

ME
Combined
(2&3)

DUI
Combined
(2&3)

Drug Pattern Group

1

White
Black
Other
Missing

-34 (17%)

166 (83%)

19 (5.6%) 205 (59.9%)
6 (1.8%)
1 (0.3%)
0
0
104
(30.4%)
7 (2%)

Male

18(9%)

104(52%)

16(4.7%)

136(39.8%)

Female

16 (8%)

62 (31%)

4 (1.2%)

75 (21.9%)

Missing

0

0

104 (30.4%)

Range

19-77

17-73

7 (2%)
18-46

---

---

--

17-68

The normal quantile plots for the four categories shown in the tables, showed nonnormal distribution~for the drug pattern groups and datasets, so a log transformation was
used for the hydrocodone concentration. The normal quantile plots for all categories are
seen in the following figures with the untransformed data and the log-transformed data for
the concentration of hydrocodone. As Figures 37,38,39, and 40 show, the logtransfornied data followed an approximately normal distribution for all drug pattern groups
and datasets, while the untransformed data did not follow an approximately normal
distribution.
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Figure 37: Normal quantile plots for DUI Group 1 (hydrocodone only) before and after log
transformation
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Figure 38: Normal quantile plots for DUI Groups 2 & 3 (hydrocodone with any drug including
ethanol) before and after log transformation
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Figure 39: Normal quantile plots for ME Group 1 (hydrocodone only) before and after log
transformation
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Figure 40: Normal quantile plots for ME Groups 2 & 3 (hydrocodone with any drug including
ethanol) before and after log transformation
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The box plots comparing the log-transformed concentrations and the untransforrned
concentrations for the source datasets for each of the drug pattern groups are seen in the
following figures. Figure 41 shows the box plots for Group 1, and Figure 42 shows the box
plots for the combined drug pattern group (Groups 2 and 3). Figure 43 shows an expanded
version of .the untransformed DUI box plot for the combined drug pattern group, but there
is not an expanded DUI box plot for Group 1 because Figure 41 shows the details with no
need to expand the scale.
DUI
Group 1
Hydrocodone
Log transformed

ME
Group 1
Hydrocodone
.og transformed

-3

-3

-3.5

-3.5

-4

-4

-4.5

-4.5

-5

-5

DUI
Group 1
Hydrocodone

ME
Group 1
Hydrocodone

Figure 41: BOXplots for Group 1 (hydrocodone only) for DUI and ME - log-transformed and
untransformed data

The mean for Group 1 for the ME dataset is -1.565 log (mg/L) units (A 0.1 19 standard
errors) [0.2 1 mg/L], and the mean for Group 1 for the DUI dataset is -3.172 log (mg/L)
units (f0.195 standard errors) [0.04 mglL]. The range for the ME dataset for Group 1
spans from -3.219 log (mglL) units [0.04 mg/L] to -0.51 1 log (mg/L) units 10.6 mg/L],
while the range for the DUI dataset for this drug pattern group is from -4.605 log (mg/L)

81
units [0.01 mg/L] to -0.968 log (mg/L) units 10.38 mg/L]. Group 1 for the ME dataset
spans a larger region than the DUI dataset, but the two datasets seem to follow a similar
pattern for Group 1.
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Figure 42: Box plots for Groups 2 & 3 (hydrocodone with any drug - including ethanol) for DUI and
ME - log-transformed and untransformed data
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Figure 43: Expanded box plot for DUI Groups 2 & 3 (hydrocodone with any drug - including ethanol)

- untransformed data
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For the drug pattern group that combined Groups 2 & 3, the mean for the ME
dataset was -2.317 log (mg/L) units (h 0.087 standard errors) [0.10 mg/L], and the mean for
the DUI dataset was -3.63 log (mg/L) units (* 0.045 standard errors) [0.027 mg/L]. The
range for the ME dataset was from -5.843 log (mg/L) units [0.0029 mgIL] to -0.693 log
(mg/L) units [2.0 mg/L]; the range for the DUI dataset is from -5.298 log (mg1L) units
[0.005 mg/L] to -1.609 log (mg/L) units [0.2 mg/L]. It is interesting to note that the range
for DUI combined drug pattern group is completely contained in the range for the ME
dataset. (All of these means and ranges are determined by using the log-transformed
concentrations of hydrocodone and by untransforming these values; they will not always be
the same as the raw means reported with the results of the ANOVA model.

An ANOVA model was fit to the hydrocodone dataset. The interaction between
group and database was not statistically significant (p-value = 0.2475), so it was

removed from the model. With only the independent fields left in the model, both were
determined to be statistically significant (p-values each less than 0.0001). Since both fields
were statistically significant, then the ME dataset and the DUI datasets were determined to
be statistically significantly different from each other within the hydrocodone dataset.
Group 1 was also determined to be statistically different from the combined drug pattern
group (Groups 2 & 3). The plots of the means for each of the variable fields are shown in
Figures 44 and 45. The concentration of hydrocodone is statistically significantly higher
for the ME dataset (mean = 0.196 k 0.018 standard errors) than for the DUI dataset (mean
= 0.039 5 0.002

standard errors), and the concentration is statistically significantly higher
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*

in Group 1 (mean = 0.173 0.02 standard errors) than it is in the combined drug pattern
group (Groups 2 & 3) (mean = 0.087 k 0.008 standard errors).
Plot of the Means
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Figure 44: Plot of the means for "database" field for log-transformed hydrocodone

Plot of th.e Means
Log-transformed concentration of hydrocodone

-3.2
poly pharmacy

hydrocodoneonly

Drug Pattern Group

Figure 45: Plot of the means for "group" field for log-transformed hydrocodone
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Once the model was fitted to the data, a residual by predicted plot was constructed
(Appendix C). This plot showed that the constant variance assumption was met, and since
there did not seem to be overall systematic pattern, the model was adequate for the data.
The residuals for this model were also plotted in a normal quantile plot to check for
normality (Appendix C), and the residuals appeared to be approximately normal.
Because the ME and DUI datasets are statistically different with respect to
hydrocodone, there is not sufficient evidence to suggest tolerances to hydrocodone. There
is not a defined clinical concentration of hydrocodone that is considered fatal.
3.3.5 Methadone (Level 111)
"German scientists synthesized methadone during World War I1 because of a
The
' . trade name for methadone is Dolophine @, and it is "used as
shortage of m ~ r ~ h i n e , " ~
an analgesic and in the treatment of narcotic addiction,932 . Ironically, methadone used to
'6

control narcotic addiction is frequently encountered on the illicit market and has been
associated with a number of overdose deathsw3'.
The methadone dataset contained 522 observations and 577 variable fields.
Consisting of 407 individuals from the ME dataset and 115 from the DUI dataset, the
methadone dataset followed the same inclusion and exclusion rules that the previous
datasets have mentioned. Three drug pattern groups were created: methadone only,
methadone and alcohol, and methadone with any other combination of drugs. The
following two tables show the frequency of observations for each category and the
demographics of each of the categories. The number of observations in each drug pattern
group and each source dataset is shown in Table 13, and Table 14 shows the itemization of
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the three drug pattern groups and the two source datasets with respect to the demographic
variable fields r a c e , g e n d e r , and age.
Table 13: Number of Observations for Categories in the Methadone Dataset

Group
1
(methadone only)
2
(methadone and ethanol)
3
(any other combination with
methadone)
Total

ME

DUI

142

14

20

27

245

74

407

115

Table 14: Demographics on the Methadone Dataset

Source Dataset
Drug Pattern
Group
White
Black

Race
Other
Missing
Male

Gender

Female
Missing

Age (in years)

Range

ME
1

2

DUI
3

1

2

3

7
45
13
(6.1%) (1 1.3%) (39.1%)
1
2
---O
(0.9%) (1.7%)
1
---0
O
(0.9%)
20
26
142
245
7
13
(34.9%) (4.9%) (60.2%) (6.1%) (11.3%) (22.6%)
9
4
17
31
97
153
(23.8%) (4.2%) (37.6%) (3.5%) (7.8%)
(27%)
18
5
45
91
3
3
(1 1.1%) (0.7%) (22.4%) (2.6%) (4.3%) (15.7%)
1
13
7
25
0
O
(0.2%) (6.1%) (11.3%) (21.7%)
18-59
17-71
18-44
22-48
18-45
18-64

--

--

--

Because all of the drug pattern groups contained at least 12 cases, none of them
were combined, and the analysis was done using all three drug pattern groups. The normal
quantile plots of the drug pattern groups and the source datasets showed non-normal
distributions, so a log transformation was done on the concentration of methadone for the

analysis. The normal quantile plots for each of the datasets and drug pattern groups are
displayed in the following figures. Figures 46 through 48 show the normal quantile plots
for all of the DUI drug pattern groups with both the untransformed and the log-transformed
data. Figures 49 through 5 1 show the normal quantile plots for the ME drug pattern
groups. The normal quantile plots of the log-transformed data show an approximately
normal distribution, and this transformed data was used for the ANOVA model.
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Figure 46: Normal quantile plots for DUI Group 1 (methadone only) before and after log
transformation
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Figure 47: Normal quantile plots for DUI Group 2 (methadone and ethanol) before and after log
transformation
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Figure 48: Normal quantile plots for DUI Group 3 (methadone with any other combination of drug)
before and after log transformation
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Figure 49: Normal quantile plots for ME Group 1 (methadone only) before and after log
transformation
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Figure 50: Normal quantile plots for ME Group 2 (methadone and ethanol) before and after log
transformation
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Figure 51: Normal quantile plots for ME Group 3 (methadone with any other combination of drug)
before and after log transformation

The next sets of figures show the box plots (log-transformed and untransformed)
comparing the ME and DUI datasets for each of the three drug pattern groups. Figure 52
displays two pairs of box plots for Group 1 (methadone only) for the log-transformed data
(left side) and the untransformed data (right side), and Figure 53 shows an expanded box
plot of the untransformed DUI Group 1 data. The expanded box plot is displayed to show
the details of the untransformed DUI data. Figures 54 and 55 show .thebox plots for Group
2 (methadone and ethanol).
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Figure 52: Box plots for Group 1 (methadone only) for DUI and ME - log-transformed and
untransformed data
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Figure 53: Expanded box plot for DUI Group 1 (methadone only) - untransformed data

The means for Group 1 of the methadone dataset are -0.678 log (mg/L) units (*
0.068 standard errors) [0.51 mg/L] for the ME dataset and -2.157 log (mg/L) units (* 0.353
standard errors) [0.116 mg/L] for the DUI dataset. The range for Group 1 for the ME
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dataset is from -5.776 log (mg/L) units [0.003 mg/L] to 1.686 log (mg/L) units [5.4 mg/L],
and the range for Group 1 for the DUI dataset is from -4.605 log (mg/L) units [0.01 m a ]
to -0.386 log (mg/L) units [0.68 mg/L]. As these ranges show, the entire range of the DUI
dataset fits within the boundaries defined by the ME range; however, the lower boundary
for the DUI dataset is higher than the lower boundary for the ME dataset. It might be of
clinical interest to inspect the ME case that has a methadone-related death with a
concentration of methadone equal to 0.0003 mg/L because it seems .that the concentration
is not a "lethal" dose.
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Figure 54: Box plots for Group 2 (methadone and ethanol) for DUI and ME - log-transformed and
untransformed data

For Group 2, the mean for the ME dataset is -1.146 log (mg/L) units (* 0.159
standard errors) [0.32 mg/L], while the mean for the DUI dataset is -2.088 log (mg/L) units
(* 0.227 standard errors) [0.124 mg/L]. The span of the concentrations for methadone in

the ME dataset ranges from -2.303 log (mg/L) units [0.1 mg/L] to 0.336 log (mg/L) units

[1.4 mg/L]. For the DUI dataset for Group 2, the range is from -5.298 log (mg/L) units

[0.005 mg/L] to -0.693 log (mg/L) units [0.5 mgIL]. In this drug pattern group, unlike
Group 1, the range for the DUI dataset starts at a lower concentration than that of the ME
dataset.
DUI
Group 3
Methadone
Log transformed

ME
Group 3
Methadone
.og transformed

DUI
Group 3
Methadone

ME
Group 3
Methadone

Figure 55: Box plots for Group 3 (methadone with any other combination of drug) for DUI and ME log-transformed and untransformed data
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Figure 56: Expanded box plot for DUI Group 3 (methadone with any other combination of drug) untransformed data

In Group 3, the means for the two datasets are -0.87 log (mg/L) units (A 0.056
standard errors) [0.419 mg/L] for the ME dataset and -2.255 log (mg/L) units (* 0.152
standard errors) [O. 105 mg/L] for the DUI dataset. The concentrations of methadone for
Group 3 for the ME dataset ranges from -3.507 log (mg/L) units [0.03 mg/L] to 2.485 log
(mg/L) units [12 mg/L], and the range for the DUI dataset is from -5.298 log (mg/L) units
[0.005 mg/L] to 0.095 log (mg/L) units [1. l mg/L]. The span of the range for the DUI
dataset for this particular drug pattern group is smaller and begins at a lower dose than the
range for the ME dataset. (All of these means and ranges were determined from the logtransformed concentrations of methadone and by untransforming these means.)
An ANOVA model was fit to the data to determine whether or not there was a
statistically significant difference in concentrations of methadone between the two source
datasets and between the three drug pattern groups. Once this model was fit, the

94
intera.ction term was determined to be not statistically significant (p-value = 0.3064), and
thus, it was removed from the model. After removing the interaction term from the
ANOVA model, the g r o u p variable field was also noted as not significant (p-value =
0.1 117), and it was removed from the model as well. The only significant variable field
left in the model was the source dataset, implying that the ME and DUI datasets are
different from each other with regard to concentration of methadone. Figure 57 shows the
plot of the means for the database field. From this plot, it can be seen that the ME
dataset has a statistically significant higher mean for concentration of methadone (mean =
0.664 mg/L

* 0.052 standard errors) than the DUI dataset (mean = 0.202 mg/L h 0.019

standard errors). (These means and standard errors are the untransformed concentrations
for methadone and are given in mg/L units.) Because the ME and the DUI datasets are
statistically significantly different from each other, there is not sufficient evidence to
suggest tolerances to methadone.
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Figure 57: Plot of the means for "database" field for log-transformed methadone

A residual by predicted plot was constructed (Appendix C) from the model with
only the field for the source datasets. This plot verified the constant variance assumption
and did not show any systematic pattern of the residuals with the predicted values that
would imply any inadequacy with the model did not fit. A normal quantile plot of the
residuals from this model was also constructed and can be seen in Appendix C. This plot
shows that the assumption of normality for the residuals is met because the residuals
follow the diagonal.
The clinically determined fatal blood concentration for methadone ranges from 0.4
to 1.8 m g , , ~ Using
~ ~ . this as the guideline to determine whether there are any interesting
DUI cases with high levels of methadone, 14 individuals (in the DUI dataset) were found
to have a concentration of methadone that fell within the "lethal" concentration; this is
visible on the box plots in Figures 53, 54, and 56 where data points for the DUI dataset fall
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within this clinically defined range. These cases offer some evidence, regardless of the
results of the analysis, that it is possible to develop a tolerance to methadone; these 14
individuals have "lethal" doses of methadone in their systems and are still attempting to
operate a motor vehicle.
3.3.6 Morphine (Level 11)
"Morphine is the naturally occumng substance in the opium poppy, Papaver
Somniferous. It is a potent narcotic analgesic, and its primary clinical use is in the
management of moderately severe and severe pain. After heroin, morphine has the greatest
dependence liability of the narcotic analgesics in common use"33. It is thought that regular
use of morphine can result in developing tolerances to the drug33.
The morphine dataset consisted of the individuals testing positive for morphine and
contained 742'cases and 577 variable fields. The morphine dataset was divided into the
same three types of drug pattern groups as the other drugs: morphine only, morphine and
ethanol, and morphine with any other combination of drugs. These drug pattern groups
were used to compare the concentration of morphine between the ME and DUI datasets and
among the three drug pattern groups. The number of observations in each of the three drug
pattern groups is seen in Table 15. The ME dataset contributed 61 1 cases to the morphine
dataset, while the DUI dataset contributed 131 cases. From the numbers in Table 15, it is
obvious that none of the categories had less than 12 cases in them, so no drug pattern
groups were combined or removed for analysis of the morphine dataset. The demographics
of a g e , g e n d e r , and race, are broken down by drug pattern group and dataset in Table
16.

Table 15: Number of Observations for Categories in the Morphine Dataset

Group
1
(morphine only)
2
(morphine and ethanol)
3
(any other combination with
morphme)
Total

ME

DUI

143

25

50

35

418

71

61 1

131

Table 16: Demographics on the Morphine Dataset

Source Dataset
Drug Pattern
Group

Race

ME

DUI

1

2

3

White

--

--

--

Black

--

--

--

--

--

--

143

50

(23.4%)(8.2%)
Male

Gender

Female

300
119
47
(19.5%) (7.7%) (49.1%)
24
118
3
(3.9%) (0.5%) (19.3%)
0

0

0

20-76

19-59

15-69

1

2

15
16
(1 1.5%) (12.2%)
2
3
(1.5%) (2.3%)
0
0

10
(7.6%)
7
(5.3%)

3
37
(28.2%)
9
(6.9%)
0

15
(1 1.5%)
4
(3.1%)

38
(29%)
8
(6.1%)

18-49

16-59

Age (in years)

Range

18-54

The normal quantile plots for the concentrations of morphine by drug pattern group
and by source dataset showed non-normal distributions, so a log transformation was used
for the concentration of morphine. The normal quantile plots seen in the following figures
show both the untransformed data and the log-transformed data. Figures 5 8 , 5 9 , and 60
show the untransformed and log-transformed box plots for the DUI dataset for Groups 1,2,
and 3. The box plots for the ME dataset are seen in Figures 61,62, and 63.
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Figure 58: Normal quantile plots for DUI Group 1 (morphine only) before and after log
transformation
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Figure 59: Normal quantile plots for DUI Group 2 (morphine and ethanol) before and after log
transformation
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Figure 60: Normal quantile plots for DUI Group 3 (morphine with any other combination of drug)
before and after log transformation

ME
Group 1
Morphine

ME
Group 1
Morphine
Log transformed

3.5-

2.5-

1.5-

0.5-3

-2

-1

0

Normal Quantile Plot

1

2

3

I

Normal Quantile Plot

Figure 61: Normal quantile plots for ME Group 1 (morphine only) before and after log transformation
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Figure 62: Normal quantile plots for ME Group 2 (morphine and ethanol) before and after log
transformation
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Figure 63: Normal quantile plots for ME Group 3 (morphine with any other combination of drug)
before and after log transformation

The next section of figures shows the pairs of box plots for each of three drug
pattern groups and compares the ME and DUI datasets. The set of box plots for Group 1
(morphine only) is seen in Figure 64. Figures 66 and 68 show the set of box plots for
Group 2 and Group 3, for the DUI and ME datasets before and after the log
transformation. For each of the three drug pattern groups, an expanded version of the
untransformed DUI data is displayed to better view the details of the box plot.
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Figure 64: Box plots for Group 1 (morphine only) for DUI and ME - log-transformed and
untransformed data
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Figure 65: Expanded box plot for DUI Group 1 (morphine only) - untransformed data

The mean for Group 1 for the ME dataset is -1.52 log (mg/L) units (k 0.089
standard errors) [0.22 mg/L], and the mean for Group 1 for the DUI dataset is -3.01 log
(mg/L) units (*0.193 standard errors) [0.05 mg/L]. The range for the ME dataset for this
group is from -4.605 log (mg/L) units [0.01 mg/L] to 1.435 log (mg/L) units [4.2 mg/L],
while the range for the DUI dataset is from -4.605 log (mg/L) units [0.01 mg/L] to -0.616
log (mg/L) units [0.54 mg/L]. Both datasets have the same lower boundary for the range,
but the ME dataset spans a much larger region than the DUI dataset.
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Figure 66: Box plots for Group 2 (morphine and ethanol) for DUI and ME - log-transformed and
untransformed data
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Figure 657: Expanded box plot for DUI Group 2 (morphine and ethanol) - untransformed data

Group 2 has a mean of - 1.903 log (mg/L) units (f0 . 1 0 9 standard errors) [O. 15
mgIL] for the ME dataset and a mean of -3.492 log (mg/L) units (* 0.139 standard errors)
[0.03 mg/L] for the DUI dataset. The range of .the ME da'taset is from -3.912 log (mg/L)
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units [0.02 m a ] to 0.182 log (mg/L) units [I. 1 2 mg/L], and the range for the DUI dataset
is fiom -5.298 log (mg/L) units [0.005 mg/L] to -2.408 log (mg/L) units [0.09 mg/L]. The

range for the DUI dataset starts at a lower concentration, but it also has a lower maximum
log concentration than the ME dataset.
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Figure 68: Box plots for Group 3 (morphine with any other combination of drug) for DUI and ME log-transformed and untransformed data
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Figure 69: Expanded box plot for DUI Group 3 (morphine with any other combination of drug) untransformed data

The means for Group 3 for the ME and DUI datasets are -2.047 log (mg/L) units (*
0.05 standard errors) C0.129 mg/L] and -3.657 log (mg/L) units (* 0.11 8 standard errors)
[0.026 mg/L], respectively. The range for the ME dataset for this group is from -6.075 log
(mg/L) units [0.0023 mg/L] to 2.079 log (mg/L) units [8 mgIL]. The DUI dataset had a
smaller range than the range for the ME dataset, and it was from -5.298 log (mg/L) units
[0.005 mg/L] to 0 log (mg/L) units 11.0 mg/L]. (The means and ranges reported in the
previous sections canie from the log-transformed concentrations for morphine and by
untransforming these values; they are not necessarily the same as the means of the
untransfonned concentrations of morphine seen in Table 17.)

An ANOVA model was run on the log-transformed data for the concentration of
morphine. Upon running the model, the interaction term was not determined to be
significant (p-value = 0.897), so it was removed from the model. After the interaction term
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was removed, the two independent fields, group and d a t a b a s e , were both determined
to be significant (p-values both less than 0.0001); therefore, there is a statistically
significant difference between the ME and DUI datasets and a statistically significant
difference between at least two of the three drug pattern groups. The plots of the means for
each of these variable fields are seen in Figures 70 and 71. In Figure 70, the plot shows
that the concentration of morphine is statistically higher for the ME dataset than for the
DUI dataset. Because the ME and DUI datasets have significantly different means, there is
not sufficient evidence to suggest of development of tolerance to morphine. The ANOVA
indicated that there was a significant difference between the levels of the drug pattern
groups, but it does not specify which differences between the means of the drug pattern
groups are statistically significantly different. A Tukey's test was done to test for all
painvise differences, and the results of this test are seen in Table 17 wh.ere levels not
connected by the same letter are significantly different. Group 1 is different from both
Groups 2 and 3, but Groups 2 and 3 are not different from each other. (The values for the
means seen in Table 17 are of the untransformed, or raw, concentrations of morphine, and
they are reported in mg/L units.)

Plot of the Means
Log-transformed concentrations of morphine

-3.6
dui

Source Dataset

Figure 70: Plot of the means for "database" field for log-transformed morphine

Plot of the Means
Log-transformed concentration of morphine

morphine only

morphine and ethanol

poiy pharmacy

Drug Pattern Group

Figure 71: Plot of the means for "group" field for log-transformed morphine

Table 17: Levels of drug pattern groups for morphine from Tukey's test

Group
Group 1
Group 2
Group 3

~etter
A
B
B

Mean(Std. Error)
0.322(0.034)
0.134(0.018)
0.207(0.022)

The residual by predicted plot shows that the constant variance assumption is met
and that there does not show a systematic pattern. There also does not seem to be any
inadequacy with the ANOVA model. A normal quantile plot of the residuals for the fitted
model was also constructed (Appendix C). This plot showed no obvious problems with the
norniality assumption as the residuals followed the diagonal in the plot.
There is not an exact range of concentration for morphine that clinicians have
determined "fatal", so there is no definite way to know if there are individuals in the DUI
dataset that had a concentration of morphine that would be termed be "lethal". Since there
was a difference in the drug pattern groups in the ANOVA model, it implies that the
concentration of morphine varies depending on whether the individual had morphine only
or morphine with any drug. (Groups 2 and 3 were not statistically significantly different
from each other). Because the database field was significant, then there is a significant
statistical difference between the ME and DUI datasets, with the ME dataset having a
higher concentration of morphine.
3.4

Conclusions
Based on the evidence provided by the ANOVA models discussed in the previous

sections, there is not sufficient evidence to suggest the development of tolerances to
diphenhydramine, cocaine, oxycodone, hydrocodone, methadone, or morphine. The only
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exception to this is in the methadone dataset, where 14 individuals from the DUI dataset
had "lethal" concentrations of methadone (determined by clinical evidence). Because there
is not sufficient evidence for the development of tolerances with the ANOVA models does
not imply that tolerances cannot be developed for any of these drugs. The collection of and
data contained in the ME and DUI datasets do not provide adequate information to fully
answer the question of tolerance with respect to these drugs. One of the reasons that the
DUI dataset does not provide adequate information is because of the underestimation bias
due to the tier system. This is a downward bias that underestimates the number of drugs
found in persons suspected of DUI, which may have been a cause as to why the source
datasets were determined to be statistically significantly different. The analyses of these
six drug-specific datasets did provide selected cases that might be of interest to analyze
further for case studies. These cases included the fourteen individuals in the DUI dataset
with "lethal" concentrations of methadone in their system, the infant with an oxycodone
death, the case in the ME dataset with a concentration of hydrocodone of 0.0003 mg/L, and
the individuals in the ME dataset with diphenhydrarnine and cocaine concentrations higher
than the upper boundary of the clinical "fatal" blood concentration. All of these cases
would be of further interest to study for specific case analyses.

CHAPTER 4

Recommendations and Future Work
4.1

Summary of Project
The datasets used for this project came from the Office of the Chief Medical

Examiner (ME dataset) and the Department of Forensic Science (DUI datasets). The
original goals for this project were to investigate concentrations of THC in order to provide
information to the Virginia General Assembly for the purpose of enacting legislation
similar to that for ethanol intoxication. This informa.tion was anticipated to pertain to THC
concentration in drivers, to concentrations of THC that "intoxicate" individuals, how
ethanol affects THC, and to see if combinations of multiple drugs have additive affects.
Unfortunately, due to the form of the database, the data collection procedures, and the
overall quality of .the data, this goal was unable to be achieved. Because the original goals
could not be met, secondary objectives were set for this project. The new goals included
comparing the concentrations of diphenhydramine, cocaine, oxycodone, hydrocodone,
methadone, and morphine between the ME and DUI datasets and between three groups:
drug only, drug and ethanol, or drug with any other combination of drug. The motivation
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for this analysis was to investigate the possibility that some individuals in the DUI dataset
have developed tolerances to some of these drugs to the point that the amount in their
system approximates the amount that would be considered a lethal concentration for most
individuals.
The first part of this thesis includes a description of each of the datasets and the
modifications made to use them in analysis. Attempts were made to identify and correct
all prob1em.s with these datasets in order to address the research questions. These problems
in the datasets included changing character fields to numeric fields, correcting grammatical
errors, addressing the missing data and underestimation issues, and creating new variable
fields needed for analysis. Multiplechanges had to be made to existing data fields in order
to combine the data across the various datasets to allow the data analysis.
Once these changes were made to the datasets, a two-factor ANOVA was done to
look for differences between the ME and DUI datasets and between the drug pattern
groups created to divide each drug dataset. It was stated a priori that if the source datasets
were not significantly different or if the concentrations in DUI dataset tended to be higher
than the cases in the ME dataset, then this would constitute evidence to suggest that
individuals in the DUI dataset that have built up tolerances to the drugs.
In the analyses of the six drug datasets, all of the datasets showed that the
database field was significant, implying that the two datasets had statistically

significant differences with respect to the drug concentration levels. Thus, there was no
evidence to suggest that individuals in the DUI datasets had developed tolerances to any of
.the six drugs. In. all of the datasets, except for morphine, the drug pattern group variable
111
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field wa.s significant, meaning that depending on whether an individual had the drug only,
the drug and ethanol, or the drug with any other combination of drug, the concentration for
that drug would vary. The analyses did not provide any evidence to support the original
hypothesis, but they did pinpoint some individuals in the DUI and ME datasets that might
be of further interest in a case study.
The main outcome of the project was that the datasets were unable to establish
evidence of tolerance. This does not mean that those stopped for DUI do not have a
tolerance to the six drugs studied, just that the analysis did not show any evidence for it.
Several reasons are possible for this result, including that the DUI dataset was collected
based on a tier system, and thus, not all concentrations for all drug were recorded in the
dataset. The tier system creates mean concentrations that are biased downward (number of
drugs and concentrations of drugs were all underestimated). Suggestions and
recommendations will be made in the next section (Section 4.2) on how to change the
datasets and data collection procedures in order to possibly allow the question of tolerance
to be answered with a future dataset. Some of these changes are already being
implemented into the ME database, and others will be given the OCME to suggest other
ways to improve their data quality.
4.2

Recommendations for Change
On average, one out of every eight death certificates in Virginia is sent back to the

medical examiner because it is "~ninterpretable"~~.
This is evidence of the problems in the
ME dataset. Another reason that the ME dataset had problems is because of the number of
people who enter the information into the database. At this time, there are no rules
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concerning how the data is entered or who enters it. Most of the fields in this database are
free text fields, which allows for any character, number, or symbol to be entered into this
field. If .the database was reorganized so that it had drop-down menus instead of free text
fields, many of the free-text problems would be eliminated. For example, in the cause
of death field, instead of having a free text field where an unlimited number of

characters or words can be entered, a menu that allows the data entry person to choose
from "drug overdose", "lethal injection", "drowning", "fall", "gunshot wound", etc., would
be more beneficial for analysis than the current design of the database. Eliminating free
text fields would ensure that all entries into the database are standardized - a more usefbl
form for analysis. The DUI datasetsdid not have many free text problems, but a dropdown menu for drugs or concentration amounts would be beneficial and a time-saving
technique for future use of the dataset.
The DUI dataset is currently designed to test blood samples using the tier system
described in Chapter 2. Because of the tier system, all drugs except ethanol are
underestimated in the DUI dataset. The tier system was designed to save time and money
for the state laboratories that do the analysis of the blood samples, and once a drug is found
at a concentration high enough for conviction, then no other drugs are tested. To avoid the
underestimation problem in the future, a random sample of blood samples from DUI
suspects could be tested for all possible drugs. Thus, the drug coiicentrations from those in
the random sample would not be underestimated. This data could then be used to give a
better idea of the number of people in Virginia that drive under the influence of drugs, and
to have a fuller range of the drugs that are being used across the state.
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The Commonwealth of Virginia sends all death certificate information to the
National Center for Health Statistics where the death certificates are used to generate
National Death Index (NDI) codes. Currently, the OCME does not automatically receive
these death codes, unless they specifically request them for research purposes. One
suggestion for the OCME is to request these codes regularly and incorporate them into the
ME database so that when research projects are being done, no fiuther categorization on
cause of death fields has to be done. Having the NDI codes would allow researchers

to compare Virginia death statistics nationally or with specific states.
Another recommendation for the ME database is to attempt to detect the drugs in a
consistent manner, i.e. in the same tissues. Usually, if the drug was detected in a tissue
other than blood, it was because a blood sample was not available or more information was
needed regarding the nature of the dea.th (i.e. suicide vs. accident120. If a standard system
existed for routinely testing drugs in specific tissues, then fewer cases would be lost when
trying to compare datasets. If a drug was tested and detected in the brain tissue, but not in
blood, then that individual was not included in the analysis for this project because it is
extremely problematic to convert brain concentrations to blood concentrations for analysis.
Another solution to this problem is to have a reference tool designed that allows drug
concentrations from one tissue to be converted into an equivalent amount for the tissue
desired. This solution would be difficult because the clinical evidence for finding
equivalent concentrations is inconclusive.
In the DUI dataset, the data collected does not provide the information needed to
check for individuals appearing in the dataset more than once. To fix this problem, the
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DUI dataset should collect and keep cross-referencing information to look for these
individuals. This information could be a combination of driver's license number, social
security number, date of birth, or full name. Keeping this information would help in
analysis to verify the independence assumption.
Some of the changes that have been suggested are currently being made to the ME
dataset. The OCME is reorganizing their database to be more "user-friendly" (including
using drop-down menus), and the Chief Medical Examiner, Dr. Marcella Fierro, sent a
statewide message to medical examiners concerning the consistency of their reporting3'.
"Furthermore, they are writing an SOP [Standard Operating Procedure] for the MEs to
f o l l o ~ " ~because
'
of what this project uncovered.
4.3

Future Work
There are many questions that were left unanswered at the end of this project, and

they are all ideas for future work with the ME and DUI datasets. One proposal is to use
the location information ( c o u r t name or place o f d e a t h ) to look at prevalence of
drugs in certain regions of Virginia. This information could be displayed by means of a
map with certain areas highlighted that show problem areas for specific drugs, displaying
the number of drugs found in a certain area, or the ratio of the number of drugs found to
the number of people (or children) in an area.
Another suggestion for future work is to redo the analysis done in this thesis, but
without using the tier system mentioned in Section 2.2.5. To have more accurate results, a
random sample of DUI suspects is needed that tests the blood samples for all possible
drugs. By doing this, the blood concentration data for the DUI dataset would not be
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underestimated. An alternative way to do this analysis would be to answer the question
"Are the two source datasets equivalent when it comes to the selected drugs?" This was
perhaps a better way to do this study.
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APPENDIX A
Testing Protocol for Drugs in the DUI Dataset
FEE SCHEDULE FOR APPROVED LABORATORY ANALYSES
OF BLOOD FOR ALCOHOJ, AND DRUGS
ALLOWED FEES
Level I

Alcohol Testing

$50

Level I1

Drug Screening
Drug IdentificatiodQuantitation

$50
$75 I Drug Class *

Level 111

Drug Screening
Drug IdentificationQuantitation

$50
$75 I Drug Class *

*

Includes results for all drugs reported in a class

ANALYTICAL SCHEME
All analyses shall be for the unconiu~ated(free) form of drugs.
1.

Analyze all samples for ethanol (Alcohol screening may be performed, if desired, using immunoassay.)
a. If ethanol is less than 0.09%, include it in the report, and go to 2.
b. If ethanol is at or above 0.09%, stop; report results.

2. Perform Level I1 Drug Screening:
a. If no drug classes are detected, go to 4.
b. If any drug is tentatively present at or above the reporting limit, go to 3.
3. Perform Level I1 IdentificatiodQuantitation:
a. If no drugs are present, or are identified as present but at a concentration below the reporting limit, go
to 4.
b. If drugs are identified as present at a concentration at or above the reporting limit, but below the stop
analysis limit, include them in the report, and go to 4.
c. If drugs are identified as present at a concentration at or above the stop analysis limit, stop;report
results.
4.

Perform Level 111 Screening:
a. If any drug is tentatively identified as present, go to 5.
b. If no drugs are present, stop;report results.

5. Perform Level I11 IdentificationtQuantitation:
a. Report results.

ANALYTICAL LIMITS
Level I

Alcohol Testing (Limits are in units of % by weight by volume)

LIMIT

LIMIT**

Ethanol

'* Do not proceed further in the analytical scheme when results at or above this concentration
are obtained.

Level I1

Drug Screening and IdentificationIQuantitation(Limits are in units of mg/L)

I-

SCREENING

DRUG CLASS

DRUG
I

Amphetamine

1 Amphetamine

REPORTING
LIMIT
0.01

I

STOP ANALYSIS
LIMIT **
0.1

( Methylenedioxyamphetamine
Barbiturate

( Amobarbital

I

Butabarbital
Butalbital
Pentobarbital
Phenobarbital
Secobarbital
Cocaine
Benzoylecgonine
Cocaethylene
Alprazolam
Chlordiazepoxide
Clonazepam
Diazepam
Lorazepam
n-Desalky lflurazepam
Nordiazepam
Oxazepam
~emaze~am
Tetrahydrocannabinol

I

Hydrocodone
Morphine
6-Acetylmorphme
Oxycodone

Cocaine1
Benzoylecgonine
Benzodiazepine

I
Cannabinoid

0.02

0.06

** Do not proceed further in the analytical scheme when results t or above this concentration are
obtained.

Level I11

Drug Identification/Quantitation(Limits are in units of mg/L)

DRUG CLASS
Antih~stamine

Antidepressant,
Antipsychotic

Hypnotic
Muscle Relaxant

Opiate/
Opiate-like

Ketamine
Phencyclidine

DRUG

REPORTING
LIMIT

Chlorphenirarnine
Brompheniramine
Dextromethorphan
Diphenhydramine
Promethazine
Amitriptyline
Buproprion
Clomipramine
Clozapine
Desipramine
Doxepin
Haloperidol
Imipramine
Mirtazapine
Nortriptyline
Nordoxepin
Trazodone
Zolpidem
Carisoprodol
Meprobamate
Methocarbamol
Cyclobenzaprine
Dlhydrocodeine
Hydromorphone
Oxyrnorphone
Meperidine
Methadone
Pentazocine
Propoxyphene
Tramadol
Ketamine
Phencyclidine

0.02
0.02
0.1
0.02
0.02
0.05
0.05
0.05
0.05
0.05
0.05
0.02
0.05
0.02
0.05
0.05
0.05
0.02
1
1
1
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.05
0.01

Appendix B
Flow Chart of Exclusion Criteria
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Appendix C
Analyses of the Residuals
Residual by Predicted Plot for diohenhvdramine

Predicted

I
Figure 66c: Residual by predicted plot for diphenhydramine

Normal Quantile Plot of Residuals - diphenhydramine
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-1

0

1

2

Normal Quantile Plot
--

Figure 67c: Normal quantile plot of residuals for diphenhydramine

Residual by Predicted Plot for cocaine

I

I

I

Predicted

Figure 68c: Residual by predicted plot for cocaine

Normal Ouantile Plot of Residuals - cocaine

I

Normal Quantile Plot

I

Figure 69c: Normal quantile plot of residuals for cocaine

I

Residual by Predicted Plot for oxycodone
1

Predicted
Figure 70c: Residual by predicted plot for oxycodone

Normal Quantile Plot of Residuals - oxycodone

Normal Quantile Plot
Figure 71c: Normal quantile plot of residuals for oxycodone

Residual by Predicted Plot for hydrocodone

I

I

Predicted

Figure 72c: Residual by predicted plot for hydrocodone

Normal Quantile Plot of Residuals - hydrocodone
, . .
3-

I

Normal Quantile Plot

I

Figure 73c: Normal quantile plot of residuals for hydrocodone

Residual by Predicted Plot for methadone

Predicted
Figure 74c: Residual by predicted plot for methadone

Normal Ouantile Plot of Residuals - methadone
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Normal Quantile Plot
Figure 75c: Normal quantile plot of residuals for methadone

Residual bv Predicted Plot for momhine

-6 -5 -4 -3 -2 -1 0 1 2
Predicted
--

--

Figure 76c: Residual by predicted plot for morphine

I

Normal Quantile Plot

Figure 77c: Normal quantile plot of residuals for morphine

Appendix D
SAS Code
libname thesis 'C:\Documentsand Settings\Owner\Desktopl;
*ME DATABASE;
*Import the JMP file - from the Excel file;
PROC IMPORT OUT= thesis.ME1
DATAFILE= "E:\Thesis Files\MEoriginal.jmpl'
DBMS=JMP REPLACE;
RUN;
proc freq data = thesis.me1;
tables fatality premise-of-death;
run ;
/*Combine asphyxia, poisoning, vehicular fatality groups and combine
premise of death street, house, water, and hospital groups*/
data thesis.meclean1;

set thesis.me1;
attrib fatalnew format=$58.;
attrib premisenew format=$19.;
if fatality = 'ASPHYXIA: ASPIRATION/CAFE CORONARY' I fatality =
'ASPHYXIA: MECHANICAL/POSITIONAL1 1 fatality =
'ASPHYXIA: PLASTIC BAG' then fatalnew = 'Asphyxia';
else if fatality = 'POISONING: CARBON MONOXIDE (FAULTY HEATER)' I
fatality = 'POISONING:CARBON MONOXIDE (FIRE SMOKE
INHALATION)' I fatality = 'POISONING: CARBON MONOXIDE
(GENERATOR)' ( fatality = 'POISONING: CARBON MONOXIDE (MOTOR
VEHICLE EXHAUST)' then fatalnew = 'CO poisoning';
else if fatality = 'POISONING: ALCOHOL-ETHANOL' I fatality =
'POISONING: DRUGS, OTHER POISONS' I fatality =
'POISONING: OTHER ALCOHOLS' then fatalnew =
'Drug Poisoning';
else if fatality = 'VEHICULAR: AUTO/TRUCK (DRIVER)' I fatality =
'VEHICULAR:AUTO/TRUCK (PASSENGER)' I
fatality = 'VEHICULAR: AUTO/TRUCK (PEDESTRIAN)'
then fatalnew = 'Vechicle';
else fatalnew = fatality;
if premise-of-death = 'STREET: ADJACEN' I premise-of-death =
'STREET: ALLEY' 1 premise-of-death = 'STREET: BRIDGE' I
premise-of-death = 'STREET: DITCH' I premise-of-death =
'STREET: DRIVEWA' I premise-of-death = 'STREET: HIGHWAY' I
premise-of-death = 'STREET: INTERST' I premise-of-death =
'STREET: NONSPEC' 1 premise-of-death = 'STREET: PARKING1 I
premise-of-death = 'STREET: SIDEWAL' then premisenew =
'Street';

else if premise-of-death = 'WATER: LAKE' ( premise-of-death =
'WATER: OTHER' then premisenew = 'Water';
else if premise-of-death = 'HOME: APARTMENT' I premise-of-death =
'HOME: GARAGE/SHf I premise-of-death = 'HOME: HOUSE/RES1 (
premise-of-death = 'HOME: NONSPECIF' I premise-of-death =
'HOME: TRAILER' I premise-of-death = 'HOME: YARD/PORC1
then premisenew = 'Home';
else if premise-of-death = 'HOSPITAL/INPATIf1
premise-of-death = 'HOSPITAL/MENTAL1( premise-of-death =
'HOSPITAL/OUTPAT'then premisenew = 'Hospital';
else premisenew = premise-of-death;
drop premise-of-death fatality;
*Remove all double spaces and any periods at the end;
index = find(cause-of-death, '
'il);
new = substrn(cause-of-death, 1, index) I I
substrn(cause-of-death, index+2, length(cause-of-death));
cause-of-death = new;
new2 = cause-of-death;
end = length(cause-of-death);
str = substrn(new2,end);
if str eq ' . ' then per = 1;
else per = 0;
if per = 1 then substr(new2, end) = " ;
cause-of-death = new2;
drop index new new2 per str end;
I ,

*Fixing drug names to match in both datasets;
if drug-s- = "METHYLENEDIOXYAMPHETAMINE" then drug-s- = "MDA";
if drug-s- = "METHYLENEDIOXYMETHAMPHETAMINE"then drug-s- =
" MDMA " ;
if drug-s- = "BENZOYL ECGONINE" then drug-s- = "BENZOYLECGONINE";
if drug-s- = "DESOXYCHLORDIAZEPOXIDE"then drug-s- =
" CHLORDIAZEPOXIDE";
if drug-s- = "MONOACETYLMORPHINE" then drug-s- = "ACETYLMORPHINE";
if drug-s- = "BUPROPION (WELLBUTRIN)" then drug-s- = "BUPROPION";
attrib gender format = $4.;
if sex = 'FEMALE' then gender = ' F ' ;
else if sex = 'MALE' then gender = 'MI;
else if sex = 'NULL' then gender = ' N ' ;
else gender = " ;
*so that blood will come first alphabetically (or last descending);
if bac = 'BLOOD(P0ST)' then bac = 'aBLOOD(P0ST)
';
if bac = 'BLOOD(PRE)' then bac = 'bBLOOD(PRE)' ;
if bac = 'BILE' then bac = 'cBILE';
if bac = 'LIVER' then bac = 'dLIVERf;
if bac = 'URINE' then bac = 'eURINE1;
if bac = 'GASTRIC' then bac = '£GASTRIC1;

if bac = 'VITREOUS' then bac = 'gVITREOUS1;
if bac = 'BRAIN' then bac = 'hBRAINt;
drug = drug-s-;
attrib database format = $3.;
database = 'me';
attrib presence format = $31.;
presence = " ;
*Count will keep track of the number of grammatical fixes
for each observation;
count = 0:
drop sex drug-s-;
run ;

proc freq data=thesis.mecleanl;
tables fatalnew premisenew;
run ;

/*match tissues to correct drug & fix cause of death misspellings
and create units of measurement*/
data thesis.metissues;
set thesis .mecleanl;
if drug = 'ETHANOL' then unit = 'Grams%';
else if bac = 'aBLOOD(P0ST)' I bac = '£GASTRIC1 I bac = 'gVITREOUS1
I bac = 'bBLOOD(PRE)' I bac = 'eURINEtthen unit = 'mg/L1;
else if bac = 'dLIVER1 I bac = 'cBILE' I bac = 'hBRAIN1 then unit =
'mg/kgq
;
else unit = " ;
index = find(cause-of-death, 'AMTRIPTYLINE', ' i t ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'AMITRIPTYLINE' I I
substrn(cause~of~death,index+l2,length(cause~of~death)
);
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'INTOXICIATION', 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'INTOXICATION' I I
substrn(cause~of~death,index+l3,length(cause~of~death)
);
count = count + 1;
end;
else temp = cause-of-death;

cause-of-death = temp;
index = find(cause-of-death, 'INTOXICATIKON','i');
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1) ( I
'INTOXICATION' I (
substrn(cause~of~death,index+l3,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'POINSONING','i');
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1) I I
'POISONING' I I
substrn(cause~of~death,index+l0,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'POISIONING','i');
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1) I I
'POISONING' 1 I
substrn(cause~of~death,index+l0,length(cause~of~death)
);
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'HOUSE FIRE', 'i');
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1) ( 1
'HOUSEFIRE' ( 1
substrn(cause~of~death,index+l0,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'HERION', 'i');
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1) I I
'HEROIN' 1 )
substrn(cause~of~death,index+6,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'HERION', 'i');

if index ne 0 then do;
II
temp = substrn(cause~of~death,l,index-1)
'HEROIN' I I
substrn(cause~of~death,index+6,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'HREOIN', 'i');
if index ne 0 then do;
II
temp = substrn(cause~of~death,l,index-1)
'HEROIN' ( 1
substrn(cause~of~death,index+6,length(cause~of~death)
);
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'HEROIN, POISONING ' , ' i t ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)I I
'HEROIN POISONING' 1 (
substrn(cause~of~death,index+l8,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-.-death= temp;
index = find(cause-of-death, 'LIKELY ' , 'i');
if index ne 0 then do;
II
temp = substrn(cause~of~death,l,index-1)
'LIKELY,' I I
substrn(cause~of~death,index+7,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'AND', 'i');
if index ne 0 then do;
II
temp = substrn(cause~of~death,l,index-1)
'&'

II

substrn(cause~of~death,index+3,length(cause~of~death));
count = count + 1;

end ;
else temp = cause-of-death;
cause-of-death = temp;
*Occurs more than once - see comment below;
index = find(cause-of-death, 'AND', 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II

'&'

II

substrn(cause~of~death,index+3,length(cause~of~death)
);
count = count + 1;

end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'DUE TO', 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
( I
'D/T' I (
substrn(cause~of~death,index+6,length(cause~of~death)
);
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
*if 'DUE TO' occurred more than once, find only picks up the
first time;
index = find(cause-of-death, 'DUE TO', 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'D/T8 I I
substrn(cause~of~death,index+6,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'D/TTO', 'i');
if index ne 0 then do;
temp = substrn.(cause~of~death,l,index-1)
1)
'D/T11 )
substrn(cause~of~death,index+6,length(cause~of~death)
1;
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, ' , & ' , 'i');
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1) I I
' & ' I1
substrn(cause~of~death,index+4,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
*Delete all spaces after commas;
index = find(cause-of-death, ' , ' ,
if index ne 0 then do;

'i');

temp = substrn(cause-of-death,l,index-1)
'

I

'

II

II

substrn(cause~of~death,index+2,length(cause~of~death));
count = count + 1;

end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, ' ,
'i');
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1)
I ,

'

1

'

II

II

substrn(cause~of~death,index+2,length(cause~of~death));
count = count + 1;

end ;
else temp = cause-of-death;
cause-of-death = temp;
*Remove all periods and replace with commas;
'if);
index = find(cause-of-death,
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1)
I

'

1

'

.

'

,

1I

II

substrn(cause~of~death,index+l,length(cause~of~death));
count = count + 1;

end ;
else temp = cause-of-death;
cause-of.-death = temp;
index = find(cause-of-death, ' ) I ' , 'i');
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1) I I
' 1 ' I1
substrn(cause~of~death,index+2,length(cause~of~death~
1;
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'OLAANZAPINE','i');
if index ne 0 then do;
1)
temp = substrn(cause~of~death,l,index-1)
'OLANZAPINE' I I
substrn(cause~of~death,index+ll,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'CINTRIBUTING','i');
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1) ( I
'CONTRIBUTING' I I

substrn(cause~of~death,index+l2,length(cause~of~death)
);
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'AUTOMOBILE', ' i ' ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
(1
'CAR' I I
substrn(cause~of~death,index+l0,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'AUTO ' , 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
(1
'CAR' I I
substrn(cause~of~death,index+5,length(cause~of~death)
);
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'DEPHENHYDRAMINE', ' i t ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
( I
'DIPHENHYDRAMINE' I I
substrn(cause~of~death,index+l5,length(cause~of~death)
;
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'DIPENHYDRAMINE', 'i');
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1) I (
'DIPHENHYDRAMINE' 1 I
substrn(cause~of~death,index+l4,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'BENADRYL',' i ' ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
I(
'DIPHENHYDRAMINE' I I
substrn(cause~of~death,index+8,length(cause~o£~death)
1;
count = count + 1;

end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'DIPHENYDRAMINE','i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'DIPHENHYDRAMINE' I I
substrn(cause~of~death,index+l4,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'DIPHENYHDRAMINE','i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'DIPHENHYDRAMINE' 1 1
substrn(cause~of~death,index+l5,length(cause~o£~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'COCANE', 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,llindex-1)
II
'COCAINE' 1 )
substrn(cause~of~death,index+6,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'CICAINE',' i t ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
1)
'COCAINE' 1 (
substrn(cause~of~death,index+7,length(cause~of~death)
);
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'COCAIN ' , 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'COCAINE' I I
substrn(cause~of~death,index+7,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;

index = find(cause-of-death, 'COCIANE',' i t ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'COCAINE' I (
substrn(cause~of~death,index+7,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'HEARD', ' i t ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
1I
'HEART' I I
substrn(cause~of~death,index+5,length(cause~of~death)
);
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'SYSTEMMIC','i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'SYSTEMIC' ( 1
substrn(cause~of~death,index+9,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'HEROINE','i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
I(
'HEROIN' I I
substrn(cause~of~death,index+7,length(cause~of~death)
1;
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'OXCODONE', 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'OXYCODONE' I I
substrn(cause~of~death,index+8,length(cause~of~death));
count = count + 1;
end;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'EXYCODONE','i');
if index ne 0 then do;

temp = substrn(cause-of-death,l,index-1)
'OXYCODONE'

II

II

substrn(cause~of~death,index+9,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, ' P X Y C O D O N E ' , 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'OXYCODONE'

II

substrn(cause~of~death,index+9,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, ' O X Y C O N T I N ' , 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'OXYCODONE' I (
substrn(cause~of~death,index+9,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, ' O C Y C O D O N E ' , ' i t ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
1)
'OXYCODONE'

II

substrn (cause-of-death,index+9,length (cause-of-death) )
count = count + 1;

;

end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, ' A L P R O Z O L A M ' , 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'ALPRAZOLAM'

II

substrn(cause~of~death,index+l0,length(cause~of~death));
count = count + 1;
end;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, ' O X Y C O C O N E ' , 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'OXYCODONE'

1)

substrn(cause~of~death,index+9,length(cause~of~death)
);

count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'OXYCONDONE', ' i t ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
I(
'OXYCODONE' ( I
substrn(cause~of~death,index+l0,length(cause~of~death));
count = count + 1;
end;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'OXYODONE', 'i');
if index ne 0 then do;
II
temp = substrn(cause~o£~death,l,index-1)
'OXYCODONE'

II

substrn(cause~of~death,index+8,length(cause~of~death));
count = count + 1;

end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'HYDROCONE', ' i ' ) ;
if index ne 0 then do;
temp = substrn (cause-of-death,1,index-1) I I
'HYDROCODONE' 1 (
substrn(cause~of~death,index+9,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'HYRDOCODONE', ' i t ) ;
if index ne 0 then do;
1)
temp = substrn(cause~of~death,l,index-1)
'HYDROCODONE'

II

substrn(cause~of~death,index+ll,length(cause~of~death));
count = count + 1;

end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'HYDROCDONE', 'i');
if index ne 0 then do;
1)
temp = substrn(cause~of~death,l,index-1)
'HYDROCODONE'

II

substrn(cause~of~death,index+l0,length(cause~o£~death));
count = count + 1;

end ;
else temp = cause-of-death;

cause-of-death = temp;
index = find(cause-of-death, 'HYDOCODONE', 'i');
if index ne 0 then do;
1)
temp = substrn(cause~of~death,l,index-1)
'HYDROCODONE'

II

substrn(cause~of~death,index+l0,length(cause~of~death));
count = count + 1;

end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'HYDROCOONE', 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)( I
'HYDROCODONE'

II

substrn(cause~of~death,index+l0,length(cause~of~death)
);
count = count + 1;

end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-de-ath, 'HYROCODONE', 'i');
if index ne 0 then do;
II
temp = substrn(cause~of~death,l,index-1)
'HYDROCODONE'

1)

substrn (cause-of-death,index+lO,length (cahse-of-death) )
count = count + 1;

;

end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'MYODROCODONE', 'i');
if index ne 0 then do;
( I
temp = substrn(cause~of~death,l,index-1)
'HYDROCODONE'

1I

substrn(cause~of~death,index+l2,length(cause~of~death));
count = count + 1;

end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'METHADON ' , 'i');
if index ne 0 then do;
( I
temp = substrn(cause~of~death,l,index-1)
'METHADONE'

II

substrn(cause~of~death,index+9,length(cause~of~death));
count = count + 1;

end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, ' C O C A I N E E ' ,

'i');

if index ne 0 then do;
II
temp = substrn(cause~of~death,l,index-1)
'COCAINE' 1 )
substrn(cause-of-death,index+8,length (cause-of-death) )
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;

;

index = find(cause-of-death, 'MENTADONE',' i t ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
( 1
'METHADONE' 1 )
substrn(cause~of~death,index+9,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'METHADNE','i');
if index ne 0 then do;
II
temp = substrn(cause~of~death,l,index-1)
'METHADONE' I I
substrn(cause~of~death,index+8,length(cause~of~death)
1;
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'METHODONE',' i t ) ;
if index ne 0 then do;
1)
temp = substrn(cause~of~death,l,index-1)
'METHADONE' 1 I
substrn(cause~of~death,index+9,length(cause~of~death)
);
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'METHADDONE','i');
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1) I I
'METHADONE' I I
substrn(cause~of~death,index+l0,length(cause~of~death)
1;
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'MEHTADONE',' i t ) ;
if index ne 0 then do;
II
temp = substrn(cause~of~death,l,index-1)
'METHADONE' I I

substrn(cause~of~death,index+9,length(cause~of~death));
count = count + 1;

end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'COODEINE', 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'CODEINE' I I
substrn(cause~of~death,index+8,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'ALCOHOL','i');
if index ne 0 then do;
II
temp = substrn(cause~of~death,l,index-1)
'ETHANOL' I I
substrn(cause~of~death,index+7,length(cause~of~death)
1;
count = count + 1;
end ;
else temp = cause-of-dea-th;
cause-of-death = temp;
index = find(cause-of-death, 'POISONINGN',' i t ) ;
if index ne 0 then do;
II
temp = substrn(cause~of~death,l,index-1)
'POISONING' I I
substrn(cause~of~death,index+l0,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'EHTANOL',' i t ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'ETHANOL' I I
substrn(cause~of~death,index+7,length(cause~o£~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'POISONING',' i t ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'POISONING' 1 )
substrn(cause~of~death,index+9,length(cause~of~death));
count = count + 1;
end ;

else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'SBBSTANCE', 'i');
if index ne 0 then do;
temp = substrn(cause~~of~death,1,index-1)
II
'SUBSTANCE' I (
substrn(cause~of~death,index+9,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'MORPH ' , 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'MORPHINE' I I
substrn(cause~of~death,index+6,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'DEXTROMETH ' , ' i t ) ;
if index ne 0 then do;
II
temp = substrn(cause~o£~death,l,index-1)
'DEXTROMETHORPHAN' 1 )
substrn(cause~of~death,index+ll,length(cause~of~death)
1;
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'COC ' , 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
I(
'COCAINE' I (
substrn(cause~of~death,index+4,length(cause~o£~death));
count = count + 1;
end;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'ALPRAZOLM','i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'ALPRAZOLAM' ( I
substrn(cause~of~death,index+9,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;

index = find(cause-of-death, 'ALPAZOLAM','i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'ALPRAZOLAM' I I
substrn(cause~of~death,index+9,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'ALPRAXOLAM','i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'ALPRAZOLAM' 1 )
substrn(cause~of~death,index+l0,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'APRAZOLAM','i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
1(
'ALPRAZOLAM' I I
substrn(cause~of~death,index+9,length(cause~of~death)
);
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'ALPROAZOLAM', 'i');
if index ne 0 then do;
1)
temp = substrn(cause~of~death,l,index-1)
'ALPRAZOLAM' 1 I
substrn(cause~of~death,index+ll,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'ALPRAZOLEM',' i t ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'ALPRAZOLAM' I I
substrn(cause~of~death,index+l0,length(cause~of~death)
);
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'ALPRA ' , 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
1)

'ALPRAZOLAM' I I
substrn(cause~of~death,index+6,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'ALPAZOLAM','i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'ALPRAZOLAM' 1 I
substrn(cause~of~death,index+9,length(cause~o£~death)
1;
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'CODIENE','i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'CODEINE' I I
substrn(cause~of~death,index+7,length(cause~o£~death)
);
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'CODEIN ' , 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'CODEINE' I I
substrn(cause~of~death,index+7,length(cause~of~death))
;
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'PROP ' , ' i t ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
( I
'PROPOXYPHENE' I I
substrn(cause~of~death,index+5,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'PROPOXYHENE','i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'PROPOXYPHENE' I I
substrn(cause~of~death,index+ll,length(cause~of~death));
count = count + 1;

end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'PROPOX ' , 'i');
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
II
'PROPOXYPHENE' I (
substrn(cause~of~death,index+7,length(cause~o£~death)
);
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'PROPOX,','i');
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1) I I
'PROPOXYPHENE' I I
substrn(cause~of~death,index+7,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'CITALOPROM',' i t ) ;
if index ne 0 then do;
temp = substrn(cause~of~death,l,index-1)
(1
'CITALOPRAM' I I
substrn(cause~of~death,index+l0,length(cause~of~death));
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'CIALOPRAM', 'i');
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1) ( I
'CITALOPRAM' 1 I
substrn(cause~of~death,index+9,length(cause~of~death)
1;
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'DRUB','i');
if index ne 0 then do;
temp = substrn(cause-of-death,l,index-1) 1 )
'DRUG' I I
substrn(cause~of~death,index+4,length(cause~of~death)
1;
count = count + 1;
end ;
else temp = cause-of-death;
cause-of-death = temp;

"Changinng all variations to poisoning;
index = find(cause-of-death, 'TOXICITY','i');
if index ne 0 then temp = substrn(cause~of~death,l,index-1)
II
'POISONING' ( 1
substrn(cause~of~death,index+8,length(cause~of~death)
1;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'INTOXICATION', ' i f ) ;
if index ne 0 then temp = substrn(cause~of~death,l,index-1)
( 1
'POISONING' \ (
substrn(cause~of~death,index+l2,length(cause~of~death~
1;
else temp = cause-of-death;
cause-of-death = temp;
index = find(cause-of-death, 'OVERDOSE', 'i');
if index ne 0 then temp = substrn(cause~of~death,l,index-1)
(1
'POISONING' ( 1
substrn(cause~of~death,index+ll,length(cause~of~death~
1;
else temp = cause-of-death;
cause-of-death = temp;
if drug-s- = 'DIPHENYLAMINE' then drug-s- = 'DIPHENHYDRAMINE';
retain count;
drop temp;
drop index;
run ;
proc print data=thesis.metissues;
var drug unit bac presence;

run;
proc freq data=thesis.metissues;
tables bac;
run ;

*sort to be in correct order to next data statement;
proc sort data=thesis.metissues;
by case-number drug descending bac;
run ;
/*Creation of new variable arrays*/
data thesis.mefina1;
set thesis.metissues;
by case-number drug descending bac;
array names {139} $100. acetaminophen-n acetone-n acetylmorphine-n
alprazolam-n amitriptyline-n amoxapine-n amphetamine-n
benzoylecgonine-n benztropine-n brompheniramine-n bupropion-n
busiprone-n butabarbital-n butalbital-n caffeine-n

carbamazepine-n carbondioxide-n carbonmonoxide-n
carisoprodol-n chlordiazepoxide-n chlorodifluoromethane-n
chlorpheniramine-n chlorpromazine-n citalopram-n
clomipramine-n clonzepam-n clozapine-n cocaethlyene-n
cocaine-n codeine-n cyanide-n cyclobenzaprine-n
desalkyflurazepam-n desipramine-n dextromethorphan-n
diazepam-n difluoroethane-n dihydrocodeine-n diltiazem-n
diphenhydramine-n doxepin-n doxylamine-n ephedrine-n
ethanol-n ethyleneglycol-n fenfluramine-n fentanyl-n
fluoxetine-n fluvoxamine-n gabapentin-n
gamrnahydroxybutyrate-n guaifenesin-n hydrocodone-n
hydromorphone-n hydroxyzine-n ibuprofen-n imipramine-n
insulin-n isopropanol-n ketamine-n lithium-n lorazepam-n
lysergicaciddiethylamide-n mda-n mdma-n meclizine-n
meperidine-n meprobamate-n metaxalone-n methadone-n
methamphetamine-n methanol-n methocarbamol-n methotrexate-n
methylphenidate-n midazolam-n mirtazapine-n molidone-n
morphine-n naproxen-n nefazodone-n nicotine-n nitricacid-n
norchlorcyclizine-n nordiazepam-n nordoxepin-n
norfluoxetine-n normeperidine-n norpropoxyphene-n
nortriptylene-n olanzapine-n orphenadrine-n oxazepam-n
oxycodone-n oxymorphone-n pancuroniumbromide-n paraquat-n
paroxetine-n pentazocine-n pentobarbital-n pentoxifylline-n
phencyclidine-n phenobarbital-n phentermine-n
phenyltoloxamine-n phenytoin-n primidone-n promethazine-n
propane-n propoxyphene-n propranolol-n propyleneglycol-n
quetiapine-n quinine-n ritalinicacid-n salicylate-n
salicylicacid-n secobarbital-n sertraline-n temazepam-n
tetrafluroethane-n tetrahydrocannabinol-n thccarboxylicacid-n
theophylline-n thiopental-n thioridazine-n toluene-n
tramadol-n tranylcypromine-n trazodone-n triazolam-n
tricyclic-n trifluoperazine-n trihexyphenidyl-n
trimipramine-n valproic-n venlafaxine-n verapamil-n
zolpidem-n ('acetaminophen','acetone','acetylmorphine',
'alprazolam','amitriptyline','amoxapine','amphetamine',
'benzoylecgonine','benztropine', 'brompheniramine',
'bupropion','busiprone','butabarbital','butalbital',
'caffeine', 'carbamazepine','carbon dioxide', 'carbon
monoxide', 'carisoprodol','chlordiazepoxide',
'chlorodifluoromethane','chlorpheniramine',
'chlorpromazine','citalopram','clomipramine', 'clonzepam',
'clozapine','cocaethlyene','cocaine','codeine','cyanide',
'cyclobenzaprine','desalkyflurazepam', 'desipramine',
'dextromethorphan','diazepam', 'difluoroethane',
'dihydrocodeine','diltiazem','diphenhydramine','doxepin',
'doxylamine', 'ephedrine','ethanol','ethyleneglycol',
'fenfluramine','fentanyl', 'fluoxetine', 'fluvoxamine',
'gabapentin', 'gammahydroxybutyrate','guaifenesin',
'hydrocodone', 'hydromorphone','hydroxyzine','ibuprofen',
'imipramine','insulin','isopropanol','ketamine',
'lithium','lorazepam','lysergicaciddiethylamide', 'mda',
'mdrna','meclizine','meperidine','meprobamate',
'metaxalone','methadone','methamphetamine','methanol',

'methocarbamol', 'methotrexate', 'methylphenidate',
'midazolam', 'mirtazapine', 'molidone', 'morphine',
'naproxen','nefazodone', 'nicotine', 'nitricacid',
'norchlorcyclizine','nordiazepam', 'nordoxepin',
'norfluoxetine', 'normeperidine','norpropoxyphene',
'nortriptylene', 'olanzapine','orphenadrine', 'oxazepam',
'oxycodone', 'oxymorphone', 'pancuroniurnbromide','paraquat',
'paroxetine', 'pentazocine', 'pentobarbital',
'pentoxifylline','phencyclidine','phenobarbital',
'phentermine', 'phenyltoloxamine','phenytoin', 'primidone',
'promethazine', 'propane','propoxyphene','propranolol',
'propyleneglycol','quetiapine', 'quinine', 'ritalinicacid',
'salicylate', 'salicylicacid','secobarbital', 'sertraline',
'temazepam', 'tetrafluroethane', 'tetrahydrocannabinol',
'thccarboxylicacid','theophylline','thiopental',
'thioridazine'
, 'toluene', 'tramadol', 'tranylcypromine',
'trazodone', 'triazolam','tricyclic', 'trifluoperazine',
'trihexyphenidyl','trimipramine','valproic', 'venlafaxine',
'verapamil', 'zolpidem');
array drugs {I391 acetaminophen acetone acetylmorphine alprazolam
amitriptyline amoxapine amphetamine benzoylecgonine
benztropine brompheniramine bupropion busiprone butabarbital
butalbital caffeine carbamazepine carbondioxide
carbonmonoxide carisoprodol chlordiazepoxide
chlorodifluoromethane chlorpheniramine chlorpromazine
citalopram clomipramine clonzepam clozapine cocaethlyene
cocaine codeine cyanide cyclobenzaprine desalkyflurazepam
desipramine dextromethorphan diazepam difluoroethane
dihydrocodeine diltiazem diphenhydramine doxepin doxylamine
ephedrine ethanol ethyleneglycol fenfluramine fentanyl
fluoxetine fluvoxamine gabapentin gammahydroxybutyrate
guaifenesin hydrocodone hydromorphone hydroxyzine ibuprofen
imipramine insulin isopropanol ketamine lithium lorazepam
lysergicaciddiethylamide mda mdma meclizine meperidine
meprobamate metaxalone methadone methamphetamine methanol
methocarbamol methotrexate methylphenidate midazolam
mirtazapine molidone morphine naproxen nefazodone nicotine
nitricacid norchlorcyclizine nordiazepam nordoxepin
norfluoxetine normeperidine norpropoxyphene nortriptylene
olanzapine orphenadrine oxazepam oxycodone oxymorphone
pancuroniurnbromide paraquat paroxetine pentazocine
pentobarbital pentoxifylline phencyclidine phenobarbital
phentermine phenyltoloxamine phenytoin primidone promethazine
propane propoxyphene propranolol propyleneglycol quetiapine
quinine ritalinicacid salicylate salicylicacid secobarbital
sertraline temazepam tetrafluroethane tetrahydrocannabinol
thccarboxylicacid theophylline thiopental thioridazine
toluene tramadol tranylcypromine trazodone triazolam
tricyclic trifluoperazine trihexyphenidyl trimipramine
valproic venlafaxine verapamil zolpidem;
array amounts {I391 acetaminophen-c acetone-c acetylmorphine-c

alprazolam-c amitriptyline-c arnoxapine-c amphetamine-c
benzoylecgonine-c benztropine-c brompheniramine-c bupropion-c
busiprone-c butabarbital-c butalbital-c caffeine-c
carbamazepine-c carbondioxide-c carbonmonoxide-c
carisoprodol-c chlordiazepoxide-c chlorodifluoromethane-c
chlorpheniramine-c chlorpromazine-c citalopram-c
clomipramine-c clonzepam-c clozapine-c cocaethlyene-c
cocaine-c codeine-c cyanide-c cyclobenzaprine-c
desalkyflurazepam-c desipramine-c dextromethorphan-c
diazepam-c difluoroethane-c dihydrocodeine-c diltiazem-c
diphenhydramine-c doxepin-c doxylamine-c ephedrine-c
ethanol-c ethyleneglycol-c fenfluramine-c fentanyl-c
fluoxetine-c fluvoxamine-c gabapentin-c
gammahydroxybutyrate-c guaifenesin-c hydrocodone-c
hydromorphone-c hydroxyzine-c ibuprofen-c imipramine-c
insulin-c isopropanol-c ketamine-c lithium-c lorazepam-c
lysergicaciddiethylamide-c mda-c mdma-c meclizine-c
meperidine-c meprobamate-c metaxalone-c methadone-c
methamphetamine-c methanol-c methocarbamol-c rnethotrexate-c
methylphenidate-c midazolam-c mirtazapine-c molidone-c
morphine-c naproxen-c nefazodone-c nicotine-c nitricacid-c
norchlorcyclizine~cnordiazepam-c nordoxepin-c
norfluoxetine-c normeperidine-c norpropoxyphene-c
nortriptylene-c olanzapine-c orphenadrine-c oxazepam-c
oxycodone-c oxymorphone-c pancuroniumbromide-c paraquat-c
paroxetine-c pentazocine-c pentobarbital-c pentoxifylline-c
phencyclidine-c phenobarbital-c phentermine-c
phenyltoloxamine-c phenytoin-c primidone-c prornethazine-c
propane-c propoxyphene-c propranolol-c propyleneglycol-c
quetiapine-c quinine-c ritalinicacid-c salicylate-c
salicylicacid-c secobarbital-c sertraline-c temazepam-c
tetrafluroethane-c tetrahydrocannabinol-c thccarboxylicacid-c
theophylline-c thiopental-c thioridazine-c toluene-c
tramadol-c tranylcypromine-c trazodone-c triazolam-c
tricyclic-c trifluoperazine-c trihexyphenidyl-c
trimipramine-c valproic-c venlafaxine-c verapamil-c
zolpidem-c;
array levels (1391 $9. acetaminophen-1 acetone-1 acetylmorphine-1
alprazolam-1 amitriptyline-1 amoxapine-1 amphetamine-1
benzoylecgonine-1 benztropine-1 brompheniramine-1 bupropion-1
busiprone-1 butabarbital-1 butalbital-1 caffeine-1
carbamazepine-1 carbondioxide-1 carbonmonoxide-1
carisoprodol-1 chlordiazepoxide-1 chlorodifluoromethane-1
chlorpheniramine-1 chlorpromazine-1 citalopram-1
clomipramine-1 clonzepam-1 clozapine-1 cocaethlyene-1
cocaine-1 codeine-1 cyanide-1 cyclobenzaprine-1
desalkyflurazepam-1 desipramine-1 dextromethorphan-1
diazepam-1 difluoroethane-1 dihydrocodeine-1 diltiazem-1
diphenhydramine-1 doxepin-1 doxylamine-1 ephedrine-1
ethanol-1 ethyleneglycol-1 fenfluramine-1 fentanyl-1
fluoxetine-1 fluvoxamine-1 gabapentin-1

a r r a y p r e s s (139) $ 3 1 . a c e t a m i n o p h e n s a c e t o n e s a c e t y l m o r p h i n e g
a l p r a z o l a m g a m i t r i p t y l i n e s amoxapines amphetamines
b e n z o y l e c g o n i n e q b e n z t r o p i n e g brompheniramine-p b u p r o p i o n q
busiproneg butabarbitals b u t a l b i t a l s c a f f e i n e 2
c a r b a m a z e p i n e j c a r b o n d i o x i d e g carbonmonoxide-p
c a r i s o p r o d o l s chlordiazepoxides chlorodifluoromethaneg
chlorpheniramine-p c h l o r p r o m a z i n e g c i t a l o p r a m g
c l o m i p r a m i n e j clonzepamg c l o z a p i n e g c o c a e t h l y e n e g
c o c a i n e j codeine2 c y a n i d e s cyclobenzaprineg
desalkyflurazepam-p d e s i p r a m i n e g d e x t r o m e t h o r p h a n g
diazepams difluoroethanes dihydrocodeineg
d i l t i a z e m s diphenhydramines d o x e p i n s doxylamines
ephedrine2 ethanolg ethyleneglycolg fenfluramine2
f e n t a n y l g f l u o x e t i n e s fluvoxamine_p g a b a p e n t i n g
gammahydroxybutyrates g u a i f e n e s i n g h y d r o c o d o n e s
hydromorphoneg h y d r o x y z i n e g i b u p r o f e n 2 i m i p r a m i n e s
i n s u l i n 2 i s o p r o p a n o l - p k e t a r n i n e s l i t h i u m 2 1orazeparn-p
lysergicaciddiethylamideg m d a g mdmag m e c l i z i n e s
m e p e r i d i n e s meprobamate2 m e t a x a l o n e 2 m e t h a d o n e s
methamphetamine3 m e t h a n o l 2 methocarbamolg m e t h o t r e x a t e g
m e t h y l p h e n i d a t e g midazolamg m i r t a z a p i n e s m o l i d o n e g
morphines naproxenq nefazodoneg n i c o t i n e 3 n i t r i c a c i d j
n o r c h l o r c y c l i z i n e g nordiazepams nordoxeping
n o r f l u o x e t i n e - p n o r m e p e r i d i n e g norpropoxyphene-p
n o r t r i p t y l e n e - p o l a n z a p i n e g o r p h e n a d r i n e s oxazepams
o x y c o d o n e s oxymorphoneg pancuroniumbromide_p p a r a q u a t g
paroxetines pentazocineg pentobarbitalg pentoxifyllineg
phencyclidineg phenobarbital3 phentermineg

phenyltoloxamine-p phenytoins primidoneq promethazines
propanes propoxyphenes propranololq propyleneglycol~
quetiapines quinines ritalinicacids salicylateq
salicylicacidq secobarbitals sertralines temazepams
tetrafluroethaneq tetrahydrocannabinols thccarboxylicacid_p
theophylline_p thiopentalq thioridazines toluenes
tramadola tranylcypromines trazodoneq triazolamq
tricyclicq trifluoperazinej trihexyphenidyls
trimipramines valproicq venlafaxineq verapamils
zolpidemq;
if first.case-number then do;
do i = 1 to 139 by 1;
drugs{i) = .;
amounts{i) = .;
levels{i} = " ;
press{i} = " ;
*number-of-drugs keeps track of the number of drugs detected (not just
tested for);
number-of-drugs = 0;
end ;
end ;
do i =1 to 139 by 1;
if drug=upcase(names{i}) then do;
drugs{i) = 1;
press{i) = presence;
levels(i) = unit;
indexl = find(drug-level, ' M I , ' i ' )
;
index2 = find(drug-level, ' P ' , ' i ' )
;
index3 = find (drug-level, ' / ' , ' i ' ) ;
if indexl ne 0 then do;
amounts{i)=input(substrn(
drug-level,l,indexl-1),4.) ;
end ;
else if index2 ne 0 then do;
amounts{i) = .;
end;
else if index3 ne 0 then do;
amounts{i)=input(substrn(
drug-level,l,index3-1),4.)

;

end ;
else do;
amounts{i)
end ;

=

input(drug-level, 8.);

if amounts{i) ne 0 & press{i} ne 'not detected'
then number-of-drugs = number-of-drugs+l;

end ;
end ;
if 1ast.case-number then output;
retain case-number acetaminophen acetone acetylmorphine
alprazolam amitriptyline amoxapine amphetamine
benzoylecgonine benztropine brompheniramine bupropion
busiprone butabarbital butalbital caffeine carbamazepine
carbondioxide carbonmonoxide carisoprodol chlordiazepoxide
chlorodifluoromethane chlorpheniramine chlorpromazine
citalopram clomipramine clonzepam clozapine cocaethlyene
cocaine codeine cyanide cyclobenzaprine desalkyflurazepam
desipramine dextromethorphan diazepam difluoroethane
dihydrocodeine diltiazem diphenhydramine doxepin doxylamine
ephedrine ethanol ethyleneglycol fenfluramine fentanyl
fluoxetine fluvoxamine gabapentin gammahydroxybutyrate
guaifenesin hydrocodone hydromorphone hydroxyzine ibuprofen
imipramine insulin isopropanol ketamine lithium lorazepam
lysergicaciddiethylamide mda mdma meclizine meperidine
meprobamate metaxalone methadone methamphetamine methanol
methocarbamol methotrexate methylphenidate midazolam
mirtazapine molidone morphine naproxen nefazodone nicotine
nitricacid norchlorcyclizine nordiazepam nordoxepin
norfluoxetine normeperidine norpropoxyphene nortriptylene
olanzapine orphenadrine oxazepam oxycodone oxymorphone
pancuroniumbromide paraquat paroxetine pentazocine
pentobarbital pentoxifylline phencyclidine phenobarbital
phentermine phenyltoloxamine phenytoin primidone promethazine
propane propoxyphene propranolol propyleneglycol quetiapine
quinine ritalinicacid salicylate salicylicacid secobarbital
sertraline temazepam tetrafluroethane tetrahydrocannabinol
thccarboxylicacid theophylline thiopental thioridazine
toluene tramadol tranylcypromine trazodone triazolam
tricyclic trifluoperazine trihexyphenidyl trimipramine
valproic venlafaxine verapamil zolpidem acetaminophen-c
acetone-c acetylmorphine-c alprazolam-c amitriptyline-c
amoxapine-c amphetamine-c benzoylecgonine-c benztropine-c
brompheniramine-c bupropion-c busiprone-c butabarbital-c
butalbital-c caffeine-c carbamazepine-c carbondioxide-c
carbonmonoxide-c carisoprodol-c chlordiazepoxide-c
chlorodifluoromethane~cchlorpheniramine-c chlorpromazine-c
citalopram-c clomipramine-c clonzepam-c clozapine-c
cocaethlyene-c cocaine-c codeine-c cyanide-c
cyclobenzaprine-c desalkyflurazepam-c desipramine-c
dextromethorphan-c diazepam-c difluoroethane-c
dihydrocodeine-c diltiazem-c diphenhydramine-c doxepin-c
doxylamine-c ephedrine-c ethanol-c ethyleneglycol-c
fenfluramine-c fentanyl-c fluoxetine-c fluvoxamine-c
gabapentin-c gammahydroxybutyrate-c guaifenesin-c
hydrocodone-c hydromorphone-c hydroxyzine-c ibuprofen-c
imipramine-c insulin-c isopropanol-c ketamine-c lithium-c

lorazepam-c ly~ergicaciddiethylamide~c
mda-c mdma-c
meclizine-c meperidine-c meprobamate-c metaxalone-c
methadone-c methamphetamine-c methanol-c methocarbamol-c
methotrexate-c methylphenidate-c midazolam-c mirtazapine-c
molidone-c morphine-c naproxen-c nefazodone-c nicotine-c
nitricacid-c norchlorcyclizine-c nordiazepam-c nordoxepin-c
norfluoxetine-c normeperidine-c norpropoxyphene-c
nortriptylene-c olanzapine-c orphenadrine-c oxazepam-c
oxycodone-c oxymorphone-c pancuroniumbromide-c paraquat-c
paroxetine-c pentazocine-c pentobarbital-c pentoxifylline-c
phencyclidine-c phenobarbital-c phentermine-c
phenyltoloxamine-c phenytoin-c primidone-c promethazine-c
propane-c propoxyphene-c propranolol-c propyleneglycol-c
quetiapine-c quinine-c ritalinicacid-c salicylate-c
salicylicacid-c secobarbital-c sertraline-c temazepam-c
tetrafluroethane-c tetrahydrocannabinol-c thccarboxylicacid-c
theophylline-c thiopental-c thioridazine-c toluene-c
tramadol-c tranylcypromine-c trazodone-c triazolam-c
tricyclic-c trifluoperazine-c trihexyphenidyl-c
trimipramine-c valproic-c venlafaxine-c verapamil-c
zolpidem-c acetaminophenj acetones acetylmorphines
alprazolams amitriptylines amoxapines amphetamine3
benzoylecgonines benztropinej brompheniramineg bupropiong
busipronej butabarbitals butalbitalj caffeine9
carbamazepinej carbondioxideq carbonmonoxidej
carisoprodolg chlordiazepoxide_p chlorodifluoromethaneg
chlorpheniraminej chlorpromazineq citalopramg
clomipraminej clonzepamg clozapineq cocaethlyeneq
cocaine2 codeine2 cyanides cyclobenzaprineq
desalkyflurazepam_p desipramine9 dextromethorphanj
diazepams difluoroethanes dihydrocodeines diltiazems
diphenhydraminej doxeping doxylaminej ephedrine2
ethanolq ethyleneglycols fenfluramine_p fentanylj
fluoxetines fluvoxamineg gabapentinj
gammahydroxybutyratej guaifenesins hydrocodonej
hydromorphoneg hydroxyzineq ibuprofenq imipraminej
insulin2 isopropanolg ketamines lithiurns lorazepamj
lysergicaciddiethylamidej m d a s m d m a j meclizineq
meperidines meprobamates metaxaloneq methadones
methamphetamines methanol9 methocarbamolq methotrexatej
methylphenidatej midazolamq mirtazapinej molidonej
morphines naproxens nefazodoneq nicotine2 nitricacidj
norchlorcyclizineq nordiazepamg nordoxepinj
norfluoxetinej normeperidineg norpropoxyphenej
nortriptyleneq olanzapines orphenadrineg oxazepamx
oxycodones oxymorphone_p pancuroniumbromideq paraquat3
paroxetineq pentazocineq pentobarbitals pentoxifyllines
phencyclidine> phenobarbital9 phentermineq
phenyltoloxamine-p phenytoinq primidonej promethazinej
propanes propoxyphenes propranololj propyleneglycolq
quetiapines quinine3 ritalinicacidg salicylatej
sa1icylicacid-p secobarbitalj sertralinej temazepamj
tetrafluroethanej tetrahydrocannabinolq thccarboxylicacid~

theophyllines thiopentals thioridazines toluenes
tramado19 tranylcypromines trazodones triazolams
tricyclics trifluoperazines trihexyphenidyls
trimipramines valproics venlafaxines verapamilx
zolpidems acetaminophen-1 acetone-1 acetylmorphine-1
alprazolam-1 amitriptyline-1 amoxapine-1 amphetamine-1
benzoylecgonine-1 benztropine-1 brompheniramine-1
bupropion-1 busiprone-1 butabarbital-1 butalbital-1
caffeine-1 carbamazepine-1 carbondioxide-1 carbonmonoxide-1
carisoprodol-1 chlordiazepoxide-1 chlorodifluoromethane-1
cocaine-1 codeine-1 cyanide-1 cyclobenzaprine-1desalkyflurazepam-1 desipramine-1 dextromethorphan-1
diazepam-1 difluoroethane-1 dihydrocodeine-1
diltiazem-1 diphenhydramine-1 doxepin-1 doxylamine-1
ephedrine-1 ethanol-1 ethyleneglycol-1 fenfluramine-1
fentanyl-1 fluoxetine-1 fluvoxamine-1 gabapentin-1
gammahydroxybutyrate-1 guaifenesin-1 hydrocodone-1
hydromorphone-1 hydroxyzine-1 ibuprofen-1 imipramine-1
insulin-1 isopropanol-1 ketamine-1 lithium-1 lorazepam-1
lysergicaciddiethylamide-1 mda-1 mdma-1 meclizine-1
meperidine-1 meprobamate-1 metaxalone-1 methadone-1
methamphetamine-1 methanol-1 methocarbamol-1 methotrexate-1
methylphenidate-1 midazolam-1 mirtazapine-1 molidone-1
morphine-1 naproxen-1 nefazodone-1 nicotine-1 nitricacid-1
norchlorcyclizine-1 nordiazepam-1 nordoxepin-1
norfluoxetine-1 normeperidine-1 norpropoxyphene-1
nortriptylene-1 olanzapine-1 orphenadrine-1 oxazepam-1
oxycodone-1 oxymorphone-1 pancuroniumbromide-1 paraquat-1
paroxetine-1 pentazocine-1 pentobarbital-1 pentoxifylline-1
phencyclidine-1 phenobarbital-1 phentermine-1
phenyltoloxamine-1 phenytoin-1 primidone-1 promethazine-1
propane-1 propoxyphene-1 propranolol-1 propyleneglycol-1
quetiapine-1 quinine-1 ritalinicacid-1 salicylate-1
salicylicacid-1 secobarbital-1 sertraline-1 temazepam-1
tetrafluroethane-1 tetrahydrocannabinol-1 thccarboxylicacid-1
theophylline-1 thiopental-1 thioridazine-1 toluene-1
tramadol-1 tranylcypromine-1 trazodone-1 triazolam-1
tricyclic-1 trifluoperazine-1 trihexyphenidyl-1
trimipramine-1 valproic-1 venlafaxine-1 verapamil-1
zolpidem-1 number-of-drugs;
drop acetaminophen-n acetone-n a.cetylmorphine-n alprazolam-n
amitriptyline-n amoxapine-n amphetamine-n benzoylecgonine-n
benztropine-n brompheniramine-n bupropion-n busiprone-n
butabarbital-n butalbital-n caffeine-n carbamazepine-n
carbondioxide-n carbonmonoxide-n carisoprodol-n
chlordiazepoxide-n chlorodifluorornethane~n chlorpheniramine-n
chlorpromazine-n citalopram-n clomipramine-n clonzepam-n
clozapine-n cocaethlyene-n cocaine-n codeine-n cyanide-n
cyclobenzaprine-n desalkyflurazepam-n desipramine-n
dextromethorphan-n diazepam-n difluoroethane-n

dihydrocodeine-n diltiazem-n diphenhydramine-n doxepin-n
doxylamine-n ephedrine-n ethanol-n ethyleneglycol-n
fenfluramine-n fentanyl-n fluoxetine-n fluvoxamine-n
gabapentin-n gammahydroxybutyrate-n guaifenesin-n
hydrocodone-n hydromorphone-n hydroxyzine-n ibuprofen-n
imipramine-n insulin-n isopropanol-n ketamine-n lithium-n
lorazepam-n lysergicaciddiethylamide-n mda-n mdma-n
meclizine-n meperidine-n meprobamate-n metaxalone-n
methadone-n methamphetamine-n methanol-n methocarbamol-n
methotrexate-n methylphenidate-n midazolam-n mirtazapine-n
molidone-n morphine-n naproxen-n nefazodone-n nicotine-n
nitricacid-n norchlorcyclizine-n nordiazepam-n nordoxepin-n
norfluoxetine-n normeperidine-n norpropoxyphene-n
nortriptylene-n olanzapine-n orphenadrine-n oxazepam-n
oxycodone-n oxymorphone-n pancuroniumbromide-n paraquat-n
paroxetine-n pentazocine-n pentobarbital-n pentoxifylline-n
phencyclidine-n phenobarbital-n phentermine-n
phenyltoloxamine-n phenytoin-n primidone-n promethazine-n
propane-n propoxyphene-n propranolol-n propyleneglycol-n
quetiapine-n quinine-n ritalinicacid-n salicylate-n
salicylicacid-n secobarbital-n sertraline-n ternazepam-n
tetrafluroethane-n tetrahydrocannabinol-n thccarboxylicacid-n
theophylline-n thiopental-n thioridazine-n toluene-n
tramadol-n tranylcypromine-n trazodone-n triazolam-n
tricyclic-n trifluoperazine-n trihexyphenidyl-n
trimipramine-n valproic-n venlafaxine-n verapamil-n
zolpidem-n i;
run ;
data thesis.mefinal1;
set thesis.mefina1;
if upcase(tox-) ne IN';
run ;
proc freq data=thesis.mefinall;
tables fatalnew;
run ;

/*Checking a drug to see if the above code workedx/
proc print data=thesis.mefinall;
var case-number doxepin doxepin-c doxepin-1 doxepins;
run ;
*DUI DATASETS;
PROC IMPORT OUT= thesis.DUIDrug1

DATAFILE= "E:\Thesis Files\DUIoriginalDrug.jrnp"
DBMS=JMP REPLACE;
RUN:
PROC IMPORT OUT= thesis.DUIDescrip1

DATAFILE= "E:\ThesisFiles\DUIoriginal~escrip.jmp"
DBMS=JMP REPLACE;
RUN;

/*Looking for duplicates in descriptive information keeping the most recent observation*/
data thesis.DUIDescrip2;
set thesis.DUIDescrip1;
by fslabnum;
*last = 1ast.fslabnum;
if 1ast.fslabnum then output;
run ;
/*Sort in order to merge two datasets*/
proc sort data=thesis.DUIDrugl;
by FSLabNum;
run ;
proc sort data=thesi~.DUIDescrip2;
by FSLabNum datesubmitted;
run ;
/*Merge the descriptive and the drug sets into one*/
data thesis.DUI1;
merge thesis.DUIDescrip2 thesis.DUIDrug1;
by FSLabNum;

run;
/*Calculating age, using current date as the last possible
date if no other date is available to calculate age*/
data thesis.DUIclean1;
set thesis.DUI1;
attrib currentdate format=MMDDYYlO.;
currentdate = 01/01/2005;
& datesubmitted ne
then
if dateofbirth ne
age-all = yrdif(dateofbirth, datesubmitted, 'ACT/ACT1);
else if dateofbirth ne
& date-case-completed ne
then
age-all = yrdif(dateofbirth, date-case-completed,
'ACT/ACT1);
else if dateofbirth ne
then age-all = yrdif(dateofbirth,
currentdate, 'ACT/ACT1);
else age-all =
age = floor(age-all);

.

.

.

.

.

.;

drop age-all dateofbirth datesubmitted submissionnum
date-case-completed;
run ;

data thesis.DUIclea1-12;
set thesis.DUIclean1;
*Fixing drug names to simplify;
if drug = '1,l-difluoroethane'then drug = 'Difluoroethane';
if drug = '6-AcetylMorphine' then drug = 'AcetylMorphinel;
if drug = 'Blood Alcohol' then drug = 'Ethanol';
if drug = 'Gamma-Hydroxybutyrate/Lactonelthen drug =
'Gamma-Hydroxybutyrate'
;

if drug = 'N-DesalkylFlurazepam' then drug =
'Desalkyflurazepam';
run ;
data thesis.DUIclean4;
set thesis.DUIclean2;

*Create new database variable;
database = 'dui';
if database = 'dui' then bac = 'BLOOD';
*Format variables to match other dataset;
drug = upcase(drug);
attrib case-number format=$lO.;
case-number = fslabnum;
*Create units of measurement - all in blood;
if drug = 'ETHANOL' then unit = 'Grams%';
else unit = 'mg/Lg;
*Set illegal ages to missing;
if age < 14 then age =

.;

drop fslabnurn;
run ;
proc f r e q data=thesis.DUIclean4;
tables presence;
run ;
data thesis.DUIclean5;
set thesis.DUIclean4;

*Edit the concentrations to reflect a more accurate amount
based on the presence variable;
if presence = 'less than' ( presence = 'present less than' then
amount = amount*.5;
else if presence = 'greater than' then amount = amount*1.15;
else if presence = 'present' I presence = 'quantitated' I
presence = 'not detected' I presence = ' ' then
amount=amount;
else amount =

.;

run ;
proc sort data=thesis.DUIclean5;
by case-number drug descending bac;
run ;
data thesis.DUIfina1;
set thesis.DUIclean5;

by case-number drug descending bac;
array names 11391 $100. acetaminophen-n acetone-n acetylmorphine-n
alprazolam-n amitriptyline-n amoxapine-n amphetamine-n
benzoylecgonine-n benztropine-n brompheniramine-n bupropion-n
busiprone-n butabarbital-n butalbital-n caffeine-n
carbamazepine-n carbondioxide-n carbonmonoxide-n
carisoprodol-n chlordiazepoxide-n chlorodifluoromethane-n
chlorpheniramine-n chlorpromazine-n citalopram-n
clomipramine-n clonzepam-n clozapine-n cocaethlyene-n
cocaine-n codeine-n cyanide-n cyclobenzaprine-n
desalkyflurazepam-n desipramine-n dextromethorphan-n
diazepam-n difluoroethane-n dihydrocodeine-n diltiazem-n
diphenhydramine-n doxepin-n doxylamine-n ephedrine-n
ethanol-n ethyleneglycol-n fenfluramine-n fentanyl-n
fluoxetine-n fluvoxamine-n gabapentin-n
gammahydroxybutyrate-n guaifenesin-n hydrocodone-n
hydromorphone-n hydroxyzine-n ibuprofen-n imipramine-n
insulin-n isopropanol-n ketamine-n lithium-n lorazepam-n
lysergicaciddiethylamide-n mda-n mdma-n meclizine-n
meperidine-n meprobamate-n metaxalone-n methadone-n
methamphetamine-n methanol-n methoca.rbamo1-n methotrexate-n
methylphenidate-n midazolam-n mirtazapine-n molidone-n
morphine-n naproxen-n nefazodone-n nicotine-n nitricacid-n
norchlorcyclizine~nnordiazepam-n nordoxepin-n
norfluoxetine-n normeperidine-n norpropoxyphene-n
nortriptylene-n olanzapine-n orphenadrine-n oxazepam-n
oxycodone-n oxymorphone-n pancuroniumbromide-n paraquat-n
paroxetine-n pentazocine-n pentobarbital-n pentoxifylline-n
phencyclidine-n phenobarbital-n phentermine-n
phenyltoloxamine-n phenytoin-n primidone-n promethazine-n
propane-n propoxyphene-n propranolol-n propyleneglycol-n
quetiapine-n quinine-n ritalinicacid-n salicylate-n
salicylicacid-n secobarbital-n sertraline-n temazepam-n
tetrafluroethane-n tetrahydrocannabinol-n thccarboxylicacid-n
theophylline-n thiopental-n thioridazine-n toluene-n
tramadol-n tranylcypromine-n trazodone-n triazolam-n
tricyclic-n trifluoperazine-n trihexyphenidyl-n
trimipramine-n valproic-n venlafaxine-n verapamil-n
zolpidem-n ('acetaminophen','acetone','acetylmorphine',
'alprazolam', 'amitriptyline','amoxapine','amphetamine',
'benzoylecgonine','benztropine','brompheniramine',
'bupropion', 'busiprone', 'butabarbital','butalbital',
'caffeine', 'carbamazepine','carbon dioxide', 'carbon
monoxide', 'carisoprodol','chlordiazepoxide',
'chlorodifluoromethane', 'chlorpheniramine',
'chlorpromazine','citalopram', 'clomipramine','clonzepam',
'clozapine','cocaethlyene','cocaine','codeine','cyanide',
'cyclobenzaprine','desalkyflurazepam','desipramine',
'dextromethorphan', 'diazepam', 'difluoroethane',
'dihydrocodeine','diltiazem','diphenhydramine', 'doxepin',
'doxylamine','ephedrine', 'ethanol', 'ethyleneglycol',
'fenfluramine','fentanyl', 'fluoxetine','fluvoxamine',
'gabapentin', 'gamrnahydroxybutyrate','guaifenesin',

'hydrocodone','hydromorphone','hydroxyzine','ibuprofen',
'imipramine','insulin','isopropanol','ketamine',
'lithium', 'lorazepam','lysergicaciddiethylamide','mda',
'mdma', 'meclizine','meperidine','meprobamate',
'metaxalone','methadone','methamphetamine','methanol',
'methocarbamol','methotrexate','methylphenidate',
'midazolam', 'mirtazapine','molidone','morphine',
'naproxen', 'nefazodone', 'nicotine','nitricacid',
'norchlorcyclizine', 'nordiazepam', 'nordoxepin',
'norfluoxetine','normeperidine','norpropoxyphene',
'nortriptylene','olanzapine','orphenadrine','oxazepam',
'oxycodone', 'oxymorphone', 'pancuroniumbromide',
'paraquat','paroxetine', 'pentazocine', 'pentobarbital',
'pentoxifylline','phencyclidine','phenobarbital',
'phentermine', 'phenyltoloxamine','phenytoin',
'primidone','promethazine','propane','propoxyphene',
'propranololl,'propyleneglycol','quetiapine', 'quinine',
'ritalinicacid','salicylate','salicylicacid',
'secobarbital', 'sertraline','temazepam',
'tetrafluroethane','tetrahydrocannabinol',
'thccarboxylicacid','theophylline', 'thiopental',
'thioridazine', 'toluene','tramadol','tranylcypromine',
'trazodone', 'triazolam', 'tricyclic','trifluoperazine',
'trihexyphenidyl','trimipramine','valproic','venlafaxine',
'verapamil', 'zolpidem');
array drugs {I391 acetaminophen acetone acetylmorphine alprazolam
amitriptyline amoxapine amphetamine benzoylecgonine
benztropine brompheniramine bupropion busiprone butabarbital
butalbital caffeine carbamazepine carbondioxide
carbonmonoxide carisoprodol chlordiazepoxide
chlorodifluoromethane chlorpheniramine chlorpromazine
citalopram clomipramine clonzepam clozapine cocaethlyene
cocaine codeine cyanide cyclobenzaprine desalkyflurazepam
desipramine dextromethorphan diazepam difluoroethane
dihydrocodeine diltiazem diphenhydramine doxepin doxylamine
ephedrine ethanol ethyleneglycol fenfluramine fentanyl
fluoxetine fluvoxamine gabapentin gammahydroxybutyrate
guaifenesin hydrocodone hydromorphone hydroxyzine ibuprofen
imipramine insulin isopropanol ketamine lithium lorazepam
lysergicaciddiethylamide mda mdma meclizine meperidine
meprobamate metaxalone methadone methamphetamine methanol
methocarbamol methotrexate methylphenidate midazolam
mirtazapine molidone morphine naproxen nefazodone nicotine
nitricacid norchlorcyclizine nordiazepam nordoxepin
norfluoxetine normeperidine norpropoxyphene nortriptylene
olanzapine orphenadrine oxazepam oxycodone oxymorphone
pancuroniumbromide paraquat paroxetine pentazocine
pentobarbital pentoxifylline phencyclidine phenobarbital
phentermine phenyltoloxamine phenytoin primidone promethazine
propane propoxyphene propranolol propyleneglycol quetiapine
quinine ritalinicacid salicylate salicylicacid secobarbital
sertraline temazepam tetrafluroethane tetrahydrocannabinol

thccarboxylicacid theophylline thiopental thioridazine
toluene tramadol tranylcypromine trazodone triazolam
tricyclic trifluoperazine trihexyphenidyl trimipramine
valproic venlafaxine verapamil zolpidem;
array amounts (1391 acetaminophen-c acetone-c acetylmorphine-c
alprazolam-c amitriptyline-c amoxapine-c amphetamine-c
benzoylecgonine-c benztropine-c brompheniramine-c bupropion-c
busiprone-c butabarbital-c butalbital-c caffeine-c
carbamazepine-c carbondioxide-c carbonmonoxide-c
carisoprodol-c chlordiazepoxide-c chlorodifluoromethane-c
chlorpheniramine-c chlorpromazine-c citalopram-c
clomipramine-c clonzepam-c clozapine-c cocaethlyene-c
cocaine-c codeine-c cyanide-c cyclobenzaprine-c
desalkyflurazepam-c desipramine-c dextromethorphan-c
diazepam-c difluoroethane-c dihydrocodeine-c diltiazem-c
diphenhydramine-c doxepin-c doxylamine-c ephedrine-c
ethanol-c ethyleneglycol-c fenfluramine-c fentanyl-c
fluoxetine-c fluvoxamine-c gabapentin-c
gammahydroxybutyrate-c guaifenesin-c hydrocodone-c
hydromorphone-c hydroxyzine-c ibuprofen-c imipramine-c
insulin-c isopropanol-c ketamine-c lithium-c lorazepam-c
lysergicaciddiethylamide-c mda-c mdrna-c meclizine-c
meperidine-c meprobamate-c metaxalone-c methadone-c
methamphetamine-c methanol-c methocarbamol-c methotrexate-c
methylphenidate-c midazolam-c mirtazapine-c molidone-c
morphine-c naproxen-c nefazodone-c nicotine-c nitricacid-c
norchlorcyclizine-c nordiazepam-c nordoxepin-c
norfluoxetine-c normeperidine-c norpropoxyphene-c
nortriptylene-c olanzapine-c orphenadrine-c oxazepam-c
oxycodone-c oxymorphone-c pancuroniurnbromide-c paraquat-c
paroxetine-c pentazocine-c pentobarbital-c pentoxifylline-c
phencyclidine-c phenobarbital-c phentermine-c
phenyltoloxamine-c phenytoin-c primidone-c promethazine-c
propane-c propoxyphene-c propranolol-c propyleneglycol-c
quetiapine-c quinine-c ritalinicacid-c salicylate-c
salicylicacid-c secobarbital-c sertraline-c temazepam-c
tetrafluroethane-c tetrahydrocannabinol-c thccarboxylicacid-c
theophylline-c thiopental-c thioridazine-c toluene-c
tramadol-c tranylcypromine-c trazodone-c triazolam-c
tricyclic-c trifluoperazine-c trihexyphenidyl-c
trimipramine-c valproic-c venlafaxine-c verapamil-c
zolpidem-c;
array levels {I391 $14. acetaminophen-1 acetone-1 acetylmorphine-1
alprazolam-1 amitriptyline-1 amoxapine-1 amphetamine-1
benzoylecgonine-1 benztropine-1 brompheniramine-1 bupropion-1
busiprone-1 butabarbital-1 butalbital-1 caffeine-1
carbamazepine-1 carbondioxide-1 carbonmonoxide-1
carisoprodol-1 chlordiazepoxide-1 chlorodifluoromethane-1
chlorpheniramine-1 chlorpromazine-1 citalopram-1
clomipramine-1 clonzepam-1 clozapine-1 cocaethlyene-1

a r r a y p r e s s {139} $ 3 1 . a c e t a m i n o p h e n q a c e t o n e s a c e t y l m o r p h i n e q
a l p r a z o l a m q a m i t r i p t y l i n e q amoxapineq amphetamines
b e n z o y l e c g o n i n e q b e n z t r o p i n e j brompheniramineq b u p r o p i o n q
busipronex butabarbitals b u t a l b i t a l j c a f f e i n e 3
c a r b a m a z e p i n e g c a r b o n d i o x i d e q carbonmonoxide_p
carisoprodol-p chlordiazepoxideq chlorodifluoromethane~
chlorpheniramine-p c h l o r p r o m a z i n e q c i t a l o p r a m q
c l o m i p r a m i n e ~c l o n z e p a m s c l o z a p i n e q c o c a e t h l y e n e 3
c o c a i n e 3 codeine3 cyanideq cyclobenzaprines
d e s a l k y f l u r a z e p a m q d e s i p r a m i n e j dextromethorphang
diazepam3 d i f l u o r o e t h a n e q dihydrocodeineq d i l t i a z e m q
diphenhydramineq d o x e p i n q d o x y l a m i n e q e p h e d r i n e q
e t h a n o l 3 ethyleneglycolq fenfluraminej fentanylq
f l u o x e t i n e j fluvoxamines gabapentinq
gammahydroxybutyrateq g u a i f e n e s i n q hydrocodone-p
hydromorphones h y d r o x y z i n e q i b u p r o f e n j i m i p r a m i n e ~
i n s u l i n q i s o p r o p a n o l j k e t a m i n e s l i t h i u m q lorazepamq
lysergicaciddiethylamideq m d a q mdmaq m e c l i z i n e q
m e p e r i d i n e s meprobamateq m e t a x a l o n e 3 m e t h a d o n e s
methamphetamineq m e t h a n o l q methocarbamolq m e t h o t r e x a t e j
m e t h y l p h e n i d a t e q midazolamq m i r t a z a p i n e s m o l i d o n e q
m o r p h i n e 3 n a p r o x e n x nefazodone-p n i c o t i n e 2 n i t r i c a c i d j

norchlorcyclizine_p nordiazepams nordoxepinj
norfluoxetines normeperidinej norpropoxyphenej
nortriptylenes olanzapinej orphenadrines oxazepamj
oxycodones oxymorphonej pancuroniumbromide_p paraquat2
paroxetinej pentazocines pentobarbitalq pentoxifyllineq
phencyclidineq phenobarbital3 phenterminej
phenyltoloxamine-p phenytoinj primidones promethazinej
propanes propoxyphenes propranololj propyleneglycolj
quetiapinej quinines ritalinicacidj salicylatej
salicylicacid-p secobarbitalj sertralinej temazepamj
tetrafluroethanej tetrahydrocannabinols thccarboxylicacidj
theophyllines thiopentalj thioridazines toluenes
tramado12 tranylcyprominej trazodonej triazolams
tricyclics trifluoperazinej trihexyphenidylj
trimipramines valproicj venlafaxines verapamilj
zolpidemj;
if first.case-number then do;
do i = 1 to 139 by 1;
drugsri} =
amounts{i} =
levels.Ii} = " ;
press{i} = " ;
number-of-drugs = 0;
end ;
end ;

.;

.;

do i =1 to 139 by 1;
if drug=upcase(names{i}) then do;
drugs{i}=l;
amounts{i}=amount;
levels{i} = unit;
pressIi} = presence;
if amounts{i} ne 0 & pressCi) ne 'not detected'
then number-of-drugs = number-of-drugs+l;
end ;
end ;
if 1ast.case-number then output;
retain case-number acetaminophen acetone acetylmorphine
alprazolam amitriptyline amoxapine amphetamine
benzoylecgonine benztropine brompheniramine bupropion
busiprone butabarbital butalbital caffeine carbamazepine
carbondioxide carbonmonoxide carisoprodol chlordiazepoxide
chlorodifluoromethane chlorpheniramine chlorpromazine
citalopram clomipramine clonzepam clozapine cocaethlyene
cocaine codeine cyanide cyclobenzaprine desalkyflurazepam
desipramine dextromethorphan diazepam difluoroethane
dihydrocodeine diltiazem diphenhydramine doxepin doxylamine

ephedrine ethanol ethyleneglycol fenfluramine fentanyl
fluoxetine fluvoxamine gabapentin gammahydroxybutyrate
guaifenesin hydrocodone hydromorphone hydroxyzine ibuprofen
imipramine insulin isopropanol ketamine lithium lorazepam
lysergicaciddiethylamide mda mdma meclizine meperidine
meprobamate metaxalone methadone methamphetamine methanol
methocarbamol methotrexate methylphenidate midazolam
mirtazapine molidone morphine naproxen nefazodone nicotine
nitricacid norchlorcyclizine nordiazepam nordoxepin
norfluoxetine normeperidine norpropoxyphene nortriptylene
olanzapine orphenadrine oxazepam oxycodone oxymorphone
pancuroniumbromide paraquat paroxetine pentazocine
pentobarbital pentoxifylline phencyclidine phenobarbital
phentermine phenyltoloxamine phenytoin primidone promethazine
propane propoxyphene propranolol propyleneglycol quetiapine
quinine ritalinicacid salicylate salicylicacid secobarbital
sertraline temazepam tetrafluroethane tetrahydrocannabinol
thccarboxylicacid theophylline thiopental thioridazine
toluene tramadol tranylcypromine trazodone triazolam
tricyclic trifluoperazine trihexyphenidyl trimipramine
valproic venlafaxine verapamil zolpidem acetaminophen-c
acetone-c acetylmorphine-c alprazolam-c amitriptyline-c
amoxapine-c amphetamine-c benzoylecgonine-c benztropine-c
brompheniramine-c bupropion-c busiprone-c butabarbital-c
butalbital-c caffeine-c carbamazepine-c carbondioxide-c
carbonmonoxide-c carisoprodol-c chlordiazepoxide-c
chlorodifluoromethane~cchlorpheniramine-c chlorpromazine-c
citalopram-c clomipramine-c clonzepam-c clozapine-c
cocaethlyene-c cocaine-c codeine-c cyanide-c
cyclobenzaprine-c desalkyflurazepam-c desipramine-c
dextromethorphan-c diazepam-c difluoroethane-c
dihydrocodeine-c diltiazem-c diphenhydramine-c doxepin-c
doxylamine-c ephedrine-c ethanol-c ethyleneglycol-c
fenfluramine-c fentanyl-c fluoxetine-c fluvoxamine-c
gabapentin-c gammahydroxybutyrate-c guaifenesin-c
hydrocodone-c hydromorphone-c hydroxyzine-c ibuprofen-c
imipramine-c insulin-c isopropanol-c ketamine-c lithium-c
lorazepam-c lysergicaciddiethylamide-c mda-c mdma-c
meclizine-c meperidine-c meprobamate-c metaxalone-c
methadone-c methamphetamine-c methanol-c methocarbamol-c
methotrexate-c methylphenidate-c midazolam-c mirtazapine-c
molidone-c morphine-c naproxen-c nefazodone-c nicotine-c
nitricacid-c norchlorcyclizine-c nordiazepam-c nordoxepin-c
norfluoxetine-c normeperidine-c norpropoxyphene-c
nortriptylene-c olanzapine-c orphenadrine-c oxazepam-c
oxycodone-c oxymorphone-c pancuroniumbromide-c paraquat-c
paroxetine-c pentazocine-c pentobarbital-c pentoxifylline-c
phencyclidine-c phenobarbital-c phentermine-c
phenyltoloxamine-c phenytoin-c primidone-c promethazine-c
propane-c propoxyphene-c propranolol-c propyleneglycol-c
quetiapine-c quinine-c ritalinicacid-c salicylate-c
salicylicacid-c secobarbital-c sertraline-c temazepam-c
tetrafluroethane-c tetrahydrocannabinol-c thccarboxylicacid-c

theophylline-c thiopental-c t h i o r i d a z i n e - c toluene-c
tramadol-c tranylcypromine-c trazodone-c triazolam-c
t r i c y c l i c - c t r i f l u o p e r a z i n e - c trihexyphenidyl-c
trimipramine-c valproic-c venlafaxine-c verapamil-c
zolpidem-c acetaminophenq a c e t o n e s a c e t y l m o r p h i n e q
a l p r a z o l a m s a m i t r i p t y l i n e s a m o x a p i n e j amphetamines
benzoylecgoninej b e n z t r o p i n e j brompheniraminej bupropionq
busiproneg b u t a b a r b i t a l j b u t a l b i t a l s c a f f e i n e j
c a r b a m a z e p i n e q c a r b o n d i o x i d e j carbonmonoxides
c a r i s o p r o d o l q chlordiazepoxide-p c h l o r o d i f l u o r o m e t h a n e ~
chlorpheniramineq chlorpromazines c i t a l o p r a m s
clomipramine-p c l o n z e p a m j c l o z a p i n e - p c o c a e t h l y e n e s
c o c a i n e j c o d e i n e 3 c y a n i d e s cyclobenzaprineg
d e s a l k y f l u r a z e p a m s d e s i p r a m i n e 3 dextromethorphan_p
diazepams d i f l u o r o e t h a n e q dihydrocodeineg d i l t i a z e m s
diphenhydramines d o x e p i n s doxylamines e p h e d r i n e 3
e t h a n o l 9 ethyleneglycols fenfluramineq f e n t a n y l j
f l u o x e t i n e q fluvoxamineq g a b a p e n t i n s
gammahydroxybutyratej g u a i f e n e s i n s h y d r o c o d o n e s
hydromorphonej h y d r o x y z i n e s i b u p r o f e n 3 i m i p r a m i n e j
i n s u l i n g isopropanolj ketaminej l i t h i u m 3 lorazepamj
lysergicaciddiethylamidej m d a q mdmas m e c l i z i n e s
m e p e r i d i n e q m e p r o b a m a t e j metaxalone* m e t h a d o n e s
methamphetamine3 m e t h a n o l 2 methocarbamolq m e t h o t r e x a t e q
m e t h y l p h e n i d a t e s midazolamq m i r t a z a p i n e s m o l i d o n e s
morphine2 n a p r o x e n j nefazodoneq n i c o t i n e 9 n i t r i c a c i d g
n o r c h l o r c y c l i z i n e q nordiazepams n o r d o x e p i n j
n o r f l u o x e t i n e q n o r m e p e r i d i n e s norpropoxyphenes
n o r t r i p t y l e n e q o l a n z a p i n e j o r p h e n a d r i n e j oxazepams
o x y c o d o n e j oxymorphones pancuroniumbromide_p p a r a q u a t 2
paroxetines pentazocinej pentobarbitals pentoxifyllineg
phencyclidineq p h e n o b a r b i t a l 3 phentermineq
phenyltoloxaminej p h e n y t o i n s primidones promethazineq
p r o p a n e s propoxyphenej p r o p r a n o l o l j p r o p y l e n e g l y c o l j
quetiapines quinines ritalinicacidj salicylateg
s a l i c y l i c a c i d j s e c o b a r b i t a l q s e r t r a l i n e q temazepamq
t e t r a f l u r o e t h a n e s tetrahydrocannabinol2 thccarboxylicacidq
t h e o p h y l l i n e q t h i o p e n t a l s t h i o r i d a z i n e s toluene*
tramadolq tranylcypromines trazodones t r i a z o l a m s
t r i c y c l i c ~t r i f l u o p e r a z i n e q t r i h e x y p h e n i d y l j
trimipraminej valproicq venlafaxines verapamils
z o l p i d e m s acetaminophen-1 acetone-1 acetylmorphine-1
alprazolam-1 a m i t r i p t y l i n e - 1 amoxapine-1 amphetamine-1
benzoylecgonine-1 benztropine-1 brompheniramine-1 bupropion-1
busiprone-1 b u t a b a r b i t a l - 1 b u t a l b i t a l - 1 caffeine-1
carbamazepine-1 carbondioxide-1 carbonmonoxide-1
carisoprodol-1 chlordiazepoxide-1 chlorodifluoromethane-1
chlorpheniramine-1 chlorpromazine-1 citalopram-1
clomipramine-1 clonzepam-1 clozapine-1 cocaethlyene-1
cocaine-1 codeine-1 cyanide-1 cyclobenzaprine-1
desalkyflurazepam-1 desipramine-1 dextromethorphan-1
diazepam-1 difluoroethane-1 dihydrocodeine-1 diltiazem-1
diphenhydramine-1 doxepin-1 doxylamine-1 ephedrine-1

ethanol-1 ethyleneglycol-1 fenfluramine-1 fentanyl-1
fluoxetine-1 fluvoxamine-1 gabapentin-1
garnmahydroxybutyrate-1 guaifenesin-1 hydrocodone-1
hydromorphone-1 hydroxyzine-1 ibuprofen-1 imipramine-1
insulin-1 isopropanol-1 ketamine-1 l i t h i m 1 lorazepam-1
lysergicaciddiethylamide-1 mda-1 mdma-1 meclizine-1
meperidine-1 meprobamate-1 metaxalone-1 methadone-1
methamphetamine-1 methanol-1 methocarbamol-1 methotrexate-1
methylphenidate-1 midazolam-1 mirtazapine-1 molidone-1
morphine-1 naproxen-1 nefazodone-1 nicotine-1 nitricacid-1
norchlorcyclizine-1 nordiazepam-1 nordoxepin-1
norfluoxetine-1 normeperidine-1 norpropoxyphene-1
nortriptylene-1 olanzapine-1 orphenadrine-1 oxazepam-1
oxycodone-1 oxymorphone-1 pancuroniumbromide-1 paraquat-1
paroxetine-1 pentazocine-1 pentobarbital-1 pentoxifylline-1
phencyclidine-1 phenobarbital-1 phentermine-1
phenyltoloxamine-1 phenytoin-1 primidone-1 promethazine-1
propane-1 propoxyphene-1 propranolol-1 propyleneglycol-1
petiapine-1 quinine-1 ritalinicacid-1 salicylate-1
salicylicacid-1 secobarbital-1 sertraline-1 temazepam-1
tetrafluroethane-1 tetrahydrocannabinol-1 thccarboxylicacid-1
theophylline-1 thiopental-1 thioridazine-1 toluene-1
tramadol-1 tranylcypromine-1 trazodone-1 triazolam-1
tricyclic-1 trifluoperazine-1 trihexyphenidyl-1
trimipramine-1 valproic-1 venlafaxine-1 verapamil-1
zolpidem-1 number-of-drugs;
drop acetaminophen-n acetone-n acetylmorphine-n alprazolam-n
amitriptyline-n amoxapine-n amphetamine-n benzoylecgonine-n
benztropine-n brompheniramine-n bupropion-n busiprone-n
butabarbital-n butalbital-n caffeine-n carbamazepine-n
carbondioxide-n carbonmonoxide-n carisoprodol-n
chlordiazepoxide-n chlorodifluoromethane-n chlorphenirarnine-n
chlorpromazine-n citalopram-n clomipramine-n clonzepam-n
clozapine-n cocaethlyene-n cocaine-n codeine-n cyanide-n
cyclobenzaprine-n desalkyflurazepam-n desipramine-n
dextromethorphan-n diazepam-n difluoroethane-n
dihydrocodeine-n diltiazem-n diphenhydramine-n doxepin-n
doxylamine-n ephedrine-n ethanol-n ethyleneglycol-n
fenfluramine-n fentanyl-n fluoxetine-n fluvoxamine-n
gabapentin-n gammahydroxybutyrate-n guaifenesin-n
hydrocodone-n hydromorphone-n hydroxyzine-n ibuprofen-n
imipramine-n insulin-n isopropanol-n ketamine-n lithium-n
lorazepam-n lysergicaciddiethylamide-n mda-n mdma-n
meclizine-n meperidine-n meprobamate-n metaxalone-n
methadone-n methamphetamine-n methanol-n methocarbamol-n
methotrexate-n methylphenidate-n midazolam-n mirtazapine-n
molidone-n morphine-n naproxen-n nefazodone-n nicotine-n
nitricacid-n norchlorcyclizine-n nordiazepam-n nordoxepin-n
norfluoxetine-n normeperidine-n norpropoxyphene-n
nortriptylene-n olanzapine-n orphenadrine-n oxazepam-n
oxycodone-n oxymorphone-n pancuroniumbromide-n paraquat-n
paroxetine-n pentazocine-n pentobarbital-n pentoxifylline-n

phencyclidine-n phenobarbital-n phentermine-n
phenyltoloxamine-n phenytoin-n primidone-n promethazine-n
propane-n propoxyphene-n propranolol-n propyleneglycol-n
quetiapine-n quinine-n ritalinicacid-n salicylate-n
salicylicacid-n secobarbital-n sertraline-n temazepam-n
tetrafluroethane-n tetrahydrocannabinol-n thccarboxylicacid-n
theophylline-n thiopental-n thioridazine-n toluene-n
tramadol-n tranylcypromine-n trazodone-n triazolam-n
tricyclic-n trifluoperazine-n trihexyphenidyl-n
trimipramine-n valproic-n venlafaxine-n verapamil-n
zolpidem-n i;
run ;

proc freq data=thesis.DUIfinal;
tables age;
run ;
/*Merge two datasets togetherk/
data thesis.combined;
set thesis.Mefinal1 thesis.DUIfina1;
indexfatal = find(fatalnew, 'POISONING',' i ' ) ;
drop tox- presence amount drug-level drug unit;
run ;

*Can either be a drug death or in the dui dataset;
data thesis.final1;
set thesis.cornbined;
if indexfatal ne 0 I database = 'dui';
drop drug-s- index1 index2 index3;
run ;
data thesis.diphenhydramine2;
set thesis.final1;
if diphenhydramine = 1 & diphenhydramine-c ne 0 &
diphenhydramineg ne 'not detected';

if (number-of-drugs = 1 & diphenhydramine = 1) then group =
' single ' ;
else if number-of-drugs = 2 & (diphenhydramine = 1 & ethanol = 1)
then group = 'with alcohol';
else if number-of-drugs >=2 then group = 'et al';
run ;
data thesis.diphenhydraminedata;
set thesis.diphenhydramine2; *or diphenhydraminel;
if bac = 'BLOOD' I bac = 'aBLOOD(P0ST)' I
bac = 'bBLOOD(PRE)' ;
run ;
data thesis.diphenhydraminefina1;

set thesis.diphenhydraminedata;
if case-number ne 'C0133260' & case-number ne
case-number ne 'C0136742' & case-number
case-number ne 'NV046032' & case-number
case-number ne 'NV046619' & case-number
case-number ne 'NV047229' & case-number
case-number ne 'NV050657' & case-number
case-number ne 'NV051115'& case-number
case-number ne 'T0059266'& case-number
case-number ne 'W0067678' & case-number
case-number ne 'W0068316'& case-number

'C0133349'&
ne 'NV045033'&
ne 'NV046331' &
ne 'NV047201'&
ne 'NV050545' &
ne 'NV050687' &
ne 'T0058619' &
ne 'T0063020' &
ne 'W0067902' &
ne 'W0068326';

run ;
data thesis.diphenfina1;
set thesis.diphenhydraminefina1;
if group = 'single' then newgroup = 1;
if group = 'with a' I group = let al' then newgroup = 2;
logdiphen = log(diphenhydramine-c);

run ;
proc glm data=thesis.diphenfinal;

class newgroup database;
model logdiphen = newgroup database newgroup*database;
run ;
data thesis.cocaine2;
set thesis.final1;
if (cocaine = 1 1 benzoylecgonine = 1) & cocaine-c ne 0
cocaine-c ne
& cocaine2 ne 'not detected';

.

&

if (number-of-drugs = 1 & cocaine = 1) I (number-of-drugs = 2
& (cocaine = 1 & benzoylecgonine = 1)) then group =
' single ' ;
else if (number-of-drugs = 2 & (cocaine = 1 & ethanol = 1)) )
(number-of-drugs = 3 & (cocaine = 1 & benzoylecgonine = 1
& ethanol = 1)) then group = 'with alcohol';
else if number-of-drugs >=2 then group = 'et al';
run ;
data thesis.cocainedata;
set thesis.cocaine2;
if bac = 'BLOOD' I bac = 'aBLOOD(P0ST)'
bac = 'bBLOOD(PRE)' ;
run ;

I

data thesis.cocainefina1;
set thesis.cocainedata;
if case-number ne 'C0131292'& case-number ne
case-number ne 'C0132494' & case-number
case-number ne 'C0133871' & case-number
case-number ne 'NV045054' & case-number

'C0131309' &
ne 'C0133717'&
ne 'C0135112'&
ne 'NV045197'&

case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number

ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne

'NV045270' &
'NV045619'&
'NV046009'&
'NV046329' &
'NV046632' &
'NV047201' &
'NV047622' &
'NV047878' &
'NV047935' &
'NV048238'&
'NV048292'&
'NV048603'&
'NV048882'&
'NV049148'&
'NV050361'&
'NV0503901&
'NV050687' &
'NV051034' &
'NV051257' &
'T0063321' &
'W0065652' &
'W0066710' &
'~0067005'&
'W0067044'&
'W0067497'&
'W0067734'&
'W0067820'&
'W0068023'&
'W0068343'&
'W0068443'&
'W0068708'&
'W0068837'&
'W0068937'&
'W0069006'&
'W0069408' ;

case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number
case-number

ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne
ne

run ;

data thesis.cocfina1;
set thesis.cocainefina1;
logcocaine = log(cocaine-c);
run ;

proc glm data=thesis.cocfinal;
class group database;
model logcocaine = group database group*database;
run ;
data thesis.oxycodone2;
set thesis.final1;
if oxycodone = 1 & oxycodonej ne 'not detected'
oxycodone-c ne 0 & oxycodone-c ne

.;

if (number-of-drugs = 1

&

&

oxycodone = 1) then group =

'single';
else if number-of-drugs = 2 & (oxycodone = 1 & ethanol
then group = 'with alcohol';
else if number-of-drugs >=2 then group = 'et al';

=

1)

run ;
data thesis.oxycodonedata;
set thesis.oxycodone2;
if bac = 'BLOOD' 1 bac = 'aBLOOD(P0ST)'
bac = 'bBLOOD(PRE)' ;
run ;

I

data thesis.oxycodonefina1;
set thesis.oxycodonedata;
if case-number ne 'T0060024' & case-number ne
case-number ne 'T00639301& case-number
case-number ne 'T00639801& case-number
case-number ne 'T0064217'& case-number
case-number ne 'W0063955'& case-number
case-number ne 'W0064135' & case-number
case-number ne 'W0064884'& case-number
case-number ne 'W0064992'& case-number
case-number ne 'W0067575' & case-number
case-number ne 'W0069583';
run ;

'T0060223'&
ne 'T0063935' &
ne 'T0064036' &
ne 'W0063194' &
ne 'W0064128' &
ne 'W0064844' &
ne 'W0064912' &
ne 'W0065793' &
ne 'W0067766' &

data thesis.oxyfina1;
set thesis.oxycodonefina1;
logoxy = log(oxycodone-c);
run ;

proc glm data=thesis.oxyfinal;
class group database;
model logoxy = group database group*database;
run ;
data thesis.hydro2;
set thesis.final1;
if hydrocodone = 1 & hydrocodone_p ne 'not detected'
hydrocodone-c ne 0 & hydrocodone-c ne

.;

&

if (number-of-drugs = 1 & hydrocodone = 1) then group =
' single ' ;
else if number-of-drugs = 2 & (hydrocodone = 1 &
ethanol = 1) then group = 'with alcohol';
else if number-of-drugs >=2 then group = let all;
run ;
data thesis.hydrodata;
set thesis.hydro2;
if bac = 'BLOOD' I bac = 'aBLOOD(P0ST)'
bac = 'bBLOOD(PRE)';

I

data thesis.hydrocodonefina1;
set thesis.hydrodata;
if case-number ne 'C0134397'& case-number ne
case-number ne "20136093' & case-number
case-number ne 'T0061306' & case-number
case-number ne 'T0063980' & case-number
case-number ne 'W0064613' & case-number
case-number ne 'W0065937' & case-number
case-number ne 'W0066632' & case-number
case-number ne 'W0067426' & case-number
case-number ne 'W0067977' & case-number
case-number ne 'W0068326' & case-number
case-number ne 'W0068382' & case-number
case-number ne 'W0068708' & case-number
case-number ne 'W0068849' & case-number
case-number ne 'W0069082' & case-number
run;

'C0134883' &
ne 'T0059266'&
ne 'T0063871' &
ne 'T0064217'&
ne 'W0064705' &
ne 'W0066627'&
ne 'W0067364'&
ne 'W0067766'&
ne 'W0068235'&
ne 'W0068348'&
ne 'W0068421'&
ne 'W0068797'&
ne 'W0068999'&
ne 'W0069583';

data thesis.hydrofina1;
set thesis.hydrocodonefina1;
if group = 'single' then newgroup = 1;
if group = 'with a' I group = let all then newgroup = 2;
else group =
loghydro = log(hydrocodone-c);
run;

.;

proc glm data=thesis.hydrofinal;
class newgroup database;
model loghydro = newgroup database newgroup*database;
run;
data thesis.meth2;
set thesis.final1;
if methadone = 1 & methadones ne 'not detected' &
methadone-c ne 0 & methadone-c ne

.;

if (number-of-drugs = 1 & methadone = 1) then group = 'single';
else if number-of-drugs = 2 & (methadone = 1 & ethanol = 1)
then group = 'with alcohol';
else if number-of-drugs >=2 then group = 'et al';
run;
data thesis.methdata;
set thesis.meth2;
if bac = 'BLOOD' I bac = 'aBLOOD(P0ST)'
bac = 'bBLOOD(PRE)';
run;

I

data thesis.methadonefina1;
set thesis.methdata;
if case-number ne 'NV046574'& case-number ne 'T0059478' &
case-number ne 'T0062596'& case-number ne 'T0063441'&

case-number
case-number
case-number
case-number
case-number

ne
ne
ne
ne
ne

'T0063548' &
'W0064013' &
'W0065458' &
'W0065559' &
'W0067338' &

case-number
case-number
case-number
case-number
case-number

ne
ne
ne
ne
ne

'T0063555' &
'W0064530' &
'W0065525' &
'W0067039' &
'W0068276';

run ;
data thesis.methfina1;

set thesis.methadonefina1;
logmeth = log(methadone-c);
run ;

proc glm data=thesis.methfinal;
class group database;
model logmeth = group database group*database;
run ;
proc g l m data=thesis.methfinal;
class group database;
model logmeth = group database;
run ;
data thesis.morphine2;

set thesis.final1;
if morphine = 1 & morphines ne 'not detected'
morphine-c ne 0 & morphine-c ne

.;

&

if number-of-drugs = 1 & morphine = 1 then group = 'single';
else if number-of-drugs = 2 & (morphine = 1 & ethanol = 1)
then group = 'with alcohol';
else if number-of-drugs >=2 then group = 'et all;
run ;
data thesis.morphinedata;

set thesis.morphine2;
if bac = 'BLOOD' I bac = 'aBLOOD(P0ST)'(
bac = 'bBLOOD(PRE)' ;
run ;
data thesis.morphinefina1;

set thesis.morphinedata;
run ;
data thesis.morphfina1;

set thesis.morphinefina1;
logmorph = log(morphine-c);
run ;

proc g l m data=thesis.morphfinal;
class group database;
model logmorph = group database group*database;
run ;

proc glm data=thesis.morphfinal;
class group database;
model logrnorph = group database;
run ;

APPENDIX E
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